

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number
WO 2004/094420 A1

(51) International Patent Classification⁷: **C07D 471/04**,
487/04

(21) International Application Number:
PCT/IB2004/001350

(22) International Filing Date: 7 April 2004 (07.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0308208.8 9 April 2003 (09.04.2003) GB
60/485,322 7 July 2003 (07.07.2003) US

(71) Applicants (for all designated States except US): **SB PHARMCO PUERTO RICO INC** [US/US]; CSC The United States Corporation Company, 105 Ponce de Leon Avenue, One Comptroller Plaza, Hato Rey, Puerto Rico, 00917 (US). **NEUROCRINE BIOSCIENCES INC** [US/US]; 10555 Science Center Drive, San Diego, California 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ANDREOTTI, Daniele** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **BERNASCONI, Giovanni** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **CASTIGLIONI, Emiliano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **CONTINI, Stefania** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **DI FABIO, Romano** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **FAZZOLARI, Elettra** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **FERIANI, Aldo** [IT/IT]; GlaxoSmithKline

SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **GENTILE, Gabriella** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MATTIOLI, Mario** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **MINGARDI, Anna** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **SABBATINI, Fabio** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT). **ST-DENIS, Yves** [CA/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37100 Verona (IT).

(74) Agent: **GIDDINGS, Peter John**; GlaxoSmithKline, Corporate Intellectual Property, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: CONDENSED N-HETEROCYCLIC COMPOUNDS AND THEIR USE AS CRF RECEPTOR ANTAGONISTS



(I)

(57) Abstract: The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof (Formula (I)) wherein the dashed line may represent a double bond; R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from: halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 lkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, hydroxy, -NR₃R₄, cyano and or a group Z; R₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano; D, G is -C- optionally substituted; X is carbon or nitrogen; Y is nitrogen or -C- optionally substituted; W is a 4-8 membered ring, which may be saturated or may

contain one to three double bonds, and in which: - one carbon atom is replaced by a carbonyl or S(O)_m; and - one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR₁₂, S(O)_m, carbonyl, and such ring may be further substituted by 1 to 8 substituents; Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 R₅ groups or a phenyl ring, which may be substituted by 1 to 4 substituents; m is an integer from 0 to 2. to processes for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF).

WO 2004/094420 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

5 The present invention relates to bicyclic derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in therapy.

10 The first corticotropin-releasing factor (CRF) was isolated from ovine hypothalami and identified as a 41-amino acid peptide (Vale et al., Science 213: 1394-1397, 1981). CRF has been found to produce profound alterations in endocrine, nervous and immune system function. CRF is believed to be the major physiological regulator of the basal and stress-release of adrenocorticotrophic hormone ("ACTH"), Bendorphin and other

15 In addition to its role in stimulating the production of ACTH and POMC, CRF appears to be one of the pivotal central nervous system neurotransmitters and plays a crucial role in integrating the body's overall response to stress.


Administration of CRF directly to the brain elicits behavioral, physiological and endocrine responses identical to those observed for an animal exposed to a stressful environment.

20 Accordingly, clinical data suggests that CRF receptor antagonists may represent novel antidepressant and/or anxiolytic drugs that may be useful in the treatment of the neuropsychiatric disorders manifesting hypersecretion of CRF.

25 The first CRF receptor antagonists were peptides (see, e.g., Rivier et al., U.S. Patent No. 4,605,642; Rivier et al., Science 224: 889, 1984). While these peptides established that CRF receptor antagonists can attenuate the pharmacological responses to CRF, peptide CRF receptor antagonists suffer from the usual drawbacks of peptide therapeutics including lack of stability and limited oral activity. More recently, small molecule CRF receptor antagonists have been reported.


30

WO 95/10506 describes inter alia compounds of general formula (A) with general CRF antagonist activity



35 wherein Y may be CR29; V may be nitrogen, Z may be carbon or nitrogen, R3 may correspond to an amine derivative and R4 may be taken together with R29 to form a 5-membered ring and is -CH(R28) when R29 is -CH(R30).


WO 95/33750 also describes compounds of general formula (B) having CRF antagonistic activity,



- 5 in which A and Y may be nitrogen and carbon and B may correspond to an amine derivative.

Recently a patent application has been published as WO 02/08895 in which the following compounds, CRF antagonists, are objects of the Patent Application:


10



In particular, R₂ and R₃ with N may form a saturated or unsaturated heterocycle, which may be substituted by a 5-6 membered heterocycle, which may be substituted by 1 to 3 groups selected among: C1-C6 alkyl, halo C1-C2 alkyl, C1-C6 alkoxy, halogen, nitro or cyano.

15

Another recent patent application has been published as WO 03/008412 in which the following compounds, CRF antagonists, are objects of the Patent Application:



20

In particular, R₂ and R₃ with N may form a 5-14 membered heterocycle, which may be substituted by a 5-6 membered heterocycle, which may be saturated or may contain one to three double bonds, and which may be substituted by 1 or more groups such as C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, hydroxy, halogen, nitro, cyano, or C(O)NR₆R₇.

25

None of the above references disclosed compounds falling into the scope of the present invention.


- 30 Due to the physiological significance of CRF, the development of biologically-active small molecules having significant CRF receptor binding activity and which are capable of

antagonizing the CRF receptor remains a desirable goal. Such CRF receptor antagonists would be useful in the treatment of endocrine, psychiatric and neurologic conditions or illnesses, including stress-related disorders in general.

- 5 While significant strides have been made toward achieving CRF regulation through administration of CRF receptor antagonists, there remains a need in the art for effective small molecule CRF receptor antagonists. There is also a need for pharmaceutical compositions containing such CRF receptor antagonists, as well as methods relating to the use thereof to treat, for example, stress-related disorders. The present invention fulfills
10 these needs, and provides other related advantages.

In particular the invention relates to novel compounds which are potent and specific antagonists of corticotropin-releasing factor (CRF) receptors.

- 15 The present invention provides compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof



wherein

20 the dashed line may represent a double bond;

R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from:

halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, hydroxy, -NR₃R₄, cyano or a group Z;

25

R₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano;

R₂ is a C1-C4 alkyl, -OR₃ or -NR₃R₄;

30

R₃ is hydrogen or C1-C6 alkyl;

R₄ is hydrogen or C1-C6 alkyl;

R₅ is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;

R₆ is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;

35

R₇ is hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;

- R_8 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4 or cyano;
 R_9 is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4 or cyano;
 5 R_{10} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4 or cyano;
 R_{11} is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR_3R_4 or cyano;
 R_{12} is R_3 or $-C(O)R_2$;
 10 D is CR_8R_9 or is CR_8 when double bonded with G;
 G is $CR_{10}R_{11}$ or is CR_{10} when double bonded with D or is CR_{10} when double bonded with X when X is carbon;
 X is carbon or nitrogen;
 Y is nitrogen or $-CR_7$;
 15 W is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and in which:
 - one carbon atom is replaced by a carbonyl or $S(O)_m$; and
 - one to four carbon atoms may optionally be replaced by oxygen, nitrogen
 20 or NR_{12} , $S(O)_m$, carbonyl, and such ring may be further substituted by 1 to 8 R_6 groups;
 Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 R_5 groups or a phenyl ring, which may be substituted by 1 to 4 R_5 groups;
 m is an integer from 0 to 2.

25

The compounds of the present invention may be in the form of and/or may be administered as a pharmaceutically acceptable salt. For a review on suitable salts see Berge et al, J. Pharm. Sci., 1977, 66, 1-19.

30

Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid or base as appropriate. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent.

35

Suitable addition salts are formed from acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, piruvate, oxalate, oxaloacetate, trifluoroacetate, saccharate, benzoate, methansulphonate, ethanesulphonate, benzenesulphonate, p-toluensulphonate, methanesulphonic, ethanesulphonic, p-toluenesulphonic, and
 40 isethionate.

Pharmaceutically acceptable base salts include ammonium salts, alkali metal salts such as those of sodium and potassium, alkaline earth metal salts such as those of calcium

and magnesium and salts with organic bases, including salts of primary, secondary and tertiary amines, such as isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexyl amine and N-methyl-D-glucamine.

- 5 Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate". Solvates of the compound of the invention are within the scope of the invention.

10

In addition, prodrugs are also included within the context of this invention.

As used herein, the term "prodrug" means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and in D. Fleisher, S. Ramon and H. Barbra "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs", Advanced Drug Delivery Reviews (1996) 19(2) 115-130, each of which are incorporated herein by reference.

15

20

Prodrugs are any covalently bonded carriers that release a compound of structure (I) in vivo when such prodrug is administered to a patient. Prodrugs are generally prepared by modifying functional groups in a way such that the modification is cleaved, either by routine manipulation or in vivo, yielding the parent compound. Prodrugs include, for example, compounds of this invention wherein hydroxy, amine or sulfhydryl groups are bonded to any group that, when administered to a patient, cleaves to form the hydroxy, amine or sulfhydryl groups. Thus, representative examples of prodrugs include (but are not limited to) acetate, formate and benzoate derivatives of alcohol, sulfhydryl and amine functional groups of the compounds of structure (I). Further, in the case of a carboxylic acid (-COOH), esters may be employed, such as methyl esters, ethyl esters, and the like. Esters may be active in their own right and /or be hydrolysable under *in vivo* conditions in the human body. Suitable pharmaceutically acceptable *in vivo* hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt.

25

30

35

With regard to stereoisomers, the compounds of structure (I) may have one or more asymmetric carbon atom and may occur as recemates, racemic mixtures and as individual enantiomers or diastereomers. All such isomeric forms are included within the present invention, including mixtures thereof.

40

Where a compound of the invention contains an alkenyl or alkenylene group, cis (E) and trans (Z) isomerism may also occur. The present invention includes the individual

stereoisomers of the compound of the invention and, where appropriate, the individual tautomeric forms thereof, together with mixtures thereof.

5 Separation of diastereoisomers or cis and trans isomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of the agent may also be prepared from a corresponding optically pure intermediate or by resolution, such as H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable
10 optically active acid or base, as appropriate.

Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a
15 complex with water is known as a "hydrate". Solvates of the compounds of the invention are within the scope of the invention.

Furthermore, some of the crystalline forms of the compounds of structure (I) may exist as polymorphs, which are included in the present invention.
20

The term C1-C6 alkyl as used herein as a group or a part of the group refers to a linear or branched alkyl group containing from 1 to 6 carbon atoms; examples of such groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert butyl, pentyl or hexyl.

25 The term C3-C7 cycloalkyl group means a non aromatic monocyclic hydrocarbon ring of 3 to 7 carbon atom such as, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl; while unsaturated cycloalkyls include cyclopentenyl and cyclohexenyl, and the like.

30 The term halogen refers to a fluorine, chlorine, bromine or iodine atom.

The term halo C1-C6 alkyl, or halo C1-C2 alkyl means an alkyl group having one or more carbon atoms and wherein at least one hydrogen atom is replaced with halogen such as for example a trifluoromethyl group and the like.
35

The term C1-C6 thioalkyl may be a linear or a branched chain thioalkyl group, for example thiomethyl, thioethyl, thiopropyl, thioisopropyl, thiobutyl, thiosec-butyl, thio*tert*-butyl and the like.

40 The term C2-C6 alkenyl defines straight or branched chain hydrocarbon radicals containing one or more double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl or 3-hexenyl and the like.

The term C1-C6 alkoxy group may be a linear or a branched chain alkoxy group, for example methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy or methylprop-2-oxy and the like.

5

The term halo C1-C6 alkoxy group may be a C1-C6 alkoxy group as defined before substituted with at least one halogen, preferably fluorine, such as OCHF₂, or OCF₃.

10

The term C2-C6 alkynyl defines straight or branched chain hydrocarbon radicals containing one or more triple bond and having from 2 to 6 carbon atoms including acetylenyl, propynyl, 1-butylnyl, 1-pentylnyl, 3-methyl-1-butylnyl and the like.

The term aryl means an aromatic carbocyclic moiety such as phenyl, biphenyl or naphthyl.

15

The term heteroaryl means an aromatic heterocycle ring of 5 to 10 members and having at least one heteroatom selected from nitrogen, oxygen and sulfur, and containing at least 1 carbon atom, including both mono-and bicyclic ring systems.

20

Representative heteroaryls include (but are not limited to) furyl, benzofuranyl, thiophenyl, benzothiophenyl, pyrrolyl, indolyl, isoindolyl, azaindolyl, pyridyl, quinoliny, isoquinoliny, oxazolyl, isooxazolyl, benzoxazolyl, pyrazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isothiazolyl, pyridaziny, pyrimidinyl, pyraziny, triaziny, cinnoliny, phthalaziny, triazolyl, tetrazolyl, quinazolinyl, and benzodioxolyl.

25

The term 5-6 membered heterocycle means, according to the above definition, a 5-6 monocyclic heterocyclic ring which is either saturated, unsaturated or aromatic, and which contains from 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, and wherein the nitrogen and sulfur heteroatoms may be optionally oxidized, and the nitrogen heteroatom may be optionally quaternized. Heterocycles include heteroaryls as defined above. The heterocycle may be attached via any heteroatom or carbon atom.

30

Thus, the term include (but are not limited to) morpholinyl, pyridinyl, pyraziny, pyrazolyl, thiazolyl, triazolyl, imidazolyl, oxadiazolyl, oxazolyl, isoxazolyl, pyrrolidinonyl, pyrrolidinyl, piperidinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl,

35

tetrahydrothiopyranyl, and the like.

The term W defines a 4-8 membered ring, which may be saturated or may contain from one to three double bonds, and in which:


- one carbon atom is replaced by a carbonyl or S(O)_m; and

40

- one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR₁₂, S(O)_m, carbonyl, and such ring may be further substituted by 1 to 8 R₆ groups;

The 4-8 membered ring means a 4-8 monocyclic carbocyclic ring which is either saturated, or unsaturated or aromatic and one to four carbon atoms may be replaced by a heteroatom as defined above. The carbocycle may be attached via any heteroatom or carbon atom. Thus, the term include (but are not limited to): cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, aziridinyl, azetidiny, pyrrolidinyl, piperidinyl, imidazolidinyl, morpholinyl, piperazinyl, hydantoinyl, valerolactamyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydropyridinyl, tetrahydropyrimidinyl, tetrahydrothiophenyl, tetrahydrothiopyranyl, 1,3-dihydro-2H-imidazol-2-one, imidazolidin-2-one, tetrahydropyrimidin-2(1H)-one, 2,5-dihydro-1,2,5-thiadiazole 1-oxide, 1,2,5-thiadiazolidine 1-oxide, 2,5-dihydro-1,2,5-thiadiazole 1,1-dioxide, 1,2,6-thiadiazinane 1-oxide, pyrrolidin-2-one, 2,5-dihydro-1,2,5-thiadiazolidine 1,1-dioxide, 1,3-oxazolidin-2-one derivative, isothiazolidine 1,1-dioxide, 2(1*H*)-pyridinone, 3(2*H*)-pyridazinone, 2,3-piperazinedione and the like.

Representative ring of the W definition include, but are not limited to, the following structure and derivatives:



in which:

- W1 represents a 1,3-dihydro-2H-imidazol-2-one derivative;
- W2 represents a imidazolidin-2-one derivative;
- W3 represents a tetrahydropyrimidin-2(1H)-one derivative;
- W4 represents a 2,5-dihydro-1,2,5-thiadiazole 1-oxide derivative;
- W5 represents a 1,2,5-thiadiazolidine 1-oxide derivative;
- W6 represents a 2,5-dihydro-1,2,5-thiadiazole 1,1-dioxide derivative;
- W7 represents a 1,2,6-thiadiazinane 1-oxide derivative;
- W8 represents a 1,2,6-thiadiazinane 1,1-dioxide derivative;
- W9 represents a pyrrolidin-2-one derivative;

W10 represents a 2,5-dihydro-1,2,5-thiadiazolidine 1,1-dioxide derivative;

W11 represents a 1,3-oxazolidin-2-one derivative;

W12 represents a isothiazolidine 1,1-dioxide derivative;


W13 represents a 2(1H)-pyridinone derivative;

5 W14 represents a 3(2H)-pyridazinone;

W15 represents a 2,3-piperazinedione derivative;

and q is an integer from 0 to 4, n is an integer from 0 to 6, p is an integer from 0 to 3 and m, R6 and R12 are defined as above.

10 The compounds of formula (II) and (IIa) are representatives of the present invention.



(II)

(IIa)

In particular they correspond to compounds (I) in which X is nitrogen or carbon and R, R1, Y, Z, W, D, and G have the meanings as previously defined.

The compounds of formula (II) are specific representatives of the present invention.


15 Particularly preferred are the compounds of formula (II), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13, and W14.

Equally preferred are the compounds of formula (II), in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.

20 Equally preferred are the compounds of formula (II), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13, and W14 and in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.

Examples of compounds of formula (II) are reported in the Experimental Part.


25 The compounds of formula (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (Ili), (III), (IIIm), (IIIn), (IIo), (IIp) and (IIq) are illustratives of the compounds of formula (II).



(IIb)

(IIc)

(IId)




They correspond to the compounds of formula (II), depending on the meaning of X and Y, and where R, R₁, R₇, Z, W, D, and G have the meanings as previously defined.

Particularly preferred are the compounds of formula (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (Iii), (III), (IIIm), (IIIn), (IIo), (IIp) and (IIq) in which W is selected in the group consisting from: W₁, W₂, W₃, W₉, W₁₀, W₁₁, W₁₂, W₁₃, and W₁₄.


Equally preferred are the compounds of formula (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (Iii), (III), (IIIm), (IIIn), (IIo), (IIp) and (IIq) in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.

Equally preferred are the compounds of formula (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (IIh), (Iii), (III), (IIIm), (IIIn), (IIo), (IIp) and (IIq) in which W is selected in the group consisting from: W₁, W₂, W₃, W₉, W₁₀, W₁₁, W₁₂, W₁₃, and W₁₄ and in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.


The compounds of formula (IIr), (IIs) and (IIt), which correspond to the compounds of formula (II) in which D and G are -CH₂ are preferred.



(IIr)



(IIIs)




(IIIt)

Particularly preferred are the compounds of formula (IIr), (IIIs) and (IIIt), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13, and W14. Equally preferred are the compounds of formula (IIr), in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.

Equally preferred are the compounds of formula (IIr), (IIIs) and (IIIt), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13, and W14 and in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.


In particular, the compounds of formula (III) are representatives of the compounds of formula (II).




(III)

They correspond to the compounds of formula (II), in which Z is a pyrazolyl derivative and R, R1, R5, Y, W, D, m and G have the meanings as previously defined and the dashed line may represent a double bond.


The compounds of formula (IIIa), (IIIb), (IIIc) and (IIId) are specific representatives of the compounds of formula (III).




(IIIa)



(IIIb)



(IIIc)




(IIId)

They correspond to the compounds of formula (III) depending on the meaning of Y, in which R, R₁, R₅, R₇, R₈, R₉, R₁₀, R₁₁, W, D, m and G have the meanings as previously defined.

- 5 Particularly preferred are the compounds of formula (IIIa), (IIIb), (IIIc) and (IIId), in which W is selected in the group consisting from: W₁, W₂, W₃, W₉, W₁₀, W₁₁, W₁₂, W₁₃, and W₁₄ and R, R₁, R₅, R₇, R₈, R₉, R₁₀, R₁₁, m, have the meanings as previously defined.

In particular, the compounds of formula (IV) are representatives of the compounds of

- 10 formula (III).




(IV)


They correspond to compounds of formula (III), in which W corresponds to a W₂ derivative and R, R₁, R₅, R₆, R₇, R₁₂, m, q, D and G have the meanings as previously defined and the dashed line may represent a double bond.

- 15


The compounds of formula (IVa), (IVb) and (IVc) are specific representatives of the compound of formula (IV)



(IVa)



(IVb)




(IVc)

They correspond to the compounds of formula (IV), in which R_7 is hydrogen and R , R_1 , R_5 , R_6 , R_7 , R_{12} , m , q , D and G have the meanings as previously defined and the dashed line may represent a double bond.

5


The compounds of formula (V) are equally representatives of the compounds of formula (II).



(V)


- 10 They correspond to the compounds of formula (II), in which W is a W_2 derivative and Z , R , R_1 , R_6 , q , Y , W , D and G have the meanings as previously defined and the dashed line may represent a double bond.

- 15 The compounds of formula (VI) are specific representatives of the compounds of formula (V), in which Y is $-CR_7$ and Z , R , R_1 , R_6 , R_7 , q , Y , W , D and G have the meanings as previously and the dashed line may represent a double bond.




(VI)


The compounds of formula (VIa), (VIb) and (VIc) are specific representatives of the compound of formula (VI)



(VIa)



(VIb)



(VIc)

They correspond to the compounds of formula (VI) in which R₇ is hydrogen and R, R₁, R₆, R₈, R₉, R₁₀, R₁₁, R₁₂, q, D and G have the meanings as previously defined and the dashed line may represent a double bond.

- 5 Particularly preferred are the compounds of formula (VIa), (VIb) and (VIc), in which Z is selected in a group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl and R, R₁, R₆, R₈, R₉, R₁₀, R₁₁, R₁₂, q, D and G have the meanings as previously defined.
- 10 Even more preferred embodiments of the invention include, but are not limited to, compounds of the formula (I), (IIb), (IIc), (IIId), (IIe), (IIIf), (IIIg), (IIH), (III), (IIIm), (IIIn), (IIIo), (IIIp), (IIlq), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (V), (VI), (VIa), (VIb), (VIc) wherein:
- 15 R₁ is C1-C3 alkyl group or halo C1-C3 alkyl group, preferably methyl or trifluoromethyl;
R₇ is hydrogen;
R₈, (R₉), R₁₀ (R₁₁) are hydrogen;
R is an aryl group selected from: 2,4-dichlorophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-trifluoromethylphenyl, 2-chloro-4-methoxyphenyl, 2,4,5-trimethylphenyl, 2,4-
- 20 dimethylphenyl, 2-methyl-4-methoxyphenyl, 2-methyl-4-ethoxyphenyl, 2-methyl-4-isopropoxyphenyl, 2-methyl-4-hydroxyphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-trifluoromethylphenyl, 2,4-dimethoxyphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-chlorophenyl, 3-methoxy-4-chlorophenyl, 2,5-dimethoxy-4-chlorophenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-
- 25 isopropylphenyl, 2-methoxy-4-methylphenyl, 2-trifluoromethyl-4-chlorophenyl, 2,4-bis-trifluoromethylphenyl, 2-trifluoromethyl-4-methylphenyl, 2-trifluoromethyl-4-methoxyphenyl, 2-difluoromethyl-4-methoxyphenyl, 2-bromo-4-isopropylphenyl, 2-methyl-4-cyanophenyl, 2-chloro-4-cyanophenyl, 2-trifluoromethyl-4-cyanophenyl, 2-trifluoromethoxy-4-cyanophenyl, 2-ethyl-4-cyanophenyl, 2-methyl-4-trifluoromethoxy-
- 30 phenyl, 4-methyl-6-dimethylaminopyridin-3-yl, 2,6-bismethoxy-pyridin-3-yl, 2-methyl-6-methoxy-pyridin-3-yl, 2-trifluoromethyl-6-methoxy-pyridin-3-yl 3-chloro-5-trichloromethyl-pyridin-2-yl, 2-methyl-4-(pyrazol-1-yl)-phenyl, 2-methoxy-4-(pyrazol-1-yl)-phenyl, 2,4,6-trimethoxyphenyl, 2-methyl-4,5-benzodioxolyl, 2-methyl-3,4-benzodioxolyl.
- 35 Preferred compounds according to the invention are:

- 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one (compound 1-1);
1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-3-methylimidazolidin-2-one (compound 1-2);
5 1-{1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one (compound 1-3);
1-(1-{1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-4);
1-{1-[1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone (compound 1-5);
10 1-Acetyl-3-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-5);
1-Acetyl-3-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-6);
15 1-(1-{1-[4-(Ethoxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-7);
1-[1-(6-Methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone (compound 1-8);
1-[1-(6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone (compound 1-9);
20 3-Methyl-4-{6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile (compound 1-10);
1-(1-{6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-11);
25 4-{6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-(trifluoromethyl)benzonitrile (compound 1-12);
1-(1-{1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-13);
4-{6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-[(trifluoromethyl)oxy]benzonitrile (compound 1-14);
30 3-Ethyl-4-{6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile (compound 1-15);
1-(1-{6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-16);
35 1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone (compound 1-17);
1-(1-{6-Methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-18);
1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone (compound 1-19);
40 1-(6-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyridinyl)-2-imidazolidinone (compound 1-20);


- 1-(4-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyrimidinyl)-2-imidazolidinone (compound 1-21);
1-(2-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-4-pyrimidinyl)-2-imidazolidinone (compound 1-22);
5 1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-23);
1-(1-{2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-24);
1-(3-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}phenyl)-2-imidazolidinone (compound 1-25);
10 1-(5-Methyl-1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-26);
1-[1-(1-{4-[(difluoromethyl)oxy]-2-methylphenyl}-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone (compound 1-27);
15 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}pyrrolidin-2-one (compound 2-1);
1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}tetrahydropyrimidin-2(1H)-one (compound 3-1);
3-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,3-oxazolidin-2-one (compound 4-1);
20 Methyl 5-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide (compound 5-1);
4-[3-(1,1-Dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (compound 5-2).
25 4-[3-(1,1-Dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (compound 6-1);
3-Methyl-1-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2(1H)-pyridinone (compound 7-1);
30 2-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-3(2H)-pyridazinone (compound 8-1);
1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,3-dihydro-2H-imidazol-2-one (compound 9-1);
1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 10-1);
35 1-(6-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-3-pyridinyl)-2-imidazolidinone (compound 11-1);
1-{1-[7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-1H-pyrazol-3-yl}-2-pyrrolidinone (compound 11-2).

40

In general, the compounds of structure (I) may be made according to the organic synthesis techniques known to those skilled in this field, as well as by the representative methods set forth in the Examples.

- 5 Compounds of formula (I), and salts and solvates thereof, may be prepared by the general methods outlined hereinafter. In the following description, the groups R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, R₉, R₁₀, R₁₁, R₁₂, m, n, q, D, G, Z, W, X, Y have the meanings as previously defined for compounds of formula (I) unless otherwise stated.
- 10 Compounds of formula (II) may be conveniently prepared, starting from compounds of formula (VII), according to the following Scheme 1:

Scheme 1



stands for conversion of the leaving group L, selected in a group consisting from: halogen or reactive residue of sulphonic acid (e.g. mesylate, tosylate), preferably chloride, in the compounds (VIII), by reaction with the suitable Z-W derivative;

step b stands for reduction of the ester group (E) with a suitable reducing agent (such as DIBAL-H) to hydroxy group of compounds (IX);

step c stands for suitable protection of an NH group eventually present in W group with a P group, such as a p-methoxybenzyl group;

step d stands for oxidation of the hydroxy group with a suitable oxidizing agent (such as Dess-Martin periodinane) to the aldehyde group of compounds (XI);

- steps e + f stands for formation of the aldehyde group of compounds (XIII) by Wittig reaction in the usual conditions, through formation of enol ether followed by acid hydrolysis (step f);
- 5 step g stands for the optional alkylation of the α position of the aldehyde by deprotonation with a suitable base (such as $\text{LiN}(\text{SiMe}_3)_2$), followed by the addition of a suitable alkylating agent (such as MeI) to form the alkylated aldehyde of compounds (XIV), (XV);
- 10 step h stands for the conversion of the aldehyde group by a Grignard reagent (such as MeMgBr) into an alcohol group of compounds (XVI) and (XVIII);
- step i stands for oxidation of the hydroxy group with a suitable oxidizing agent (such as Dess-Martin periodinane) to the ketone group of compounds (XVII);
- 15 step j stands for conversion of the hydroxy group in the suitable protecting group of compounds (XIX) (such as TBS: tert-butyldimethylsilyl);
- step k stands for a Buchwald coupling reaction with the suitable amine RNH_2 to give the compounds of formula (XX);
- 20 step l stands for the deprotection reaction to give the hydroxy group of compounds (XXI);
- step m stands for intramolecular cyclisation after conversion of the hydroxy group of compounds (XXI) in a suitable leaving group (such as bromide, by reaction with CBr_4 and PPh_3) to give the cyclized compounds (XXII);
- 25 step n stands for the deprotection reaction of the protected NH group eventually present in W group, to give final compounds (II);
- step o stands for oxidation by a suitable oxidating agent (such as DDQ) in order to give formation of the double bond of compounds (II), when D is CHR_8 and G is CHR_{10} .


30

Compounds of formula (VII) are known compounds or may be prepared according to known method in the literature.

35

Alternatively, compounds of formula (IIr) may be conveniently prepared, starting from compounds of formula (XXIII), in which R, R_1 , Z and W are defined as above, according to the following Scheme 2:

Scheme 2




in which:

- 5 step a' stands for the formation of the pyrrolidinone moiety of compounds (XXIV), which will form the cycle B present in the final compounds (IIr), by reacting the compounds (XXIII) with a reactive derivative of the butyric acid, such as 4-chlorobutyl chloride; followed by a cyclisation reaction in basic conditions (e.g. K⁺tBu⁻);
- 10 step b' stands for amidine formation by reacting the compounds (XXIV) with a 3-aminocrotonate derivative and POCl₃ when X₁ is oxygen; or stands for alkylation of the amidine formation by reacting the compound (XXIV) with a butynoate derivative, when X₁ is NH;
- 15 step c' stands for the cyclisation of the compounds (XXV) or (XXVa) in basic conditions (e.g. tBuOK) to give the hydroxy pyridine precursor of cycle A in the final compounds (IIr);
- step d' stands for the formation of a reactive derivative (i.e. a leaving group, Lg) of the hydroxy pyridine (for example selected in a group consisting of


- triflate, halogen, and mesylate) of compounds (XXVI) by reaction with, for example, triflic anhydride;
- 5 step e' stands for nucleophilic displacement of the leaving group of compounds (XXVII) to give the halogenated compounds (XXVIII), preferably iodinated or brominated compounds;
- 10 step f' stands for the arylation reaction with the suitable $-Z-W$ derivative by a metal catalysed coupling reaction (for example a Buchwald reaction or a Suzuki coupling) procedure to give the final compounds (IIr); such $-Z-W$ derivative may be suitably protected with a P group, as defined in Scheme 1,
- 15 step g' stands for activation of carbon 3 by the addition of an electron-withdrawing group (e.g. acylation to give an ester group such as acylation with diethyl carbonate to give the ethyl ester derivative, E);
- 20 step h' corresponds to step b)' when X1 is oxygen.
- 25 step i' stands for a metal-halogen exchange reaction (with a suitable base, such as *n*-BuLi) followed by a trans-metalation reaction with a suitable metalating agent (such as a trialkylborate or a trialkylstannyl chloride);
- 30 step j' stands for the cyclisation of the β -amidoester of formula (XXIVb) with a salt (e.g. hydrochloride) of a substituted amidine (such as acetamidine hydrochloride) in order to form the pyrimidine cycle A, when Y is N;
- 35 step m' stands for conversion of the hydroxy group into an halogen by the halogenation reaction carried out using, for example, treatment with $PO(Hal)_3$, wherein Hal is preferably chlorine.
- 40 In general, the starting compounds of formula (XXIII) are known compounds or may be prepared according to known methods in the literature.
- The process of Scheme 2 is particularly convenient for the preparation of compounds of general formula (IV), (V), (VI).
- 30 The compounds of general formula (XXIV), (XXIVb), (XXVI), (XXVII), (XXVIII), (XXIX) are novel intermediates useful for the preparation of the CRF antagonists object of the present invention or other CRF antagonists, which may be conveniently prepared using such intermediates. Representative CRF antagonists which may be prepared using the
- 35 above intermediates include, but are not limited to, those disclosed in the above cited Patent Applications: WO 95/10506, WO 95/33750, WO 02/08895 and WO 03/008412.
- 40 The above cited publications, including but not limited to patents and patent applications, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

In particular, the compounds of formula (XXVIA), corresponding to the compounds of formula (XXVI) when Y corresponds to a carbon atom, may exist in the tautomeric form (XXVIB).



5

The compounds of general formula (II) may be prepared in an alternative way according to the method described in the International Patent Application WO 02/088095, as illustrated in the following Scheme 3.



10

in which

step a)'' stands for reduction of the ester with a suitable reducing agent (such as DIBAL-H) to give compounds (XXXI);

step b)'' stands for conversion of the hydroxy group in the suitable protecting group of compounds (XXXII) (such as TBS: *tert*-butyldimethylsilyl);

step c)'' stands for a nucleophilic displacement reaction with the suitable amine RNH_2 to give the compounds of formula (XXXIII);

step d)'' stands for the deprotection reaction to give the hydroxy group of compounds (XXXIV);

step e)'' stands for intramolecular cyclisation after conversion of the hydroxy group of compounds (XXXIV) in a suitable leaving group (such as mesylate, by reaction with Et_3N and CH_3SO_2Cl) to give the cyclized compounds (XXXV);

step f'' stands for a metal mediated coupling reaction with a suitable Z-W derivative to give compounds

The starting material is already known in literature, as acid derivative (see Snider, Barry B.; Ahn, Yong; Foxman, Bruce M. Synthesis of the tricyclic triamine core of martinelline and martinellie acid. *Tetrahedron Letters* (1999), 40(17), 3339-3342).

When the -Z-W moiety of compounds of formula (I) is not a known compound already described in the literature, it may be prepared in analogy to the following Schemes.


The Schemes represent the preparation of specific derivatives of -Z-W moieties, sometimes without the presence of further substituents as defined above, in order to simplify the understanding of the chemical processes.

This does not limit at all the availability of such processes for the preparations of derivatives containing more substituents or linked to different moieties.

Examples of the following preparations can be found in the Experimental section.

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II) in which Z corresponds to a pyrazolyl derivative and W is a W2 derivative, for example 1-(1*H*-pyrazol-3-yl)imidazolidin-2-one (intermediate 8):

Scheme 4



in which


step a''' stands for the reaction of 3-aminopyrazole with chloroethyl isocyanate in DMF at 0°C;

step b''' stands for cyclisation reaction with KO^t-Bu in THF at r.t.;

step c''' stands for deprotection reaction by LiOH in MeOH/H₂O at 80°C.

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II) in which Z corresponds to a pyrazolyl derivative and W is a W9 derivative, for example of 1-(1*H*-pyrazol-3-yl)pyrrolidin-2-one (intermediate 10):

Scheme 5




in which

- step a^{iv} stands for reaction of 3-aminopyrazole with 4-chloro butyryl chloride in presence of K₂HPO₄, and in CH₂Cl₂;
- step b^{iv} stands for cyclisation reaction with NaH, in DMF, at r.t.;
- step c^{iv} stands for deprotection reaction by MeONa/MeOH, at r.t..

5

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II), in which Z corresponds to a pyrazolyl derivative and W is a W3 derivative, for example of 1-(1*H*-pyrazol-3-yl)tetrahydropyrimidin-2(1*H*)-one (intermediate 13)

Scheme 6



Intermediate 13

10

in which


- step a^v stands for the reaction of 3-aminopyrazole with chloropropyl isocyanate, in DMF, at 0°C;
- step b^v stands for cyclisation reaction with KO*t*-Bu, in THF, at r.t.;
- step c^v stands for deprotection reaction by LiOH, in MeOH/H₂O, at 80°C.

15

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II), in which Z corresponds to a pyridyl derivative and W is a W2 derivative, for example, protected 1-(6-bromo-2-pyridinyl)-2-imidazolidinone (intermediate 96).

20

Scheme 7



Intermediate 96

in which


- step a^{vi} stands for the condensation of 1-chloro-2-isocyanatoethane with 6-bromo-2-pyridinamine to give the urea;
- step b^{vi} stands for the cyclisation reaction in basic conditions (*t*-BuOK in THF);
- step c^{vi} stands for protection of the urea NH group with a suitable protecting group (such as a *para*-methoxybenzyl group).

30

Scheme for the synthesis of derivatives suitable for the preparation of the compounds of formula (II), in which Z corresponds to a pyrimidinyl derivative and W is a W2 derivative,

for example, protected 1-(4-bromo-2-pyrimidinyl)-2-imidazolidinone (intermediate 102) and protected 1-(2-bromo-4-pyrimidinyl)-2-imidazolidinone (intermediate 104).

Scheme 8



5

in which
step a^{vii}

stands for the condensation of 1-chloro-2-isocyanatoethane with 4-methoxybenzyl amine to give the urea derivative;

step b^{vii}

stands for the cyclisation reaction in basic conditions (*t*-BuOK in THF);

10

step c^{vii}

stands for the nucleophilic substitution of the cyclic urea on 2,4-dichloropyrimidine in basic conditions (such as NaH in DMF);

step d^{vii}


stands for exchange of the chloride group into a bromide group by reaction with TMSBr (trimethylsilyl bromide).

15

Scheme for the synthesis of the compounds of formula (II), in which Z is a triazolyl or pyrazolyl derivative. In particular the synthesis of the compounds (IIr) in which Z is triazolyl or pyrazolyl derivative and W is a W2 derivative, 1-(1*H*-1,2,4-triazol-3-yl)-2-imidazolidinone substituent (R₅=H, X=N) and 1-(5-methyl-1*H*-pyrazol-3-yl)-2-imidazolidinone substituent (R₅=Me, X= C)

20

Scheme 9



in which

step a^{viii}

stands for the arylation reaction with a 3-aminoheterocycle by a metal catalysed coupling reaction (for example a Buchwald reaction) procedure;

5 step b^{viii}


stands for the condensation of 1-chloro-2-isocyanatoethane with the amino heterocycle to give the urea;

step c^{viii}

stands for the cyclisation reaction in basic conditions (*t*-BuOK in THF).

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II), in which Z corresponds to a phenyl derivative and W is a W2 derivative, for example, 1-phenyl-2-imidazolidinone substituent.

Scheme 10



15 in which

step a^{ix}

stands for step f)' as defined in Scheme 2 (Suzuki coupling with the boronic acid derivative);

step b^{ix}


stands for the condensation of 1-chloro-2-isocyanatoethane with 6-bromo-2-pyridinamine to give the urea;

20 step c^{ix}

stands for the cyclisation reaction in basic conditions (*t*-BuOK in THF).

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II), in which Z corresponds to a pyrazolyl derivative and W is a W11, W13, or a W14 derivative, for example, 3-(1*H*-pyrazol-3-yl)-1,3-oxazolidin-2-one (intermediate 16), 3-methyl-1-(1*H*-pyrazol-3-yl)-2(1*H*)-pyridinone (intermediate 26) and 2-(1*H*-pyrazol-3-yl)-3(2*H*)-pyridazinone (intermediate 28).

Scheme 11



Intermediates 16, 26 and 28

In which

step a^x


stands for the protection of 3-bromopyrazole with a suitable protecting group (such as a trityl group);

step b^xstands for the copper catalysed coupling reaction between the protected bromopyrazole and 1,3-oxazolidin-2-one, 3-methyl-2(1*H*)-pyridinone and 3(2*H*)-pyridazinone, respectively;step c^x

stands for the deprotection reaction to give the desired bicyclic derivative.

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (IIr), in which Z corresponds to a pyrazolyl derivative and W is a W10 derivative, for example, 2-(1*H*-pyrazol-3-yl)-1,2,5-thiadiazolidine 1,1-dioxide substituent.

Scheme 12



in which

step a^{xi}

stands for alkylation of the amino group using ethyl 2-bromoacetate as an alkylating agent;


step b^{xi}stands for reduction of the ester group into the alcohol, using a suitable reducing agent (such as LiAlH₄);step c^{xi}

stands for cyclisation of the amino alcohol using Burgess' reagent ((methoxycarbonylsulfamoyl)triethylammonium hydroxide inner salt) to give the cyclic sulfonyleurea;

step d^{xi}stands for the deprotection of the sulfonyleurea using basic conditions (such as NaOH in a CH₂Cl₂/MeOH mixture).

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (II), in which Z corresponds to a pyrazolyl derivative and W is a W12 derivative, for example, 2-(1*H*-pyrazol-3-yl)isothiazolidine 1,1-dioxide substituent.

5 Scheme 13



in which

step a^{xii}


stands for alkylation of the amino group using 1,2-oxathiolane 2,2-dioxide as an alkylating agent;

step b^{xii}

stands for the cyclisation step mediated by the addition of POCl₃.

Scheme for the synthesis of a derivative suitable for the preparation of the compounds of formula (IIr), in which Z corresponds to a pyrazolyl derivative and W is a W1 derivative, for example, 1-(1*H*-pyrazol-3-yl)-1,3-dihydro-2*H*-imidazol-2-one substituent.

Scheme 14



in which

step a^{xiii}

stands for the preparation of the phenyl carbamate using phenyl chloroformate;

step b^{xiii}

stands for the addition of aminoacetaldehyde dimethyl acetal to the activated carbamate group;

step c^{xiii}

stands for the cyclisation reaction in the presence of an acid (such as HCl) to give the 2*H*-imidazol-2-one substituent.

The R group present in compounds of formula (I) is generally a known compound.

When such R group is not a compound already described in the literature, it may be prepared in analogy to the following Schemes.


The Schemes represent the preparation of specific derivatives of R groups, sometimes without the presence of further substituents J as defined above, in order to simplify the understanding of the chemical processes.

This does not limit at all the availability of such processes for the preparations of R groups containing more J substituents.

Examples of the following preparations can be found in the Experimental section.

Scheme for the synthesis of 2-(difluoromethyl)-4-(methyloxy)aniline.

5 Scheme 15



10 in which


step a^{xiv} stands for reduction of the acid group with a suitable reducing agent (such as cyanuric chloride/NMM/NaBH₄);

step b^{xiv} stands for oxydation of the alcohol to the aldehyde with a suitable oxidizing agent (such as Dess-Martin periodinane);

15 step c^{xiv} stands for difluorination of the aldehyde using a suitable fluorinating agent (such as DAST: (diethylamino)sulfur trifluoride);

step d^{xiv} stands for the reduction of the nitro group with a suitable reducing agent (such as H₂, catalysed with palladium on activated charcoal).

20 Scheme for the preparation of 2-(Methyloxy)-4-(1*H*-pyrazol-1-yl)aniline (intermediate 88).
Scheme 16




Intermediate 88

In which

25 step a^{xv} stands for the copper catalysed coupling reaction between 4-bromo-2-(methyloxy)aniline and pyrazole.

Compounds of formula (II_n) may be conveniently prepared according to the following Scheme 4 and where the starting material was prepared according to WO 02/088095 A1

30 Scheme 17



in which

step a^{xvi} stands for the cyclisation of the β -ketoester of formula (XXIVb) with a salt (e.g. hydrochloride) of a substituted amidine (such as acetamidine hydrochloride);

5 step b^{xvi} stands for the transformation of the hydroxy group of formula (XXVIb) into a suitable leaving group, selected in a group consisting from: halogen or reactive residue of sulphonic acid (e.g. mesylate, tosylate), preferably chloride;

10 step c^{xvi} stands for conversion of the leaving group L in the compounds (XXVIIIb), by reaction with the suitable -Z-W derivative;

step d^{xvi} corresponds to previous step o in Scheme 1.

15 In particular, when J is a group -OCHF₂, this can be introduced directly in the R group by methods already known in the literature or, eventually, the group -OCH₃ may be deprotected using one of the methods listed in the Greene's reference cited below. Then, the hydroxyl group may be alkylated by using a suitable fluoroalkylating agent, such as CF₂Br₂, as exemplified for Intermediate 125.

20 Those skilled in the art will appreciate that in the preparation of the compound of the invention or a solvate thereof it may be necessary and/or desirable to protect one or more sensitive groups in the molecule to prevent undesirable side reactions. Suitable protecting groups for use according to the present invention are well known to those skilled in the art and may be used in a conventional manner. See, for example, "Protective groups in organic synthesis" by T.W. Greene and P.G.M. Wuts (John Wiley & sons 1991) or
25 "Protecting Groups" by P.J. Kocienski (Georg Thieme Verlag 1994). Examples of suitable amino protecting groups include acyl type protecting groups (e.g. formyl, trifluoroacetyl, acetyl), aromatic urethane type protecting groups (e.g. benzyloxycarbonyl (Cbz) and substituted Cbz), aliphatic urethane protecting groups (e.g. 9-fluorenylmethoxycarbonyl (Fmoc), t-butyloxycarbonyl (Boc), isopropylloxycarbonyl, cyclohexyloxycarbonyl) and alkyl
30 type protecting groups (e.g. benzyl, trityl, chlorotriyl). Examples of suitable oxygen protecting groups may include for example alkyl silyl groups, such as trimethylsilyl or tert-butyldimethylsilyl; alkyl ethers such as tetrahydropyranyl or tert-butyl; or esters such as acetate.

35 Pharmaceutical acceptable salts may also be prepared from other salts, including other pharmaceutically acceptable salts, of the compound of formula (I) using conventional methods.

40 The compounds of formula (I) may readily be isolated in association with solvent molecules by crystallisation or evaporation of an appropriate solvent to give the corresponding solvates.

When a specific enantiomer of a compound of general formula (I) is required, this may be obtained for example by resolution of a corresponding enantiomeric mixture of a compound of formula (I) using conventional methods. Thus the required enantiomer may be obtained from the racemic compound of formula (I) by use of chiral HPLC procedure.

5

The subject invention also includes isotopically-labelled compounds, which are identical to those recited in formula (I) and following, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention and pharmaceutically acceptable salts thereof include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulphur, fluorine, iodine, and chlorine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I and ^{125}I .

10

Compounds of the present invention and pharmaceutically acceptable salts of said compounds that contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of the present invention. Isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as ^3H , ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., ^3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. ^{11}C and ^{18}F isotopes are particularly useful in PET (positron emission tomography), and ^{125}I isotopes are particularly useful in SPECT (single photon emission computerized tomography), all useful in brain imaging. Further, substitution with heavier isotopes such as deuterium, i.e., ^2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of formula I and following of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

20

25

30

The CRF receptor antagonists of the present invention demonstrate activity at the CRF receptor site and may be used in the treatment of conditions mediated by CRF or CRF receptors.

35

The effectiveness of a compound as a CRF receptor antagonist may be determined by various assay methods. Suitable CRF antagonists of this invention are capable of inhibiting the specific binding of CRF to its receptor and antagonizing activities associated with CRF. A compound of structure (I) may be assessed for activity as a CRF antagonist by one or more generally accepted assays for this purpose, including (but not limited to) the assays disclosed by DeSouza et al. (J. Neuroscience 7: 88,1987) and Battaglia et al. (Synapse 1: 572,1987).

40

The CRF receptors-binding assay was performed by using the homogeneous technique of scintillation proximity (SPA). The ligand binds to recombinant membrane preparation expressing the CRF receptors which in turn bind to wheatgerm agglutinin coated SPA beads. In the Experimental Part will be disclosed the details of the experiments.

5

With reference to CRF receptor binding affinities, CRF receptor antagonists of this invention have a K_i less than 10 μm .

10

Compounds of the invention are useful in the treatment of central nervous system disorders where CRF receptors are involved. In particular in the treatment or prevention of major depressive disorders including bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, the treatment of anxiety and the treatment of panic disorders. Other mood disorders encompassed within the term major depressive disorders include dysthymic disorder with early or late onset and with or without atypical features, neurotic depression, post traumatic stress disorders, post operative stress and social phobia; dementia of the Alzheimer's type, with early or late onset, with depressed mood; vascular dementia with depressed mood; mood disorders induced by alcohol, amphetamines, cocaine, hallucinogens, inhalants, opioids, phencyclidine, sedatives, hypnotics, anxiolytics and other substances; schizoaffective disorder of the depressed type; and adjustment disorder with depressed mood. Major depressive disorders may also result from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion, etc.

15

20

25

Compounds of the invention are also useful in the treatment or prevention of schizophrenic disorders including paranoid schizophrenia, disorganised schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, residual schizophrenia.

30

35

40

Compounds of the invention are useful as analgesics. In particular they are useful in the treatment of traumatic pain such as postoperative pain; traumatic avulsion pain such as brachial plexus; chronic pain such as arthritic pain such as occurring in osteo-, rheumatoid or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathy, AIDS related neuropathy, occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, reflex sympathetic dystrophy, phantom limb pain; various forms of headache such as migraine, acute or chronic tension headache, temporomandibular pain, maxillary sinus pain, cluster headache; odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; nerve entrapment pain; sport's injury pain; dysmenorrhoea; menstrual pain; meningitis; arachnoiditis; musculoskeletal pain; low back pain e.g. spinal stenosis; prolapsed disc; sciatica; angina; ankylosing spondylitis; gout; burns; scar pain; itch; and thalamic pain such as post stroke thalamic pain.

Compounds of the invention are also useful for the treatment of dysfunction of appetite and food intake and in circumstances such as anorexia, anorexia nervosa and bulimia.

- 5 Compounds of the invention are also useful in the treatment of sleep disorders including dysomnia, insomnia, sleep apnea, narcolepsy, and circadian rhythmic disorders.

Compounds of the invention are also useful in the treatment or prevention of cognitive disorders. Cognitive disorders include dementia, amnesic disorders and cognitive
10 disorders not otherwise specified.

Furthermore compounds of the invention are also useful as memory and/or cognition enhancers in healthy humans with no cognitive and/or memory deficit.

- 15 Compounds of the invention are also useful in the treatment of tolerance to and dependence on a number of substances. For example, they are useful in the treatment of dependence on nicotine, alcohol, caffeine, phencyclidine (phencyclidine like compounds), or in the treatment of tolerance to and dependence on opiates (e.g. cannabis, heroin, morphine) or benzodiazepines; in the treatment of cocaine, sedative ipnotic, amphetamine
20 or amphetamine- related drugs (e.g. dextroamphetamine, methylamphetamine) addiction or a combination thereof.

Compounds of the invention are also useful as anti-inflammatory agents. In particular they are useful in the treatment of inflammation in asthma, influenza, chronic bronchitis and
25 rheumatoid arthritis; in the treatment of inflammatory diseases of the gastrointestinal tract such as Crohn's disease, ulcerative colitis, postoperative gastric ileus (POI), inflammatory bowel disease (IBD) and non-steroidal anti-inflammatory drug induced damage; inflammatory diseases of the skin such as herpes and eczema; inflammatory diseases of the bladder such as cystitis and urge incontinence; and eye and dental inflammation.

30 Compounds of the invention are also useful in the treatment of allergic disorders, in particular allergic disorders of the skin such as urticaria, and allergic disorders of the airways such as rhinitis.

- 35 Compounds of the invention are also useful in the treatment of emesis, i.e. nausea, retching and vomiting. Emesis includes acute emesis, delayed emesis and anticipatory emesis. The compounds of the invention are useful in the treatment of emesis however induced. For example, emesis may be induced by drugs such as cancer
40 chemotherapeutic agents such as alkylating agents, e.g. cyclophosphamide, carmustine, lomustine and chlorambucil; cytotoxic antibiotics, e.g. dactinomycin, doxorubicin, mitomycin-C and bleomycin; anti-metabolites, e.g. cytarabine, methotrexate and 5-fluorouracil; vinca alkaloids, e.g. etoposide, vinblastine and vincristine; and others such as

cisplatin, dacarbazine, procarbazine and hydroxyurea; and combinations thereof; radiation sickness; radiation therapy, e.g. irradiation of the thorax or abdomen, such as in the treatment of cancer; poisons; toxins such as toxins caused by metabolic disorders or by infection, e.g. gastritis, or released during bacterial or viral gastrointestinal infection; pregnancy; vestibular disorders, such as motion sickness, vertigo, dizziness and Meniere's disease; post-operative sickness; gastrointestinal obstruction; reduced gastrointestinal motility; visceral pain, e.g. myocardial infarction or peritonitis; migraine; increased intercranial pressure; decreased intercranial pressure (e.g. altitude sickness); opioid analgesics, such as morphine; and gastro-oesophageal reflux disease, acid indigestion, over-indulgence of food or drink, acid stomach, sour stomach, waterbrash/regurgitation, heartburn, such as episodic heartburn, nocturnal heartburn, and meal-induced heartburn and dyspepsia.

Compounds of the invention are of particular use in the treatment of gastrointestinal disorders such as irritable bowel syndrome (IBS); skin disorders such as psoriasis, pruritis and sunburn; vasospastic diseases such as angina, vascular headache and Reynaud's disease; cerebral ischaemia such as cerebral vasospasm following subarachnoid haemorrhage; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders related to immune enhancement or suppression such as systemic lupus erythematosus and rheumatic diseases such as fibrositis; and cough.

Compounds of the invention are useful for the treatment of neurotoxic injury which follows cerebral stroke, thromboembolic stroke, hemorrhagic stroke, cerebral ischemia, cerebral vasospasm, hypoglycemia, hypoxia, anoxia, perinatal asphyxia cardiac arrest.

The invention therefore provides a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for use in therapy, in particular in human medicine.

There is also provided as a further aspect of the invention the use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for use in the treatment of conditions mediated by CRF.

In an alternative or further aspect there is provided a method for the treatment of a mammal, including man, in particular in the treatment of condition mediated by CRF, comprising administration of an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or a solvate thereof.

While it is possible that, for use in therapy, a compound of the present invention may be administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation e. g. when the agent is in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

5 In a further aspect, the invention provides a pharmaceutical composition comprising at least one compound of the invention or a pharmaceutically acceptable derivative thereof in association with a pharmaceutically acceptable carrier and/or excipient. The carrier and/or excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

10 Accordingly, the present invention further provides a pharmaceutical formulation comprising at least one compound of the invention or a pharmaceutically acceptable derivative thereof, in association with a pharmaceutically acceptable carrier and/or excipient. The carrier and/or excipient must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

15 There is further provided by the present invention a process of preparing a pharmaceutical composition, which process comprises mixing at least one compound of the invention or a pharmaceutically acceptable derivative thereof, together with a pharmaceutically acceptable carrier and/or excipient.

20 The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier or excipient. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985).
25 The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as – or in addition to – the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

30 Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

35 There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or
40 parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it

should be able to remain stable during transit through the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

- 5 Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing
10 flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions
15 may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

For some embodiments, the agents of the present invention may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-
20 inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e. g. as a carrier, diluent or solubiliser.
25 Alpha-, beta and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

In a preferred embodiment, the agents of the present invention are delivered systemically (such as orally, buccally, sublingually), more preferably orally.
30

Hence, preferably the agent is in a form that is suitable for oral delivery.

It is to be understood that not all of the compounds need be administered by the same route. Likewise, if the composition comprises more than one active component, then
35 those components may be administered by different routes.

The compounds of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the
40 invention may be prepared by processes known in the art, for example see International Patent Application No. WO 02/00196 (SmithKline Beecham).

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically

acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium starch glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the composition may take the form of tablets or formulated in conventional manner.

The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative.

The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

The compounds of the invention may be formulated for topical administration in the form of ointments, creams, gels, lotions, pessaries, aerosols or drops (e.g. eye, ear or nose drops). Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Ointments for administration to the eye may be manufactured in a sterile manner using sterilised components.

Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents. Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, stabilising agents, solubilising agents or suspending agents. They may also contain a preservative.

The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

- 5 The compounds of the invention may also be formulated as depot preparations. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly
10 soluble derivatives, for example, as a sparingly soluble salt.

For intranasal administration, the compounds of the invention may be formulated as solutions for administration via a suitable metered or unitary dose device or alternatively as a powder mix with a suitable carrier for administration using a suitable delivery device.
15

A proposed dose of the compounds of the invention is 1 to about 1000mg per day. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient and the precise dosage will be ultimately at the discretion of the attendant physician or veterinarian. The dosage will also
20 depend on the route of administration and the particular compound selected.

Thus for parenteral administration a daily dose will typically be in the range of 1 to about 100 mg, preferably 1 to 80 mg per day. For oral administration a daily dose will typically be within the range 1 to 300 mg e.g. 1 to 100 mg.

25 EXAMPLES

In the Intermediates and Examples unless otherwise stated:

All temperatures refer to °C. Infrared spectra were measured on a FT-IR instrument.
30 Compounds were analysed by direct infusion of the sample dissolved in acetonitrile into a mass spectra operated in positive electro spray (ES⁺) ionisation mode. Proton Magnetic Resonance (¹H-NMR) spectra were recorded at 400 MHz, chemical shifts are reported in ppm downfield (d) from Me₄Si, used as internal standard, and are assigned as singlets (s), broad singlets (bs), doublets (d), doublets of doublets (dd), triplets (t), quartets (q) or
35 multiplets (m). A strategy comprising of NOE (Nuclear Overhauser Effect) correlation and/or ¹H,¹⁵N long range scalar correlations measurements has been implemented in order to allow elucidation of possible regio-isomers structure of compounds of the present invention. Proposed structures were verified by measurement of the vicinity in the space of key hydrogens, thus 1D Nuclear Overhauser difference spectra were used to measure
40 ¹H,¹H-dipole-dipole correlations.

In cases where NOE measurements were not conclusive, ¹H,¹⁵N long range scalar correlations were measured via ¹H,¹⁵N-HMBC experiments. A delay corresponding to an average long range scalar coupling 2,3J(¹H,¹⁵N) of 6Hz was set for optimal result.

Column chromatography was carried out over silica gel (Merck AG Darmstadt, Germany). The following abbreviations are used in the text: EtOAc = ethyl acetate, cHex = cyclohexane, CH₂Cl₂ = dichloromethane, Et₂O = diethyl ether, DMF = N,N'-dimethylformamide, DIPEA = N,N-diisopropylethylamine, DME = ethylene glycol dimethyl ether, MeOH = methanol, Et₃N = triethylamine, TFA = trifluoroacetic acid, THF = tetrahydrofuran, DIBAL-H = diisobutylaluminium hydride, DMAP = dimethylaminopyridine, LHMDs = lithiumhexamethyldisilazane, KO^tBu = potassium tert-butoxide, NMP = N-methyl-2-pyrrolidinone, MTBE = methyl-*tert*-butyl ether, IPA = isopropanol, DAST = (diethylamino)sulfur trifluoride, TMSBr = trimethylsilyl bromide, DDQ = 2,3-dichloro-5,6-dicyano-1,4-benzoquinone, SCX = strong cation exchanger, Tlc refers to thin layer chromatography on silica plates, and dried refers to a solution dried over anhydrous sodium sulphate, r.t. (RT) refers to room temperature.

Intermediate 1

1-(4-Methoxy-2-methylphenyl)pyrrolidin-2-one

To a solution of Et₃N (156 mL, 1 eq) and 4-methoxy-2-methylaniline (150 g, 1.09 mole) in anh. THF (2.4 L), in a 10 L reaction vessel, at 0°C, under N₂, was added dropwise a solution of 4-chlorobutyryl chloride (126 mL, 1 eq) in anh. THF (480 mL). The internal temperature was maintained at *circa* 10°C and the reaction mixture was stirred for 1.5 hr. It was cooled down to 0°C and KO^t-Bu 1M/THF (2.64 L, 2.4 eq) was added dropwise over a period of 1.5 hr, keeping the internal temperature <10°C. The reaction mixture was stirred at that temperature for 30 min. Water (1.5 L) was then added slowly (20 min) and the phases were separated. The organic layer was treated with conc. HCl (250 mL) and water (1.26 L) and the phases were separated. The combined aqueous layers were extracted with EtOAc (2.6 L) and the combined organic layers were washed with brine (2 L). The solvent was evaporated and the residue purified by flash chromatography (Biotage 150, EtOAc/cHex 8:2) to give the title compound as a pale brown solid (206 g, 92%).

NMR (¹H, CDCl₃): δ 7.05 (d, 1H), 6.79-6.72 (m, 2H), 3.75 (s, 3H), 3.64 (t, 2H), 2.18 (s, 6H).

MS (m/z): 206 [MH]⁺.

Intermediate 2

Ethyl 3-{[1-(4-methoxy-2-methylphenyl)pyrrolidin-2-ylidene]amino}but-2-enoate

To a solution of intermediate 1 (8.3 g, 40.49 mmol) in anh. 1,2-dichloroethane (100 mL), at r.t., under N₂, was added POCl₃ (7.5 mL, 2 eq) dropwise followed by ethyl 3-aminocrotonate (5.17 mL, 1 eq). The reaction mixture was heated at 60°C for 3.5 hr. It

was then cooled down to r.t. and neutralized to pH 7 by the careful addition of sat.aq. NaHCO₃. The neutralized solution was extracted with CH₂Cl₂ (3 x 50 mL). The combined organic extracts were washed with sat.aq. NaCl and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was used as such in the next

5 step (17.8 g).

Alternatively, to a solution of intermediate 91 (3 g, 14.7 mmol) in anh. THF (18 mL), at r.t., under N₂, was added ethyl-2-butynoate (2.23 mL, 1.3 eq). The reaction mixture was heated to reflux for 14 hr and was then cooled down to r.t.. The reaction mixture was evaporated to dryness. The crude oil was used as such in the next step (5.05 g).

10 MS (m/z): 317 [MH]⁺.

Intermediate 3

1-(4-Methoxy-2-methylphenyl)-6-methyl-1,2,3,7-tetrahydro-4H-pyrrolo[2,3-b]pyridin-4-one

15 A solution of intermediate 2 (17.8 g, 55 mmol) in anh. DMF (50 mL) was added dropwise to a suspension of NaH 60%/oil (4.5 g, 2 eq) in anh. DMF. The reaction mixture was heated at 100°C for 8 hr. More NaH 60%/oil (2.25 g, 1 eq) was added and the reaction mixture was heated for an additional 4 hr. It was cooled down to r.t. and carefully poured in sat.aq. NH₄Cl. The aqueous solution was extracted with CH₂Cl₂ (5 x 50 mL) and the

20 combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent was evaporated. The crude compound was purified by flash chromatography (Biotage 75, CH₂Cl₂/MeOH 95:5 → 80:20). The title compound was obtained as a brown oil (952 mg, 9%, two steps)

25 Alternatively, to a solution of intermediate 2 (2.46 g, 7.77 mmol) in anh. THF (10 mL), at r.t., under N₂, was added 1M *t*-BuOK/THF (15.6 mL, 2eq). The reaction mixture was heated to reflux and stirred for 6 hr. The solution was allowed to cool down to r.t., evaporated to *circa* 10 mL and diluted with MTBE (10 mL). The organic layer was extracted with water (10 mL), the organic phase discarded while the aqueous one was diluted with sat.aq. NH₄Cl (10 mL). The aqueous layer was extracted with CH₂Cl₂ (10 mL).

30 The combined organic extracts were evaporated to dryness and the crude product thus obtained was used as such in the next step (1.32 g).

NMR (¹H, DMSO-d₆): δ 9.8 (b, 1H), 7.08 (d, 1H), 6.80 (d, 1H), 6.75 (dd, 1H), 5.92 (s, 1H), 3.72 (s, 3H), 3.68 (t, 2H), 2.89 (t, 2H), 2.12 (s, 3H), 2.02 (s, 3H).

MS (m/z): 271 [MH]⁺.

Intermediate 4

1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl trifluoromethanesulfonate

40 To a solution of intermediate 3 (9.0 g, 33.3 mmol) in anh. CH₂Cl₂ (64 mL), at r.t., under N₂, was added pyridine (5.08 mL, 1.8 eq). The solution was cooled down to -20°C and triflic anhydride (5.9 mL, 1.1 eq) was added dropwise over 50 min. The temperature never

exceeded -10°C. The reaction mixture was allowed to warm up to ambient and stirred for 30 min. Sat.aq NaHCO₃ (31.2 mL) was added and the phases separated. The organic layer was further washed with water (31.2 mL) and concentrated to an oil, which was passed through a pad of silica gel (12.7 g, EtOAc/cHex 1/9). The crude product thus obtained was diluted with MTBE (38.1 mL) and washed twice with 10% HCl (63.5 mL). The combined aqueous layers were treated with conc. NH₄OH (38.1 mL) and extracted with CH₂Cl₂ (25.4 mL). The organic layer was further washed with 10% NaCl (12.7 mL) and evaporated to an oil. The oil was dissolved with IPA (38.1 mL) and seeded with authentic intermediate 4 (0.02 g). The suspension was stirred for 30 min. Water (38 mL) was added over 30 min and the mixture left standing for 1.5 hr. The suspension was filtered, the cake washed with a 1:1 mixture of IPA/water (12.7 mL), collected and dried in the oven at 40°C under high vacuum for 14 hr. The title compound was obtained as a pale yellow solid (3.8 g, 42%).

NMR (¹H, DMSO-d₆): δ 7.17 (d, 1H), 6.85 (d, 1H), 6.77 (dd, 1H), 6.40 (s, 1H), 3.89 (t, 2H), 3.73 (s, 3H), 3.16 (t, 2H), 2.17-2.11 (2s, 6H)

M/S (m/z): 403 [MH]⁺

Intermediate 5

4-Iodo-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine

To a solution of intermediate 4 (913 mg, 2.27 mmol) in anh. NMP (7 mL) was added KI (1.13 g, 3 eq) and the reaction mixture was stirred at 150°C for 18 hr. It was then cooled down to r.t. and diluted in water/sat.aq. NaCl. The aqueous phase was extracted with EtOAc (3 x 30 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a clear oil, which solidified upon standing (681 mg, 79%).

NMR (¹H, CDCl₃): δ 7.14 (d, 1H), 6.81-6.74 (m, 2H), 6.70 (s, 1H), 3.84 (t, 2H), 3.81 (s, 3H), 3.03 (t, 2H), 2.22 (s, 6H).

MS (m/z): 381 [MH]⁺.

Intermediate 6

N-(2-Chloroethyl)-3-({[(2-chloroethyl)amino]carbonyl}amino)-1H-pyrazole-1-carboxamide

To a solution of 3-aminopyrazole (500 mg, 6 mmol) in anh. DMF (3 mL), at 0°C, under N₂, was added 3-chloroethyl isocyanate (1.53 mL, 3 eq) and the reaction mixture was stirred at r.t. for 2 hr, after which the solvent was evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound (1.593 g, 89%).

NMR (¹H, DMSO): δ 9.20 (s, 1H), 8.26 (m, 1H), 8.10 (d, 1H), 7.25 (bs, 1H), 6.37 (d, 1H), 3.74 (m, 2H), 3.66 (m, 2H), 3.58 (m, 2H), 3.46 (m, 2H).

MS (m/z): 296 [MH]⁺.

Intermediate 7N-(2-Chloroethyl)-3-(2-oxoimidazolidin-1-yl)-1H-pyrazole-1-carboxamide

- 5 To a solution of intermediate 6 (100 mg, 0.34 mmol) in anh. THF (4 mL), at r.t., under N₂, was added KO^t-Bu (42 mg, 1.1 eq) and the reaction mixture was stirred for 2 hr. Water (0.5 mL) was added and the solvent was evaporated. The aqueous phase was diluted with H₂O and extracted with EtOAc (3 x 20 mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 8:2, then 9:1) to give the title compound as a white solid (39 mg, 44%)
- 10 NMR (¹H, DMSO): δ 8.18 (bt, 1H), 8.11 (d, 1H), 7.14 (bs, 1H), 6.75 (d, 1H), 3.89 (m, 2H), 3.73 (m, 2H), 3.56 (m, 2H), 3.40 (m, 2H).
MS (m/z): 258 [MH]⁺.

15

Intermediate 81-(1H-Pyrazol-3-yl)imidazolidin-2-one

- 20 To a solution of intermediate 7 (190 mg, 0.74 mmol) in a 2:1 mixture of MeOH/H₂O (15 mL), at r.t., under N₂, was added LiOH (177 mg, 10 eq) and the reaction mixture was heated at 80°C for 3 hr. It was cooled down to r.t. and neutralized to pH 7 with 2M HCl. Silica gel was then added and the solvents were evaporated. The adsorbed crude product was purified by flash chromatography (silica gel, EtOAc/MeOH 9:1) to give the title compound as a white solid (80 mg, 71%)
- 25 NMR (¹H, DMSO): δ 12.10 (bs, 1H), 7.6 (s, 1H), 6.7 (s, 1H), 6.4 (s, 1H), 3.8 (t, 2H), 3.4 (t, 2H).
MS (m/z): 152 [MH]⁺.

Intermediate 9

- 30 4-Chloro-N-[1-(4-chlorobutanoyl)-1H-pyrazol-3-yl]butanamide

- 35 To a solution of 3-aminopyrazole (300 mg, 3.61 mmol) in anh. CH₂Cl₂ (6 mL), at r.t., under N₂, was added K₂HPO₄ (1.26 g, 2 eq) and the reaction mixture was stirred at r.t. for 15 min. 4-Chloro-butyryl chloride (406 μL, 3.6 mmol) was then added and the reaction mixture was stirred for 24 hr. It was then poured into water and the phases were separated. The aqueous layer was extracted with EtOAc (2x20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a white solid (354 mg, 34%)
- 40 NMR (¹H, CDCl₃): δ 8.09 (d, 1H), 7.83 (bs, 1H), 6.98 (s, 1H), 3.64 (m, 2H), 3.17 (m, 1H), 2.57 (m, 1H), 2.21 (m, 2H).
MS (m/z): 292 [M]⁺.

Intermediate 101-(1H-Pyrazol-3-yl)pyrrolidin-2-one

- 5 To a suspension of NaH 80%/oil (31 mg, 1.1 eq) in anh. DMF (1.5 mL), at r.t., under N₂, was added a solution of intermediate 9 (340 mg, 1.16 mmol) in anh. DMF (1 mL). The reaction mixture was stirred at r.t. for 1 hr, after which it was quenched carefully with water. The aqueous phase was extracted with EtOAc (3x20 mL) and the combined organic extracts were washed with sat.aq. NaCl and dried over anh. Na₂SO₄. The solids
10 were filtered and the solvent evaporated. The crude product (70 mg, 0.27 mmol) was dissolved in anh. MeOH (3 mL), at r.t., under N₂, and 1M MeONa/MeOH was added until pH 9 was reached. The reaction mixture was stirred at r.t. for 30 min and water was added. The aqueous phase was extracted with EtOAc (3x20 mL) and the combined organic extracts were washed with sat.aq. NaCl and dried over anh. Na₂SO₄. The solids
15 were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a white solid (35 mg, 20%).
NMR (¹H, CDCl₃): δ 7.46 (s, 1H), 6.55 (s, 1H), 3.90 (t, 2H), 2.59 (t, 2H), 2.18 (m, 2H).
MS (m/z): 152 [M]⁺.

Intermediate 11N-(3-Chloropropyl)-3-({[(3-chloropropyl)amino]carbonyl}amino)-1H-pyrazole-1-carboxamide

- 25 To a solution of 3-aminopyrazole (500 mg, 6 mmol), in anh. DMF (10 mL), at r.t., under N₂, was added 3-chloropropyl isocyanate (1.2 mL, 2 eq) and the reaction was stirred for 24 hr. The reaction was not complete and more isocyanate (1.2 mL, 2 eq) was added. The reaction mixture was stirred for an additional 48 hr. It was then poured into CH₂Cl₂/sat.aq. NaCl and the phases were separated. The aqueous layer was extracted
30 with CH₂Cl₂ (2x20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (Biotage 40, cHex/EtOAc 7:3) to give the title compound as a white solid (620 mg, 32%).
NMR (¹H, DMSO): δ 9.05 (s, 1H), 8.25 (t, 1H), 8.08 (d, 1H), 7.17 (t, 1H), 6.30 (d, 1H), 4.7-4.6 (m, 4H), 3.37 (q, 2H), 3.26 (q, 2H), 2.05-1.87 (m, 4H).
35 MS (m/z): 322 [MH]⁺.

Intermediate 12N-(3-Chloropropyl)-3-(2-oxotetrahydropyrimidin-1(2H)-yl)-1H-pyrazole-1-carboxamide

- 40 To a solution of intermediate 11 (620 mg, 1.93 mmol) in anh. THF (20 mL), at r.t., under N₂, was added KO^t-Bu (237 mg, 1.1 eq). The reaction mixture was stirred at r.t. for 2 hr.

Water was then added and the solvent was evaporated. The aqueous phase was extracted with EtOAc (3x20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (Flash Master, 10g SiO₂, cHex/EtOAc 7:3, then 100% EtOAc) to give the title compound as a white solid (200 mg, 37%)

NMR (¹H, DMSO): δ 8.23 (t, 1H), 8.06 (d, 1H), 6.93 (bs, 1H), 6.82 (d, 1H), 3.86 (t, 2H), 3.57 (t, 2H), 3.34 (m, 2H), 3.19 (m, 2H), 1.98 (m, 2H), 1.91 (m, 2H).

MS (m/z): 286 [MH]⁺.

10 Intermediate 13

1-(1H-Pyrazol-3-yl)tetrahydropyrimidin-2(1H)-one

A solution of intermediate 12 (180 mg, 0.63 mmol) and LiOH (265 mg, 10 eq) in a 2:1 mixture of MeOH/H₂O (7.5 mL), in a sealed vial, was subjected to microwave irradiation (80°C) for 10 min. The reaction mixture was then cooled down to r.t., and the solvent was evaporated to dryness. The residue was purified on an SCX cartridge (EtOAc/MeOH 8:2, then 100% MeOH) to give the title compound as a white solid (102 mg, 98%)

NMR (¹H, DMSO): δ 12.13 (bs, 1H), 7.50 (s, 1H), 6.60 (bs, 1H), 6.46 (s, 1H), 3.73 (m, 2H), 3.15 (m, 2H), 1.88 (m, 2H).

MS (m/z): 167 [MH]⁺.

Intermediate 14

3-Bromo-1-(triphenylmethyl)-1H-pyrazole

To a solution of 3-bromo-pyrazole (2.0 g, 13.6 mmol) in anh. CH₂Cl₂ (40 mL), at r.t., under N₂, were added triphenylmethyl chloride (4.17 g, 1.1 eq) and Et₃N (2.1 mL, 1.1 eq). The reaction mixture was stirred at r.t. for 4 hr. It was poured into water/CH₂Cl₂. The phases were separated and the aqueous layer was further extracted with CH₂Cl₂ (2x30 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, 100% CH₂Cl₂) to give the title compound as a white solid (3.39 g, 64%).

NMR (¹H, DMSO-d₆): δ 7.34 (m, 10H), 7.01 (m, 6H), 6.45 (d, 1H).

MS (m/z): 412 [M+Na]⁺.

Intermediate 15

3-[1-(Triphenylmethyl)-1H-pyrazol-3-yl]-1,3-oxazolidin-2-one

A mixture of intermediate 14 (389 mg, 1mmol), 1,3-oxazolidin-2-one (87 mg, 1 mmol), CuI (20 mg, 10 mol%), (1*R*,2*R*)-diaminomethylcyclohexane (43 mg, 30 mol%) and K₂CO₃ (414 mg, 3 mmol) in anh. NMP (2mL) in a sealed vial was stirred at 130°C for 4 hr. It was poured into water/EtOAc. The phases were separated and the aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh.

Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, EtOAc/cHex 2:8) to give the title compound as a white solid (210 mg, 53%).

5 NMR (¹H, CDCl₃): δ 7.28 (m, 9H), 7.21 (d, 1H), 7.13 (m, 6H), 6.64 (d, 1H), 4.40 (t, 2H), 3.98 (t, 2H).

MS (m/z): 418 [M+Na]⁺.

Intermediate 16

3-(1H-Pyrazol-3-yl)-1,3-oxazolidin-2-one

10

To a solution of intermediate 15 (210 mg, 0.53 mmol) in anh. MeOH (4 mL), under N₂, was added trifluoroacetic acid (0.2 mL, 2.66 mmol). The reaction mixture was subjected to microwave irradiation (100°C) for 15 min. The solvent was evaporated and the residue was purified on an SCX cartridge (100% CH₂Cl₂, then 0.5M NH₃/MeOH) to give the title compound as a white solid (30 mg, 37%).

15

NMR (¹H, DMSO-d₆): δ 7.64 (d, 1H), 6.40 (d, 1H), 4.41 (t, 2H), 3.97 (t, 2H).

MS (m/z): 155 [MH]⁺.

Intermediate 17

20

N-1H-Pyrazol-3-ylacetamide

To a solution of 3-aminopyrazole (20 g, 0.24 mol) in H₂O (36 mL), at 5-10°C, was slowly added NaHCO₃ (9.1 g, mol, 3 eq) and then Ac₂O (6.79 ml, 2 eq). The reaction mixture was refluxed for 8 hr. It was cooled down to r.t. and was left standing at this temperature for 12 hr to allow crystallization. The white solid was filtered (12.9 g) and the mother liquor volume was reduced. A second batch of white solid (3.4 g) was obtained after crystallization. The two batches were combined to give the title compound (16.3 g, 54%).

25

NMR (¹H, DMSO-d₆): δ 12.22 (bs, 1H), 10.28 (bs, 1H), 7.53 (bs, 1H), 6.43 (bs, 1H), 1.96 (s, 1H).

30

MS (m/z): 126 [MH]⁺, 148 [M+Na]⁺.

Intermediate 18

N-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)acetamide

35

A mixture of intermediate 5 (500 mg, 1.32 mmol), intermediate 17 (329 mg, 2 eq.), CuI (50 mg, 0.2 eq.), K₂CO₃ (382 mg, 2.1 eq.), dodecane (60 μL, 0.2 eq.) and (+/-)-trans-1,2-diaminocyclohexane (45 μL, 0.3 eq.) in anh. NMP (5 mL), in a sealed vial, was heated at 150°C for 4 hr. It was cooled down to r.t. and poured into sat.aq. NH₄Cl. EtOAc was added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified on an SCX cartridge

40

(silica gel, CH₂Cl₂, then MeOH, then conc. NH₄OH in MeOH, 25:75) and then by flash chromatography (cHex/EtOAc 7:3) to give the title compound as a white solid (358 mg, 72%).

5 NMR (¹H, DMSO-d₆): δ 10.62 (bs, 1H), 8.24 (d, 1H), 7.15 (d, 1H), 6.84 (d, 1H), 6.78-6.73 (m, 3H), 3.83 (t, 2H), 3.74 (s, 3H), 3.4 (t, 2H), 2.16 (s, 3H), 2.14 (s, 3H), 2.04 (s, 3H).
MS (m/z): 378 [MH]⁺.

Intermediate 19

10 1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-amine

To a dispersion of intermediate 18 (358 mg, 0.95 mmol) in EtOH (7 mL), at r.t., was added 25% NaOH (2.5 mL) and the reaction mixture was subjected to microwave irradiation (130°C) for 20 min. The EtOH was evaporated and the crude product was partitioned
15 between EtOAc and sat.aq. NaCl. The phases were separated and the aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to give the title compound (282 mg, 89%) which was used in the next step without any further purification.
NMR (¹H, DMSO-d₆): δ 7.98 (d, 1H), 7.12 (d, 1H), 6.83 (d, 1H), 6.75 (dd, 1H), 6.67 (s, 1H),
20 5.77 (d, 1H), 5.10 (bs, 2H), 3.78 (t, 2H), 3.74 (s, 3H), 3.35 (t, 2H), 2.13 (s, 3H), 2.12 (s, 3H).
MS (m/z): 336 [MH]⁺.

Intermediate 20

25 Ethyl N-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)glycinate

To a solution of intermediate 19 (200 mg, 0.6 mmol) in anh. DMF (5 mL), at r.t., under N₂, was added NaH 60%/oil (26 mg, 1.1 eq). The reaction mixture was stirred at r.t. for 20
30 min, ethyl 2-bromoacetate (73 μL, 1.1 eq) was then added dropwise and the reaction mixture was heated at 80°C. Continuous additions of the alkyl bromide were done at 80°C over a period of 7.2 h (5 x 36 μL, 5 x 0.55 eq). The reaction mixture was cooled down to r.t. and poured into H₂O. EtOAc was added and the phases were separated. The aqueous
35 layer was further extracted with EtOAc (2 x 10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a yellow oil (155 mg, 62%).

NMR (¹H, DMSO-d₆): δ 8.09 (d, 1H), 7.13 (d, 1H), 6.83 (d, 1H), 6.76 (dd, 1H), 6.37 (s, 1H),
40 6.17 (t, 1H), 5.86 (d, 1H), 5.73 (s, 1H), 4.09 (q, 2H), 3.89 (d, 2H), 3.77 (t, 2H), 3.74 (s, 3H), 3.36 (t, 2H), 2.13 (bs, 6H), 1.17 (t, 3H).
MS (m/z): 422 [MH]⁺.

Intermediate 21

2-[(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)amino]ethanol

- 5 To a cold (-78°C) solution of 1N LiAlH₄/THF (0.5 mL, 2.7 eq), under N₂, was added dropwise a solution of intermediate 20 (77.5 mg, 0.184 mmol) in anh. THF (5 mL). The reaction mixture was stirred at -78°C for 20 min. Continuous additions of 1N LiAlH₄/THF were done at this temperature over a period of 40 min (3 x 200 µL, 3 x 1.09 eq). To the reaction mixture was added water (42 µL), 1N NaOH (42 µL) and water (125 µL) and a precipitate was formed. The solid was filtered and washed with EtOAc (2x) and CH₂Cl₂ (2x). The combined organic extracts were concentrated and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a yellow solid (25 mg, 36%).
- 10 NMR (¹H, DMSO-d₆): δ 8.04 (d, 1H), 7.13 (d, 1H), 6.83 (d, 1H), 6.76 (dd, 1H), 6.66 (s, 1H), 5.82 (d, 1H), 5.58 (t, 1H), 4.59 (t, 1H), 3.78 (t, 2H), 3.74 (s, 3H), 3.55 (q, 2H), 3.40 (t, 2H), 3.20 (q, 2H), 2.13 (bs, 6H).
- 15 MS (*m/z*): 380 [MH]⁺.

Intermediate 22

- 20 3-[(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)amino]-1-propanesulfonic acid

- To a suspension of intermediate 19 (25 mg, 0.0746 mmol) in *n*-BuOH (1 mL), at r.t., under N₂, was added 1,2-oxathiolane 2,2-dioxide (30 µL, 3 eq). The reaction mixture was subjected to microwave irradiation (20+60+60 min, T=150/180°C). The solvent was evaporated and the residue was purified by flash-chromatography (silica gel, 100% EtOAc → 7:3 EtOAc /sol. NH₃ in MeOH (0.5 M)) and SCX cartridge (Eluents: MeOH and a sol. of NH₃ in MeOH (0.5 M)) to give the title compound as a yellow oil (10 mg, 30%).
- 25 NMR (¹H, CDCl₃): δ 7.54 (bs, 1H), 7.05 (d, 1H), 6.72 (m, 1H), 6.66 (m, 1H), 6.48 (bs, 1H), 5.78 (bs, 1H), 3.72 (m, 5H), 3.3 (m, 4H), 2.97 (m, 2H), 2.03-2.2 (m, 8H).
- 30 MS (*m/z*): 458 [MH]⁺.

Intermediate 23

- 35 Phenyl (1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)carbamate

- To a suspension of intermediate 19 (391 mg, 1.17 mmol) in anh. CH₂Cl₂ (8 mL), at 0°C, under N₂, were added pyridine (103 µL, 1.1 eq) and phenyl chloroformate (161 µL, 1.1eq). The reaction mixture was stirred at r.t. for 1 hr. The solvent was evaporated in vacuo, sat.aq. NaCl (50 mL) was then added and the solution extracted with EtOAc (3x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvents evaporated in vacuo. The crude compound thus obtained was purified by
- 40

flash chromatography (silica gel, MeOH-Ammonia solution in MeOH 0.5 M) to give 284 mg (53%) of the title compound as a white solid.

NMR (^1H , CDCl_3): δ 10.8 (bs, 1H) 8.28 (d, 1H), 7.39 (m, 2H), 7.18 (m, 4H), 6.73 (dd, 1H), 6.64 (s, 1H), 3.81 (t, 2H), 3.72 (s, 3H), 3.32 (t, 2H), 2.14 (s, 3H), 2.12 (s, 3H).

5 MS (m/z): 456 $[\text{MH}]^+$.

Intermediate 24

Phenyl (1-{6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)carbamate

10 A mixture of intermediate 23 (284mg, 0.62 mmol), pyridine (50 μL , 1.2 eq) and 2,2-bis(ethoxy)ethanamine (108 μL , 1.2 eq) was heated for 3 hr at 60°C. H_2O (50 mL) was then added and the solution extracted with CH_2Cl_2 (3x15 mL). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated
15 in vacuo. The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give 214 mg (84%) of the title compound as a white solid.

NMR (^1H , CDCl_3): δ 9.21 (s, 1H), 8.24 (d, 1H), 7.15 (d, 1H), 6.95 (bs, 1H), 6.95 (d, 1H), 6.78 (dd, 1H), 6.72 (s, 1H), 6.42 (s, 1H), 4.5 (m, 1H), 3.82 (t, 2H), 3.60 (m, 1H), 3.48 (m, 1H), 3.65 (s, 3H), 3.3 (s, 6H), 3.23 (t, 2H), 3.16 (s, 3H), 2.14 (s, 3H).

20 MS (m/z): 495 $[\text{MH}]^+$.

Intermediate 25

3-Methyl-1-[1-(triphenylmethyl)-1H-pyrazol-3-yl]-2(1H)-pyridinone

25 A solution of intermediate 14 (300 mg, 0.77 mmol), 3-methylpyridinone (168 mg, 1 eq), CuI (146 mg, 1 eq), K_2CO_3 (223 mg, 2.1 eq), N-N'-dimethyl *trans*-cyclohexanediamine (109 mg, 0.5 eq) in anh. NMP (4 mL) was heated at 150°C for 24 hr. Sat.aq. NH_4Cl (100 mL) was then added and the mixture extracted with CH_2Cl_2 (250 mL). The organic layer was dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated in vacuo.

30 The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 95:5) to give 80 mg (25%) of the title compound as white solid.

NMR (^1H , CDCl_3): δ 7.76(d, 1H), 7.30(m, 11H), 7.15 (m, 6H), 6.98(d, 1H), 6.06 (t, 1H), 2.15 (s, 3H).

MS (m/z): 440 $[\text{M}+\text{Na}]$.

Intermediate 26

3-Methyl-1-(1H-pyrazol-3-yl)-2(1H)-pyridinone

40 CF_3COOH (3 mL) was added to a solution of intermediate 25 (80 mg, 0.19 mmol) in an anh. mixture of $\text{MeOH}/\text{CH}_2\text{Cl}_2$ 2:1 (3 mL) at r.t., under N_2 . The solution was heated at 80°C for 18 hr. The solvents were evaporated in vacuo. The crude compound thus

obtained was purified on an SCX cartridge (1g, preconditioned with CH₂Cl₂) to give 13 mg (39%) of the title compound as a white solid.

NMR (¹H, CDCl₃): δ 7.61(d, 1H), 7.55(s, 1H), 7.24 (m, 1H), 7.1(d, 1H), 6.76 (d, 1H), 6.16 (t, 1H), 2.15 (s, 3H).

5 MS (m/z): 176 [MH]⁺.

Intermediate 27

2-[1-(Triphenylmethyl)-1H-pyrazol-3-yl]-3(2H)-pyridazinone

10 A solution of intermediate 14 (200 mg, 0.52 mmol), pyridazinone (50 mg, 1 eq), CuI (100 mg, 1 eq), K₂CO₃ (148 mg, 2.eq) and N-N'-dimethyl *trans*-cyclohexanediamine (73 mg, 0.5eq.) in anh. NMP (4 mL) was heated at 150°C for 8 hr. Sat.aq. NH₄Cl (100 mL) was then added and the solution extracted with CH₂Cl₂ (250 mL). The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvents evaporated in vacuo. The
15 crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 1:9) to give a solution of the title compound in NMP, which was used in the next step without further purification.

MS (m/z): 443 [M+K], 427 [M+Na].

20 Intermediate 28

2-(1H-Pyrazol-3-yl)-3(2H)-pyridazinone

The solution of intermediate 27 obtained above was dissolved in a mixture of MeOH/CH₂Cl₂ 2:1 (3 mL) and CF₃COOH (2.5 mL) was added, at r.t., under N₂. The
25 reaction mixture was heated at 80°C for 4 hr. The solvents were evaporated in vacuo. The crude compound thus obtained was purified on an SCX cartridge (1g, preconditioned with CH₂Cl₂) to give 20 mg (24%, two steps) of the title compound as a white solid.

NMR (¹H, CDCl₃): δ 7.91(d, 1H), 7.59(m, 1H), 7.24 (m, 1H), 7.07(m, 1H), 6.76 (d, 1H).

MS (m/z): 163 [MH]⁺.

30

Intermediate 29

1-Acetyl-3-{1-[1-(4-hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone

35 To a solution of example 1-6 (80 mg, 0.179 mmol) in anh. CH₂Cl₂ (1.8 mL), at r.t., under N₂, was added BBr₃ 1.0M/CH₂Cl₂ (0.72 mL, 5 eq) dropwise. The reaction mixture was stirred at r.t. for 90 min. MeOH (1 mL) was added and the solvent was evaporated. The residue was taken up in EtOAc/sat.aq. NaHCO₃ and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (2x10 mL) and the combined organic extracts
40 were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude compound was further purified by flash chromatography (silica gel, 100% EtOAc → 5% MeOH/EtOAc) to give the title compound as a white solid (29 mg, 37%).

NMR (^1H , DMSO- d_6): δ 9.3 (s, 1H), 8.40 (d, 1H), 7.00 (d, 1H), 6.85 (d, 1H), 6.75 (s, 1H), 6.65 (d, 1H), 6.60 (dd, 1H), 4.00-3.70 (m, 6H), 3.40 (t, 2H), 2.45 (s, 3H), 2.15 (s, 3H), 2.05 (s, 3H).

MS (m/z): 433 [MH] $^+$.

5

Intermediate 30

1-Acetyl-3-(1-{1-[4-(ethyloxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

- 10 To a solution of intermediate 29 (13.6 mg, 0.0315 mmol) in anh. DMF (1 mL), at r.t., under N_2 , was added NaH 60%/oil (2.5 mg, 2 eq) and the reaction mixture was stirred at r.t. for 20 min. Iodoethane (10 μL , 4 eq) was added and the reaction mixture was stirred at r.t. for 1 hr. It was poured into EtOAc/sat.aq. NaCl and the phases were separated. The organic layer was washed with sat.aq. NaCl (2x10 mL) and dried over anh. Na_2SO_4 . The solids were filtered and the solvent was evaporated. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 1:1). The mixed fraction were re-purified by flash chromatography (silica gel, cHex/EtOAc 7:3). The title compound was obtained as a white solid (5 mg, 34%)

15 NMR (^1H ,): δ 7.87 (d, 1H), 7.13 (d, 1H), 6.95 (d, 1H), 6.79 (d, 1H), 6.74 (d, 1H), 6.53 (s, 1H), 4.11-3.97 (m, 6H), 3.86 (t, 2H), 3.43 (t, 2H), 2.58 (s, 3H), 2.31 (s, 3H), 2.09 (s, 3H), 1.39 (t, 3H).

20 MS (m/z): 461 [MH] $^+$.

Intermediate 31

- 25 1-Acetyl-3-[1-(6-methyl-1-{2-methyl-4-[(1-methylethyl)oxy]phenyl}-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone

To a solution of intermediate 29 (14 mg, 0.032 mmol) in anh. DMF (1 mL), at r.t., under N_2 , was added NaH 60%/oil (3 mg, 2 eq) and the reaction mixture was stirred at r.t. for 20 min. 2-Iodopropane (13 μL , 4 eq) was added and the reaction mixture was stirred at r.t. for 1 hr. It was poured into EtOAc/sat.aq. NaCl and the phases were separated. The organic layer was washed with sat.aq. NaCl (2x10 mL) and dried over anh. Na_2SO_4 . The solids were filtered and the solvent was evaporated. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 2:8). The title compound was obtained as a clear oil (11 mg, 79%) in an inseparable 2:1 mixture with 1-(1-methylethyl)-3-[1-(6-methyl-1-{2-methyl-4-[(1-methylethyl)oxy]phenyl}-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone.

35 MS (m/z): 475 [MH] $^+$.

- 40 Intermediate 32

1-(2,4-Dichlorophenyl)-2-pyrrolidinone

As in intermediate 1, except that 2,4-dichloroaniline was used instead of 4-methoxy-2-methylaniline.

NMR (^1H , CDCl_3): δ 7.18-7.35 (m, 3H), 3.72 (t, 2H), 2.53 (t, 2H), 2.22 (t, 2H).

MS (m/z): 230 $[\text{MH}]^+$.

5

Intermediate 33

Ethyl 1-(2,4-dichlorophenyl)-2-oxo-3-pyrrolidinecarboxylate

10 To a solution of intermediate 32 (3.6 g, 15.65 mmol) in $(\text{EtO})_2\text{CO}$ (25.2 mL, 13.2 eq), at r.t., under N_2 , was added $t\text{-BuOK}$ 1M/THF (47 mL, 3 eq) dropwise. The stirred reaction mixture was heated at 80°C for 2 hr, then it was cooled to r.t. and poured on ice. The mixture was then acidified with 6N HCl, extracted with CH_2Cl_2 (300 mL), washed with sat.aq. NaHCO_3 (100 mL), sat.aq. NaCl (100 mL) and water (100 mL). The organic layer was dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The
15 crude product was purified by flash chromatography (silica gel, cHex/EtOAc 6:4) to give the title compound as a yellow oil (3.2 g, 67%).

NMR (^1H , $\text{DMSO}-d_6$): δ 7.61 (s, 1H), 7.44 (m, 2H), 4.16 (q, 2H), 3.80 (m, 2H), 3.61 (t, 1H), 2.51 (m, 2H), 1.24 (t, 3H).

MS (m/z): 302 $[\text{MH}]^+$.

20

Intermediate 34

Ethyl 1-(2,4-dichlorophenyl)-2-([3-(ethyloxy)-1-methyl-3-oxo-1-propen-1-yl]imino)-3-pyrrolidinecarboxylate

25 To a mixture of intermediate 33 (0.5 g, 1 eq) and ethyl (2Z)-3-amino-2-butenolate (0.43 g, 2 eq), was added POCl_3 (4 mL, 26 eq) and the resulting reaction mixture was stirred at 100°C for 4 hr. The reaction mixture was then cooled to r.t., evaporated, poured on ice, neutralized with sat.aq. NaHCO_3 and extracted with EtOAc (200 mL). The organic layer was dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The
30 crude product was used in the next step without further purification.

MS (m/z): 413 $[\text{M}]^+$.

Intermediate 35

1-(2,4-Dichlorophenyl)-6-methyl-1,2,3,7-tetrahydro-4H-pyrrolo[2,3-b]pyridin-4-one

35

A solution of crude intermediate 34 in anh. DMF (10 mL) was added to a suspension of NaH 60%/oil (111 mg, 2 eq) in anh. DMF (10 mL), at r.t., under N_2 . The reaction mixture was heated at 100°C for 6 hr. The mixture was then cooled to r.t. and the pH adjusted to 5 with sat.aq. NH_4Cl . The reaction mixture was then partitioned between EtOAc/sat.aq.
40 NH_4Cl (200 mL/100 mL). The phases were separated and the organic layer was dried over anh. Na_2SO_4 , the solids were filtered, the solvent evaporated and the crude product

was purified by flash chromatography (silica gel, cHex/EtOAc 1:1 → EtOAc/MeOH 1:1) to give the title compound as a brown oil (0.038 g, 7%, two steps).

NMR (^1H , CDCl_3): δ 7.33 (m, 2H), 7.17 (m, 1H), 6.00 (s, 1H), 2.88 (t, 2H), 2.98 (t, 2H), 2.22 (s, 3H).

5 MS (m/z): 295 $[\text{M}]^+$.

Intermediate 36

1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl
trifluoromethanesulfonate

10

As in intermediate 4.

NMR (^1H , CDCl_3): δ 7.48 (s, 1H), 7.34 (d, 1H), 7.26 (d, 1H), 6.35 (s, 1H), 4.01 (t, 2H), 3.25 (t, 2H), 2.32 (s, 3H).

MS (m/z): 427 $[\text{M}]^+$.

15

Intermediate 37

1-(2,4-Dichlorophenyl)-4-iodo-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine

As in intermediate 5.

20 NMR (^1H , CDCl_3): δ 7.42 (m, 3H), 6.81 (s, 1H), 3.96 (t, 2H), 3.04 (t, 2H), 2.24 (s, 3H).

MS (m/z): 405 $[\text{M}]^+$.

Intermediate 38

Ethyl 2-chloro-6-methyl-4-[3-(2-oxoimidazolidin-1-yl)-1H-pyrazol-1-yl] nicotinate

25

To a solution of intermediate 8 (9.73 g, 1.5 eq) in anh. DMF (150 mL), at r.t., under N_2 , was added NaH 60%/oil (1.7 g, 1 eq) and the reaction mixture was stirred at r.t. for 20 min. A solution of ethyl 2,4-dichloro-6-methyl-3-pyridinecarboxylate (10 g, 42.9 mmol) was then added dropwise and the reaction mixture was stirred at 80°C for 4 hr. It was then cooled down to r.t. and quenched with ice water. The addition of EtOAc caused a precipitate to form. The white solid was collected by filtration, washed with water and dried in vacuo (5.2 g). The filtrate was transferred into a separatory funnel and the aqueous layer was extracted with EtOAc (2x100 mL). The combined organic layers were washed with sat.aq. NaCl, dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was treated with EtOAc and left at r.t. overnight. The precipitate was filtrated, dried in vacuo and combined with the previous batch to give the title compound as a white solid (7.2 g, 48%).

30

35

NMR (^1H , $\text{DMSO}-d_6$): δ 8.53 (d, 1H), 7.77 (s, 1H), 7.18 (bs, 1H), 6.89 (d, 1H), 4.32 (q, 2H), 3.75 (t, 2H), 3.42 (t, 2H), 3.31 (s, 3H), 1.26 (t, 3H).

40 MS (m/z): 350 $[\text{MH}]^+$.

Intermediate 39

1-{1-[2-Chloro-3-(hydroxymethyl)-6-methyl-4-pyridinyl]-1H-pyrazol-3-yl}-2-imidazolidinone

To a suspension of intermediate 38 (7.2 g, 20.6 mmol) in anh. CH₂Cl₂ (120 mL), at 0°C, under N₂, was added dropwise DIBAL-H 1M/CH₂Cl₂, (41.2 mL, 2 eq). At the end of the addition the resulting solution was allowed to warm to r.t. and stirred for 2 hr. More DIBAL-H was added until the reaction was complete (3x20.5 mL), each time cooling at 0°C and then stirring at r.t. for 1 hr. The reaction mixture was then cooled to 0°C, quenched by the slow addition of a Rochelle salt solution (50 mL) and stirred at r.t. overnight. The white lattice was treated with 4 L of Roschell's salt solution and 3 L of CH₂Cl₂ and stirred at r.t. for 20 hr. The two phases were separated and the aqueous layer was extracted with CH₂Cl₂ (5x500 mL). The combined organic extracts were washed with sat.aq. NaCl, dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to give the title compound as a white solid (4 g, 63%).

NMR (¹H, DMSO-d₆): δ 8.36 (d, 1H), 7.49 (s, 1H), 7.12 (bs, 1H), 6.86 (d, 1H), 5.47 (t, 1H), 4.61 (d, 2H), 3.88 (t, 2H), 3.44 (t, 2H), 3.30 (s, 3H).

MS (m/z): 308 [MH]⁺.

Intermediate 401-{1-[2-Chloro-3-(hydroxymethyl)-6-methyl-4-pyridinyl]-1H-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a suspension of intermediate 39 (100 mg, 0.325 mmol) in anh. DMF (6.5 mL), at r.t., under N₂, was added NaH 60%/oil (13 mg, 1 eq.). The reaction mixture was stirred at r.t. until a pale yellow solution was obtained (*circa* 10 min). After cooling to 0°C, 1-(chloromethyl)-4-(methyloxy)benzene (44 μL, 1 eq) was added and the reaction mixture was stirred for 1.5 hr. It was partitioned between EtOAc/sat.aq. NaCl, the phases were separated and the organic layer was dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 6:4 → 7:3) to give the title compound as a white solid (45.5 mg, 33%).

NMR (¹H, CDCl₃): δ 7.85 (d, 1H), 7.20 (dd, 2H), 7.15 (d, 1H), 7.10 (s, 1H), 6.89 (dd, 2H), 4.85 (s, 2H), 4.40 (s, 2H), 3.84 (t, 2H), 3.80 (s, 3H), 3.43 (t, 2H), 2.6 (s, 3H).

MS (m/z): 428 [MH]⁺, 450 [M+23]⁺

Intermediate 412-Chloro-6-methyl-4-[3-(3-{[4-(methyloxy)phenyl]methyl}-2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-3-pyridinecarbaldehyde

To a solution of intermediate 40 (925 mg, 2.16 mmol) in CH₂Cl₂ (90 mL), was added Dess Martin periodinane (1.38 g, 1.5 eq) in three portions and the reaction mixture was stirred at r.t. for 2 hr. More Dess Martin periodinane (750 mg, 0.2 eq) was added and the reaction mixture was stirred for an additional 30 min. Na₂S₂O₃ (5 eq) in a sat.aq. NaHCO₃ (100 mL) was added and the phases were separated. The aqueous layer was extracted with CH₂Cl₂

(3x50 mL) and the combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 6:4 → 7:3) to give the title compound as a white solid (520 mg, 57%).

- 5 NMR (¹H, CDCl₃): δ 10.26 (s, 1H), 7.85 (d, 1H), 7.23 (dd, 2H), 7.20 (s, 1H), 7.13 (d, 1H), 6.89 (dd, 2H), 4.41 (s, 2H), 3.84 (t, 2H), 3.80 (s, 3H), 3.39 (t, 2H), 2.6 (s, 3H).
MS (*m/z*): 426 [MH]⁺.

Intermediate 42

- 10 1-(1-(2-Chloro-6-methyl-3-[(*E*)-2-(methoxyloxy)ethenyl]-4-pyridinyl)-1*H*-pyrazol-3-yl)-3-{[4-(methoxyloxy)phenyl]methyl}-2-imidazolidinone

- 15 *n*-BuLi 1.6M/Hexane (0.44 mL, 3 eq) was added dropwise to a suspension of (methoxymethyl)-triphenylphosphonium chloride (224 mg, 3 eq) in THF (5 mL) at 0°C, under N₂. At the end of the addition the reaction mixture was allowed to warm to r.t. and stirred for 20 min. A solution of intermediate 41 (100 mg, 0.235 mmol) in THF (8 mL) was added and the reaction mixture stirred at r.t. for an additional 1.5 hr. The mixture was treated with water, EtOAc was added and the phases were separated. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated in vacuo to a residue which was purified on an SCX cartridge (100% cHex → cHex/EtOAc 7:3) to give the title compound as a white solid (68 mg, 63%) as a 7:3 mixture of trans:cis isomers.

- 20 NMR (¹H, CDCl₃): δ 7.36 (d, 1H), 7.24 (m, 3H), 6.99 (d, 1H), 6.87 (d, 2H), 6.58 (d, 2H), 5.59 (d, 2H), 4.40 (s, 2H), 3.89 (m, 2H), 3.78 (s, 3H), 3.64 (s, 3H), 3.37 (m, 2H), 2.50 (s, 3H).
25 MS (*m/z*): 454 [MH]⁺.

Intermediate 43

- 30 {2-Chloro-6-methyl-4-[3-(3-{[4-(methoxyloxy)phenyl]methyl}-2-oxo-1-imidazolidinyl)-1*H*-pyrazol-1-yl]-3-pyridinyl}acetaldehyde

- 35 To a solution of intermediate 42 (5.5 g, 12.5 mmol) in THF (120 mL), at r.t., was added 6.0M HCl (60 mL, 28.4 eq.) and the reaction mixture was stirred for 18 hr. The reaction mixture was quenched with sat.aq. NaHCO₃ untill neutral pH, the solvent partially removed and the crude mixture partitioned between EtOAc/water. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 4:6) to give the title compound as a white solid (4.6 g, 86%).

- 40 NMR (¹H, CDCl₃): δ 9.73 (s, 1H), 7.70 (d, 1H), 7.23 (d, 2H), 7.06 (m, 2H), 6.88 (d, 2H), 4.40 (s, 2H), 4.01 (s, 2H), 3.80 (s, 3H), 3.76 (t, 2H), 3.37 (t, 2H), 2.58 (s, 3H).
MS (*m/z*): 440 [MH]⁺.

Intermediate 44

1-{1-[2-Chloro-3-(2-hydroxyethyl)-6-methyl-4-pyridinyl]-1H-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

5

To a solution of intermediate 43 (4.4 g, 9.96 mmol) in anh. MeOH (100 mL) at 0°C, under N₂, was added NaBH₄ (397 mg, 1.0 eq) in small portions and the reaction mixture was warmed up to r.t. and stirred for 30 min. The reaction mixture was quenched with water, the solvent partially removed and partitioned between EtOAc/water. The phases were

10

separated and the organic layer was washed with sat.aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc1:1) to give the title compound as a white solid (4.26 g, 96%).

NMR (¹H, CDCl₃): δ 7.65 (d, 1H), 7.24 (d, 2H), 7.09 (d, 1H), 6.97 (s, 1H), 6.89 (d, 2H), 4.45 (s, 2H), 3.96 (m, 4H), 3.83 (s, 3H), 3.41 (t, 2H), 3.14 (t, 2H), 2.55 (s, 3H).

15

MS (m/z): 442 [MH]⁺.

Intermediate 45

1-{1-[2-Chloro-3-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-6-methyl-4-pyridinyl]-1H-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

20

To a solution of intermediate 44 (4.26 g, 7.66 mmol) in anh. DMF (100 mL), at 0°C, under N₂, were added imidazole (7.19 g, 11 eq), DMAP (122 mg, 0.1 eq), TBDMSCI (4.07 g, 2.8 eq) and the reaction mixture was warmed up to r.t. and stirred for 1 hr. It was then

25

partitioned between EtOAc/sat.aq. NH₄Cl. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc7:3) to give the title compound as a yellow oil (4.92 g, 92%).

NMR (¹H, CDCl₃): δ 8.05 (d, 1H), 7.28 (d, 2H), 7.15 (s, 1H), 7.05 (d, 1H), 6.91 (d, 2H), 4.45 (s, 2H), 3.96 (m, 4H), 3.83 (s, 3H), 3.40 (t, 2H), 3.14 (t, 2H), 2.55 (s, 3H), 0.83 (s, 9H), 0.00 (s, 6H).

MS (m/z): 556 [MH]⁺.

Intermediate 46

1-{1-[3-(2-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}ethyl)-6-methyl-2-{(2-methyl-4-[(trifluoromethyl)oxy]phenyl)amino}-4-pyridinyl]-1H-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

35

To a solution of intermediate 45 (500 mg, 0.703 mmol) in anh. DME (10 mL), at r.t., under N₂, were added Pd₂(dba)₃ (82 mg, 0.1 eq), dicyclohexyl(2'-methyl-2-biphenyl)phosphane (98 mg, 0.3 eq), K₃PO₄ (573 mg, 3 eq) and 2-methyl-4-[(trifluoromethyl)oxy]aniline (258

40

mg, 1.5 eq) and the reaction mixture was stirred and heated at reflux for 3 hr. It was then partitioned between EtOAc/sat.aq. NH₄Cl. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a white solid (555 mg, 86%).

NMR (¹H, CDCl₃): δ 7.97 (m, 1H), 7.63 (m, 2H), 7.44 (m, 1H), 7.28 (d, 2H), 7.01 (m, 2H), 6.91 (m, 2H), 6.62 (s, 1H), 4.45 (s, 2H), 4.18 (t, 2H), 3.88 (t, 2H), 3.83 (s, 3H), 3.41 (t, 2H), 2.87 (t, 2H), 2.47 (s, 3H), 2.31 (s, 3H), 0.84 (s, 9H), 0.00 (s, 6H).

MS (m/z): 711 [MH]⁺.

Intermediate 47

1-{1-[3-(2-Hydroxyethyl)-6-methyl-2-({2-methyl-4-[(trifluoromethyl)oxy]phenyl}amino)-4-pyridinyl]-1H-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a solution of intermediate 46 (555 mg, 0.930 mmol) in anh. THF (5 mL), at r.t., under N₂, was added Et₃N·3HF (637 μL, 5 eq) and the reaction mixture was stirred at r.t. for 18 hr. It was then partitioned between EtOAc/water. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound as a white solid (281 mg, 60%).

NMR (¹H, CDCl₃): δ 7.92 (d, 1H), 7.61 (d, 1H), 7.35 (s, 1H), 7.25 (d, 2H), 7.01 (m, 2H), 6.89 (d, 2H), 6.58 (s, 1H), 4.41 (s, 2H), 4.14 (m, 2H), 3.86 (t, 2H), 3.80 (s, 3H), 3.38 (t, 2H), 2.88 (t, 2H), 2.44 (s, 3H), 2.28 (s, 3H).

MS (m/z): 597 [MH]⁺.

Intermediate 48

1-[1-(6-Methyl-1-{2-methyl-4-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a solution of intermediate 47 (281 mg, 0.486 mmol) in CH₂Cl₂ (10 mL), under N₂, were added I₂ (240 mg, 2 eq), PPh₃ (247 mg, 2 eq) and Et₃N (131 μL, 2 eq) and the reaction mixture was stirred at r.t. for 2 hr. The solvent was then evaporated and the crude product was purified on an SCX cartridge (100% CH₂Cl₂ → 2.0M Et₃N in MeOH) and flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound as a white solid (168 mg, 62%).

NMR (¹H, CDCl₃): δ 7.84 (d, 1H), 7.29 (d, 1H), 7.26 (d, 2H), 7.08 (m, 3H), 6.89 (d, 2H), 6.62 (s, 1H), 4.42 (s, 2H), 3.91 (m, 4H), 3.81 (s, 3H), 3.48 (t, 2H), 3.40 (t, 2H), 2.36 (s, 3H), 2.29 (s, 3H).

MS (m/z): 579 [MH]⁺.

Intermediate 49

4-({3-(2-((1,1-Dimethylethyl)(dimethyl)silyl)oxy)ethyl)-6-methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2-pyridinyl}amino)-3-methylbenzonitrile

5

As in intermediate 46, except that 4-amino-3-methylbenzonitrile was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

NMR (¹H, CDCl₃): δ 8.21 (d, 1H), 7.89 (s, 1H), 7.6 (d, 1H), 7.42 (dd, 1H), 7.36 (bs, 1H), 7.23 (d, 2H), 6.99 (d, 1H), 6.87 (d, 2H), 6.71 (s, 1H), 4.41 (s, 2H), 4.19 (m, 2H), 4.04 (broad, 2H), 3.79 (s, 3H), 3.36 (t, 2H), 2.85 (t, 2H), 2.5 (s, 3H), 2.3 (s, 3H), 0.77 (s, 9H), -0.08 (s, 6H).

10

MS (m/z): 652 [MH]⁺.

Intermediate 50

15

4-({3-(2-Hydroxyethyl)-6-methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2-pyridinyl}amino)-3-methylbenzonitrile

As in intermediate 47.

NMR (¹H, CDCl₃): δ 8.14 (d, 1H), 7.92 (s, 1H), 7.61 (d, 1H), 7.46 (dd, 1H), 7.4 (bs, 1H), 7.23 (d, 2H), 7.02 (d, 1H), 6.87 (d, 2H), 6.69 (s, 1H), 4.4 (s, 2H), 4.2 (m, 2H), 3.84 (t, 2H), 3.79 (s, 3H), 3.37 (t, 2H), 3.15 (bs, 1H), 2.86 (m, 2H), 2.48 (s, 3H), 2.28 (s, 3H).

20

MS (m/z): 538 [MH]⁺.

Intermediate 51

25

3-Methyl-4-{6-methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile

As in intermediate 48.

NMR (¹H, CDCl₃): δ 7.83 (d, 1H), 7.54 (bs, 1H), 7.48 (dd, 1H), 7.35 (d, 1H), 7.23 (d, 2H), 7.02 (d, 1H), 6.87 (d, 2H), 6.67 (s, 1H), 4.41 (s, 2H), 3.94 (m, 4H), 3.79 (s, 3H), 3.48 (t, 2H), 3.38 (t, 2H), 2.34 (s, 3H), 2.29 (s, 3H).

30

MS (m/z): 520 [MH]⁺.

Intermediate 52

35

1-[1-(3-(2-((1,1-Dimethylethyl)(dimethyl)silyl)oxy)ethyl)-6-methyl-2-{[2-methyl-4-(1H-pyrazol-1-yl)phenyl]amino}-4-pyridinyl)-1H-pyrazol-3-yl]-3-{4-(methyloxy)phenyl}methyl]-2-imidazolidinone

As in intermediate 46, except that intermediate 83 (2-methyl-4-(1H-pyrazol-1-yl)aniline) was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

40

NMR (¹H, CDCl₃): δ 8.07 (d, 1H), 7.88 (d, 1H), 7.70 (s, 1H), 7.57 (m, 3H), 7.46 (dd, 1H), 7.25 (d, 2H), 7.03 (d, 1H), 6.91 (d, 2H), 6.60 (s, 1H), 6.45 (t, 1H), 4.44 (s, 2H), 4.18 (t,

2H), 3.92 (t, 2H), 3.88 (s, 3H), 3.40 (s, 2H), 2.87 (t, 2H), 2.46 (s, 3H), 2.36 (s, 3), 0.84 (s, 9H), 0.00 (s, 6H).

MS (*m/z*): 693 [MH]⁺.

5 Intermediate 53

1-[1-(3-(2-Hydroxyethyl)-6-methyl-2-([2-methyl-4-(1*H*-pyrazol-1-yl)phenyl]amino)-4-pyridinyl)-1*H*-pyrazol-3-yl]-3-([4-(methyloxy)phenyl]methyl)-2-imidazolidinone

As in intermediate 47.

10 NMR (¹H, CDCl₃): δ 7.94 (d, 1H), 7.81 (d, 1H), 7.65 (d, 1H), 7.57 (m, 2H), 7.48 (d, 1H), 7.38 (dd, 1H), 7.22 (d, 2H), 6.97 (d, 1H), 6.86 (d, 2H), 6.54 (s, 1H), 6.37 (t, 1H), 4.38 (t, 2H), 4.10 (m, 2H), 3.82 (t, 2H), 3.78 (s, 3H), 3.32 (t, 2H), 2.83 (t, 2H), 2.40 (s, 3H), 2.27 (s, 3H).

MS (*m/z*): 579 [MH]⁺.

15

Intermediate 54

1-(1-{6-Methyl-1-[2-methyl-4-(1*H*-pyrazol-1-yl)phenyl]-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl}-1*H*-pyrazol-3-yl)-3-([4-(methyloxy)phenyl]methyl)-2-imidazolidinone

20 As in intermediate 48.

NMR (¹H, CDCl₃): δ 7.90 (d, 1H), 7.85 (d, 1H), 7.71 (m, 1H), 7.67 (m, 1H), 7.63 (m, 1H), 7.36 (d, 1H), 7.24 (d, 2H), 7.03 (d, 1H), 6.90 (d, 2H), 6.62 (s, 1H), 6.45 (t, 1H), 4.43 (s, 2H), 3.96 (m, 4H), 3.81 (s, 3H), 3.49 (t, 2H), 3.40 (t, 2H), 2.34 (s, 3H), 2.29 (s, 6H).

MS (*m/z*): 561 [MH]⁺.

25

Intermediate 55

4-({3-(2-([1,1-Dimethylethyl)(dimethyl)silyloxy)ethyl)-6-methyl-4-[3-(3-([4-(methyloxy)phenyl]methyl)-2-oxo-1-imidazolidinyl)-1*H*-pyrazol-1-yl]-2-pyridinyl}amino)-3-(trifluoromethyl)benzonitrile

30

As in intermediate 46, except that 4-amino-3-(trifluoromethyl)benzonitrile was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

35 NMR (¹H, CDCl₃): δ 8.41 (d, 1H), 8.32 (s, 1H), 7.92 (d, 1H), 7.74 (m, 2H), 7.35 (m, 3H), 7.12 (d, 1H), 6.96 (d, 2H), 4.52 (s, 2H), 4.18 (t, 2H), 4.00 (m, 2H), 3.90 (s, 3H), 3.48 (t, 2H), 3.21 (t, 2H), 2.63 (s, 3H), 0.91 (s, 9H), 0.07 (s, 6H).

MS (*m/z*): 706 [MH]⁺.

Intermediate 56

40 4-({3-(2-Hydroxyethyl)-6-methyl-4-[3-(3-([4-(methyloxy)phenyl]methyl)-2-oxo-1-imidazolidinyl)-1*H*-pyrazol-1-yl]-2-pyridinyl}amino)-3-(trifluoromethyl)benzonitrile

As in intermediate 47.

NMR (^1H , CDCl_3): δ 8.28 (d, 1H), 8.20 (s, 1H), 7.77 (d, 1H), 7.61 (dd, 1H), 7.56 (d, 1H), 7.16 (d, 2H), 6.98 (d, 1H), 6.81 (d, 2H), 6.72 (s, 1H), 6.14 (t, 1H), 4.35 (s, 2H), 4.06 (t, 2H), 3.78 (t, 2H), 3.73 (s, 3H), 3.32 (t, 2H), 2.84 (t, 2H), 2.43 (s, 3H).
MS (m/z): 592 $[\text{MH}]^+$.

5

Intermediate 57

4-{6-Methyl-4-[3-(3-{[4-(methyloxy)phenyl]methyl}-2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile

10

As in intermediate 48.

NMR (^1H , CDCl_3): δ 8.00 (d, 1H), 7.85 (d, 1H), 7.81 (dd, 1H), 7.68 (d, 1H), 7.25 (d, 2H), 7.05 (d, 1H), 6.89 (d, 2H), 6.75 (s, 1H), 4.42 (s, 2H), 3.93 (m, 4H), 3.52 (t, 2H), 3.48 (s, 3H), 3.40 (t, 2H), 2.35 (s, 3H).
MS (m/z): 574 $[\text{MH}]^+$.

15

Intermediate 58

1-{1-[2-{[2-(Difluoromethyl)-4-(methyloxy)phenyl]amino}-3-(2-{[(1,1-dimethylethyl)(dimethyl)silyloxy]ethyl}-6-methyl-4-pyridinyl)-1H-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

20

As in intermediate 46, except that intermediate 87 (2-(difluoromethyl)-4-(methyloxy)aniline) was used instead of 2-methyl-4-[(trifluoromethoxy)aniline].

NMR (^1H , CDCl_3): δ 7.62 (d, 1H), 7.56 (d, 1H), 7.50 (s, 1H), 7.26 (d, 2H), 7.13 (d, 1H), 7.01-6.98 (m, 2H), 6.87-6.92 (m, 2H), 6.73 (t, 1H, $J_{\text{H-F}} = 56.1$ Hz), 6.55 (s, 1H), 4.44 (s, 2H), 4.11 (t, 2H), 3.86 (t, 2H), 3.84 (s, 3H), 3.82 (s, 3H), 3.39 (t, 2H), 2.84 (t, 2H), 2.35 (s, 3H), 0.82 (s, 9H), 0.00 (s, 6H).

25

MS (m/z): 693 $[\text{MH}]^+$.

Intermediate 59

30

1-{1-[2-{[2-(Difluoromethyl)-4-(methyloxy)phenyl]amino}-3-(2-hydroxyethyl)-6-methyl-4-pyridinyl]-1H-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 47.

NMR (^1H , $\text{DMSO}-d_6$): δ 8.32 (bs, 1H), 8.02 (d, 1H), 7.34-7.30 (m, 1H), 7.21 (d, 2H), 7.05-7.07 (m, 2H), 6.9 (d, 2H), 6.86 (t, 1H, $J_{\text{H-F}} = 54.9$ Hz), 6.76 (d, 1H), 6.63 (s, 1H), 5.29 (t, 1H), 4.31 (s, 2H), 3.73-3.84 (m, 10H), 3.34 (t, 2H), 2.77 (t, 2H), 2.19 (s, 3H).

35

MS (m/z): 579 $[\text{MH}]^+$.

Intermediate 60

40

1-(1-{1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 48.

NMR (^1H , CDCl_3): δ 7.84 (d, 1H), 7.21-7.26 (m, 4H), 7.02-7.06 (m, 2H), 6.87-6.89 (m, 2H), 6.87 (t, 1H, $J_{\text{H-F}} = 55.5$ Hz), 6.64 (s, 1H), 4.23 (s, 2H), 3.81-3.97 (m, 10H), 3.37-3.49 (m, 4H), 2.32 (s, 3H).

5 MS (m/z): 561 $[\text{MH}]^+$.

Intermediate 61

10 4-({3-(2-((1,1-Dimethylethyl)(dimethyl)silyloxy)ethyl)-6-methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2-pyridinyl}amino)-3-[(trifluoromethyl)oxy]benzonitrile

As in intermediate 46, except that 4-amino-3-[(trifluoromethyl)oxy]benzonitrile was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

MS (m/z): 722 $[\text{MH}]^+$.

Intermediate 62

4-({3-(2-Hydroxyethyl)-6-methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2-pyridinyl}amino)-3-[(trifluoromethyl)oxy]benzonitrile

20 As in intermediate 47.

NMR (^1H , CDCl_3): δ 8.84 (d, 1H), 8.56 (d, 1H), 7.61 (d, 1H), 7.5 (dd, 1H), 7.48 (bs, 1H), 7.23 (d, 2H), 7.02 (d, 1H), 6.87 (d, 2H), 6.87 (d, 2H), 6.74 (s, 1H), 4.4 (s, 2H), 4.2 (m, 2H), 3.84 (t, 2H), 3.79 (s, 3H), 3.37 (t, 2H), 3.1 (bs, 1H), 2.86 (m, 2H), 2.5 (s, 3H).

MS (m/z): 608 $[\text{MH}]^+$.

Intermediate 63

4-[6-Methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-[(trifluoromethyl)oxy]benzonitrile

30 As in intermediate 48.

NMR (^1H , CDCl_3): δ 8.05 (d, 1H), 7.84 (m, 1H), 7.54 (bs, 1H), 7.5 (m, 1H), 7.23 (m, 1H), 7.03 (m, 1H), 6.87 (d, 2H), 6.78 (s, 1H), 4.41 (s, 2H), 4.11 (m, 2H), 3.91 (m, 2H), 3.79 (s, 3H), 3.5 (t, 2H), 3.38 (t, 2H), 2.41 (s, 3H).

MS (m/z): 590 $[\text{MH}]^+$.

Intermediate 64

35 4-({3-(2-((1,1-Dimethylethyl)(dimethyl)silyloxy)ethyl)-6-methyl-4-[3-(3-{4-(methyloxy)phenyl}methyl)-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2-pyridinyl}amino)-3-ethylbenzonitrile

40 As in intermediate 46, except that 4-amino-3-ethylbenzonitrile was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

MS (*m/z*): 666 [MH]⁺.

Intermediate 65

5 3-Ethyl-4-({3-(2-hydroxyethyl)-6-methyl-4-[3-(3-{[4-(methyloxy)phenyl]methyl}-2-oxo-1-imidazolidinyl)-1*H*-pyrazol-1-yl]-2-pyridinyl}amino)benzonitrile

As in intermediate 47.

10 NMR (¹H, CDCl₃): δ 8.11 (d, 1H), 7.92 (s, 1H), 7.61 (d, 1H), 7.43 (dd, 1H), 7.42 (bs, 1H), 7.23 (d, 2H), 7.01 (d, 1H), 6.87 (d, 2H), 6.69 (s, 1H), 4.41 (s, 2H), 4.19 (m, 2H), 3.84 (t, 2H), 3.79 (s, 3H), 3.37 (t, 2H), 3.2 (bs, 1H), 2.86 (m, 2H), 2.64 (m, 2H), 2.47 (s, 3H), 1.27 (t, 3H).

MS (*m/z*): 552 [MH]⁺.

Intermediate 66

15 3-Ethyl-4-{6-methyl-4-[3-(3-{[4-(methyloxy)phenyl]methyl}-2-oxo-1-imidazolidinyl)-1*H*-pyrazol-1-yl]-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-1-yl}benzonitrile

As in intermediate 48.

20 NMR (¹H, CDCl₃): δ 7.83 (d, 1H), 7.6 (bs, 1H), 7.48 (dd, 1H), 7.35 (d, 1H), 7.23 (d, 2H), 7.02 (d, 1H), 6.87 (d, 2H), 6.65 (s, 1H), 4.41 (s, 2H), 3.92 (m, 4H), 3.79 (s, 3H), 3.48 (t, 2H), 3.38 (t, 2H), 2.66 (q, 2H), 2.32 (s, 3H), 1.22 (t, 3H).

MS (*m/z*): 534 [MH]⁺.

Intermediate 67

25 1-[1-(3-(2-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}ethyl)-6-methyl-2-{[2-(methyloxy)-4-(1*H*-pyrazol-1-yl)phenyl]amino}-4-pyridinyl)-1*H*-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 46, except that intermediate 88 (2-(methyloxy)-4-(1*H*-pyrazol-1-yl)aniline) was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

30 NMR (¹H, CDCl₃): δ 7.88 (d, 1H), 7.76 (d, 1H), 7.65 (d, 1H), 7.5 (bs, 1H), 7.35 (d, 1H), 7.21 (m, 3H), 7.16 (dd, 1H), 7.02 (d, 1H), 6.88 (d, 2H), 6.69 (d, 1H), 6.54 (s, 1H), 6.44 (t, 1H), 4.41 (s, 2H), 4.11 (t, 2H), 3.95 (s, 3H), 3.86 (t, 2H), 3.79 (s, 3H), 3.36 (t, 2H), 2.85 (t, 2H), 2.51 (s, 3H), 0.79 (s, 9H), 0.07 (s, 6H).

MS (*m/z*): 709 [MH]⁺

Intermediate 68

1-[1-(3-(2-Hydroxyethyl)-6-methyl-2-{[2-(methyloxy)-4-(1*H*-pyrazol-1-yl)phenyl]amino}-4-pyridinyl)-1*H*-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

40 As in intermediate 47.

NMR (¹H, CDCl₃): δ 8.66 (m, 1H), 7.88 (d, 1H), 7.69 (d, 1H), 7.62 (d, 1H), 7.5 (bs, 1H), 7.38 (d, 1H), 7.21 (m, 3H), 7.16 (dd, 1H), 7.02 (d, 1H), 6.88 (d, 2H), 6.54 (s, 1H), 6.44 (t,

1H), 4.41 (s, 2H), 4.11 (t, 2H), 3.98 (s, 3H), 3.9 (t, 2H), 3.79 (s, 3H), 3.40 (t, 2H), 2.9 (t, 2H), 2.49 (s, 3H).

MS (*m/z*): 595 [MH]⁺.

5 Intermediate 69

1-(1-{6-Methyl-1-[2-(methyloxy)-4-(1*H*-pyrazol-1-yl)phenyl]-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl}-1*H*-pyrazol-3-yl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 48.

10 NMR (¹H, CDCl₃): δ 7.88 (d, 1H), 7.83 (d, 1H), 7.70 (d, 1H), 7.59 (d, 1H), 7.42 (d, 1H), 7.22 (m, 3H), 7.00 (d, 1H), 6.88 (d, 2H), 6.63 (s, 1H), 6.43 (t, 1H), 4.41 (s, 2H), 3.98 (m, 4H), 3.90 (s, 3H), 3.78 (s, 3H), 3.40 (m, 4H), 2.34 (s, 3H).

Intermediate 70

15 1-(1-{3-(2-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}ethyl)-6-methyl-2-[(6-methyl-1,3-benzodioxol-5-yl)amino]-4-pyridinyl}-1*H*-pyrazol-3-yl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 46, except that intermediate 89 (6-methyl-1,3-benzodioxol-5-amine) was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

20 NMR (¹H, CDCl₃): δ 7.57 (d, 1H), 7.43 (bs, 1H), 7.25 (bs, 1H), 7.21 (d, 2H), 6.94 (d, 1H), 6.86 (d, 2H), 6.64 (d, 1H), 6.48 (bs, 1H), 5.88 (s, 2H), 4.40 (s, 2H), 4.08 (m, 2H), 3.83 (m, 2H), 3.79 (s, 3H), 3.35 (t, 2H), 2.78 (t, 2H), 2.38 (bs, 3H), 2.16 (s, 3H), 0.80 (s, 9H), -0.04 (s, 6H).

25 MS (*m/z*): 671 [MH]⁺.

Intermediate 71

1-(1-{3-(2-Hydroxyethyl)-6-methyl-2-[(6-methyl-1,3-benzodioxol-5-yl)amino]-4-pyridinyl}-1*H*-pyrazol-3-yl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

30

As in intermediate 47.

NMR (¹H, CDCl₃): δ 7.59 (d, 1H), 7.39 (bs, 1H), 7.24 (m, 2H), 7.21, 6.99 (d, 1H), 6.87 (d, 2H), 6.70 (bs, 1H), 6.65 (s, 1H), 6.48 (s, 1H), 5.89 (s, 2H), 4.40 (s, 2H), 4.33 (t, 1H), 4.08 (m, 2H), 3.85 (t, 2H), 3.78 (s, 3H), 3.36 (t, 2H), 2.85 (t, 2H), 2.38 (s, 3H), 2.17 (s, 3H).

35 MS (*m/z*): 557 [MH]⁺.

Intermediate 72

1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

40

As in intermediate 48.

NMR (^1H , CDCl_3): δ 7.81 (d, 1H), 7.23 (m, 2H), 6.99 (d, 1H), 6.87 (d, 2H), 6.73 (d, 2H), 6.56 (s, 1H), 5.90 (s, 2H), 4.40 (s, 2H), 3.92 (t, 2H), 3.78 (m, 5H), 3.39 (m, 4H), 2.31 (s, 3H), 2.15 (s, 3H).

MS (m/z): 539 $[\text{MH}]^+$.

5

Intermediate 73

1-[1-(3-(2-((1,1-Dimethylethyl)(dimethyl)silyloxy)ethyl)-6-methyl-2-((2,4,6-tris(methyloxy)phenyl)amino)-4-pyridinyl)-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone

10

As in intermediate 46, except that 2,4,6-tris(methyloxy)aniline was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

MS (m/z): 703 $[\text{MH}]^+$.

15

Intermediate 74

1-[1-(3-(2-Hydroxyethyl)-6-methyl-2-((2,4,6-tris(methyloxy)phenyl)amino)-4-pyridinyl)-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone

As in intermediate 47.

20

MS (m/z): 589 $[\text{MH}]^+$.

Intermediate 75

1-[[4-(Methyloxy)phenyl]methyl]-3-(1-(6-methyl-1-[[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-*b*]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone

25

As in intermediate 48.

NMR (^1H , $\text{DMSO}-d_6$): δ 8.84 (d, 1H), 7.24 (bs, 2H), 7.01 (bs, 1H), 6.88-6.83 (d-d, 2H), 6.54 (s, 1H), 6.20 (d, 1H), 6.18 (s, 1H), 4.44 (s, 2H), 3.92-3.84 (m, 2H), 3.81-3.72 (m, 14H), 3.48-3.36 (m, 4H), 2.40 (bs, 3H).

30

MS (m/z): 451 $[\text{MH}]^+$.

Intermediate 76

1-(1-(3-(2-((1,1-Dimethylethyl)(dimethyl)silyloxy)ethyl)-6-methyl-2-[[4-methyl-1,3-benzodioxol-5-yl]amino]-4-pyridinyl)-1H-pyrazol-3-yl)-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone

35

As in intermediate 46, except that 4-methyl-1,3-benzodioxol-5-amine (prepared as described in the US Patent 5965595 A) was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

40

NMR (^1H , CDCl_3): δ 7.57 (d, 1H), 7.41 (bs, 1H), 7.21 (m, 3H), 7.00 (d, 1H), 6.95 (d, 2H), 6.87 (d, 1H), 6.47 (s, 1H), 5.92 (s, 2H), 4.40 (s, 2H), 4.11 (m, 2H), 3.83 (s, 3H), 3.35 (t, 2H), 2.79 (t, 2H), 2.33 (s, 3H), 2.04 (s, 3H), 0.79 (s, 9H), -0.04 (s, 6H).

MS (*m/z*): 671 [MH]⁺.

Intermediate 77

5 1-(1-{3-(2-Hydroxyethyl)-6-methyl-2-[(6-methyl-1,3-benzodioxol-5-yl)amino]-4-pyridinyl}-1*H*-pyrazol-3-yl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 47.

10 NMR (¹H, CDCl₃): δ 7.59 (d, 1H), 7.20 (m, 3H), 7.10 (d, 1H), 6.99 (d, 1H), 6.87 (d, 2H), 6.70 (d, 1H), 6.47 (s, 1H), 5.93 (s, 2H), 4.40 (s, 2H), 4.08 (m, 2H), 3.85 (t, 2H), 3.78 (s, 3H), 3.36 (t, 2H), 2.85 (t, 2H), 2.35 (s, 3H), 2.09 (s, 3H).

MS (*m/z*): 557 [MH]⁺.

Intermediate 78

15 1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl]-1*H*-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 48.

20 NMR (¹H, CDCl₃): δ 7.81 (d, 1H), 7.23 (m, 2H), 6.99 (d, 1H), 6.88 (d, 2H), 6.72 (dd, 2H), 6.56 (s, 1H), 5.95 (s, 2H), 4.40 (s, 2H), 3.92 (t, 2H), 3.81 (t, 2H), 3.78 (s, 3H), 3.39 (m, 4H), 2.31 (s, 3H), 2.08 (s, 3H).

MS (*m/z*): 539 [MH]⁺

Intermediate 79

25 1-{1-[2-{[2,4-Bis(trifluoromethyl)phenyl]amino}-3-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}ethyl)-6-methyl-4-pyridinyl]-1*H*-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 46, except that 2,4-bis(trifluoromethyl)aniline was used instead of 2-methyl-4-[(trifluoromethyl)oxy]aniline.

30 NMR (¹H, CDCl₃): δ 8.33 (d, 1H), 7.99 (bs, 1H), 7.78 (bs, 1H), 7.63 (m, 2H), 7.24 (m, 2H), 6.99 (m, 1H), 6.85 (d, 2H), 6.77 (bs, 1H), 4.40 (s, 2H), 4.05 (m, 2H), 3.83 (m, 2H), 3.78 (s, 3H), 3.36 (t, 2H), 2.90 (t, 2H), 2.49 (s, 3H), 0.73 (s, 9H), -0.11 (s, 6H).

MS (*m/z*): 749 [MH]⁺.

35 Intermediate 80

1-{1-[2-{[2,4-Bis(trifluoromethyl)phenyl]amino}-3-(2-hydroxyethyl)-6-methyl-4-pyridinyl]-1*H*-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 47.

40 NMR (¹H, CDCl₃): δ 8.37 (d, 1H), 7.90 (bs, 1H), 7.79 (bs, 1H), 7.67 (m, 2H), 7.61 (d, 1H), 7.51 (m, 1H), 7.03 (bs, 1H), 6.88 (d, 2H), 6.72 (s, 1H), 4.40 (s, 2H), 4.20 (t, 2H), 4.05 (bs, 1H), 3.85 (t, 2H), 3.78 (s, 3H), 3.37 (t, 2H), 2.89 (t, 2H), 2.47 (s, 3H).

MS (*m/z*): 635 [MH]⁺.

Intermediate 81

5 1-(1-{1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1*H*-pyrrolo[2,3-*b*]pyridin-4-yl}-1*H*-pyrazol-3-yl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

As in intermediate 48.

10 NMR (¹H, CDCl₃): δ 7.96 (s, 1H), 7.84 (d, 1H), 7.79 (bs, 1H), 7.58 (d, 1H), 7.22 (d, 2H), 7.02 (d, 1H), 6.88 (d, 2H) 6.70 (s, 1H), 4.41 (s, 2H), 3.92 (m, 4H), 3.79 (s, 3H), 3.49 (t, 2H), 3.37 (t, 2H), 2.31 (s, 3H).

MS (*m/z*): 617 [MH]⁺.

Intermediate 82

15 1,1-Dimethylethyl (4-bromo-2-methylphenyl)carbamate

To a solution of 4-bromo-2-methylaniline (1 g, 5.37 mmol,) in 1,4-dioxane (11 mL) and H₂O (4 mL), at r.t., were added Et₃N (2.7 mL, 1.2 eq) and BOC₂O (4.2 g, 1.2 eq). The reaction mixture was stirred at r.t. for 96 hr. Sat.aq. NH₄Cl and EtOAc (20 mL) were added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x20 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified on an SCX cartridge (CH₂Cl₂, MeOH and NH₃(0.5 M in MeOH)) to give the title compound as a white solid (1.22 g, 79%).

25 NMR (¹H, DMSO-*d*₆): δ 8.55 (s, 1H), 7.35 (m, 1H), 7.28 (m, 2H), 2.17 (s, 3H), 1.44 (s, 9H).
MS (*m/z*): 230 [MH-*t*Bu]⁺, 186 [MH-BOC]⁺.

Intermediate 83

2-Methyl-4-(1*H*-pyrazol-1-yl)aniline

30 A solution of intermediate 82 (200 mg, 0.7 mmol), 1*H*-pyrazole (95 mg, 2 eq), CuI (133 mg, 1 eq), K₂CO₃ (290 mg, 2.1 eq) and (1*R*,2*R*)-diaminomethylcyclohexane (100 mg, 1 eq) in anh. NMP (1 mL), under N₂, was heated at 150°C for 6 hr. It was cooled down to r.t. and poured into water. EtOAc was added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash-chromatography (silica gel, *c*Hex/EtOAc 8:2) to give the title compound as a white solid (85.6 mg, 70%).

35 NMR (¹H, CDCl₃): δ 7.77 (dd, 1H), 7.66 (d, 1H), 7.39 (d, 1H), 7.29 (dd, 1H), 6.72 (d, 1H), 6.40 (t, 1H), 2.85 (bs, 1H).

40 MS (*m/z*): 174 [MH]⁺.

Intermediate 84

(5-Methoxy-2-nitro-phenyl)-methanol

To a suspension of cyanuric chloride (1.84 g, 1 eq) in anh. DME (60 mL) at r.t., under N₂, was added NMM (1.1 mL, 1 eq). The reaction mixture was stirred for 2 min and a precipitate was formed. A solution of 5-(methoxy)-2-nitrobenzoic acid (2.0 g, 10 mmol) in anh. DME (20 mL) was added and the reaction mixture was stirred for 4 hr. The suspension was filtered and a solution of NaBH₄ (0.57 g, 1.5 eq) in water (30 mL) was added at 0°C. The reaction mixture was stirred for 20 min at 0°C. It was then diluted with Et₂O (10 mL) and acidified to pH 5 by addition of sat. aq. NH₄Cl. The phases were separated and the aqueous layer was extracted with Et₂O (2x100 mL). The combined organic extracts were washed with sat. aq. Na₂CO₃ and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated to dryness. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound (958 mg, 53 %).

NMR (¹H, CDCl₃): δ 8.15 (d, 1H), 7.19 (m, 1H), 6.85 (dd, 1H), 4.95 (d, 2H), 3.89 (s, 3H), 2.5 (t, 1H).

Intermediate 855-(Methoxy)-2-nitrobenzaldehyde

To a solution of intermediate 84 (1.44 g, 7.9 mmol) in anh. CH₂Cl₂ (40 mL) at r.t., under N₂, was added Dess-Martin periodinane (3.68 g, 1.1 eq). The reaction mixture was stirred for 3 hr at r.t., then sat.aq. Na₂S₂O₃ (5 mL) and sat.aq. NaHCO₃ (20 mL) were added. The phases were separated and the aqueous layer was extracted with EtOAc (2x100 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to dryness to give 1.45 g (100%) of the title compound.

NMR (¹H, CDCl₃): δ 10.47 (s, 1H), 8.14 (d, 1H), 7.31 (d, 1H), 7.13 (dd, 1H), 3.94 (s, 3H).

Intermediate 862-(Difluoromethyl)-4-(methoxy)-1-nitrobenzene

To a solution of intermediate 85 (250 mg, 1.38 mmol) in anh. CH₂Cl₂ (10 mL), at -78°C, under N₂, was added slowly DAST (2x0.4 mL, 2.2 eq). The reaction mixture was stirred at r.t. for 1.5 hr, after which was added sat.aq. NaCl. The phases were separated and the aqueous layer was extracted with EtOAc (3x20 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent was evaporated to dryness. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound (176 mg, 63 %) as a yellow oil.

NMR (¹H, CDCl₃): δ 8.21 (d, 1H), 7.43 (t, 1H, J_(H-F) = 54.9 Hz), 7.33 (d, 1H), 7.06 (dd, 1H), 3.95 (s, 3H).

Intermediate 87

2-(Difluoromethyl)-4-(methyloxy)aniline

To a solution of intermediate 86 (176 mg, 0.87 mmol) in anh. MeOH (8.7 mL), at r.t., under N₂, was added Pd/C 10% (88 mg, 5% wt). The reaction mixture was placed under an atmosphere of H₂ for 5 hr. The catalyst was filtered off and the solution obtained was evaporated to dryness. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound (27 mg, 20 %) as a yellow oil.

NMR (¹H, CDCl₃): δ 6.88-6.80 (m, 2H), 6.7-6.67 (m, 1H), 6.62 (t, 1H, J_(H-F) = 55.6 Hz), 3.8-3.5 (bs, 2H), 3.76 (s, 3H)

MS (*m/z*): 174 [MH]⁺.

Intermediate 882-(Methyloxy)-4-(1*H*-pyrazol-1-yl)aniline

To a solution of 4-bromo-2-(methyloxy)aniline (400 mg, 1.979 mmol) in anh. NMP (4 mL), at r.t., under N₂, were added pyrazole (269 mg, 2 eq), K₂CO₃ (819 mg, 3 eq), CuI (377 mg, 1 eq) and (1*R*,2*R*)-diaminomethylcyclohexane (281 mg, 1 eq). The reaction mixture was stirred at 150°C for 3 hr. It was cooled down to r.t. and poured into EtOAc/sat.aq. NaCl. The phases were separated and the organic layer was washed with sat.aq. NH₄Cl (20 mL) and sat.aq. NaCl (20 mL). The combined aqueous layers were extracted back with EtOAc (20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a brown oil (336 mg, 90%)

NMR (¹H, CDCl₃): δ 7.78 (d, 1H), 7.65 (d, 1H), 7.21 (d, 1H), 6.97 (dd, 1H), 6.73 (d, 1H), 6.40 (m, 1H), 4.05 (bs, 2H), 3.87 (s, 3H).

MS (*m/z*): 190 [MH]⁺.

Intermediate 896-Methyl-1,3-benzodioxol-5-amine

A mixture of 5-methyl-6-nitro-benzo(1,3)dioxole (50 mg, 0.28 mmol), Fe (54 mg, 3.5 eq) and ammonium chloride (51.2 mg, 3.5 eq) in a 1:1 mixture of MeOH/H₂O (2.8 mL) was subjected to microwave irradiation (60W, P=100p.s.i.) at 80°C for four 10 min periods.

The brown solution was allowed to cool to r.t. and more Fe (3.5 eq) and ammonium chloride (3.5 eq) were added. The mixture was subjected to microwave irradiation (60W, P=100p.s.i.) at 80°C for an additional 10 min. Fe was filtered off and the solvent evaporated. The crude product was purified on an SCX cartridge (cHex/EtOAc 9:1) to give the title compound as a brown solid (40 mg, 93%).

NMR (¹H, CDCl₃): δ 6.54 (s, 1H), 6.27 (s, 1H), 5.80 (s, 2H), 2.27 (bs, 2H), 2.07 (s, 3H).

MS (*m/z*): 152 [MH]⁺.

Intermediate 904-[[2-Methyl-4-(methyloxy)phenyl]amino]butanenitrile

5 A solution of DIPEA (39 mL, 1 eq) and 4-methoxy-2-methylaniline (30g, 0.22 mol) in anh. DMF (90mL), under N₂, was heated at 100°C. 4-Bromobutanenitrile (21 mL, 1 eq) was added dropwise. The internal temperature was raised to 110°C and the reaction mixture was stirred for 2 hr. The mixture was cooled down to r.t. and diluted with MTBE (240 mL). Water (270 mL) was added and the phases were separated. The organic layer was further washed with water (150 mL) and evaporated to 150 mL. Fresh MTBE (150 mL) was added and the mixture again evaporated to 150 mL. The mixture was treated with cHex (540 mL) over 20 min and the resulting suspension left at room temperature for 1.5 hr. The suspension was filtered and the cake washed with a mixture MTBE (30 mL)/cHex (90 mL). The title compound was collected as a violet solid (23.8 g, 53%).

10 NMR (¹H, DMSO-d₆): δ 6.65 (d, 1H), 6.63 (dd, 1H), 6.47 (d, 1H), 4.49 (bt, 1H), 3.64 (s, 3H), 3.10 (q, 2H), 2.59 (t, 2H), 2.09 (s, 3H), 1.86 (m, 2H).

15 MS (m/z): 205 [MH]⁺.

Intermediate 911-[2-Methyl-4-(methyloxy)phenyl]-2-pyrrolidinimine

20 To a suspension of intermediate 90 (35.0 g, 0.173 mol) in anh. IPA (280 mL), at r.t., under N₂, was added 6N HCl/IPA (51.45 mL, 1.5 eq). The mixture was heated to reflux for 4 hr, allowed to cool down to r.t. and evaporated to 140 mL. Water (350 mL) was added, the clear solution evaporated again to 140 mL and treated with 10% NaOH (140 mL). The mixture was extracted with CH₂Cl₂ (350 mL) and the organic layer further washed with 10% NaCl (140 mL). The organic layer was evaporated to dryness. The crude product was used as such in the next step (36.4 g, 100%)

25 NMR (¹H, DMSO-d₆): δ 7.09 (d, 1H), 6.87 (d, 1H), 6.80 (dd, 1H), 5.8-5.4 (b, 1H), 3.75 (s, 1H), 3.54 (t, 2H), 2.51 (t, 2H), 2.11 (s, 3H), 2.01 (m, 2H).

30 MS (m/z): 205 [MH]⁺.

Intermediate 924-Bromo-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine

35 To a solution of intermediate 4 (50.0 g, 0.15 mol) in anh. DMF (175 mL), at r.t., under N₂, was added CH₃SO₃H (58.1 mL, 1.2 eq) followed by NaBr (19.18 g, 1.5 eq) and the resulting mixture was heated at 85°C for 2 hr. It was then diluted with MTBE (250 mL) and washed with 1N NaOH (250 mL). The aqueous phase was extracted with MTBE (150 mL) and the combined organic extracts washed twice with water (250 mL), then dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated to give the title compound (38.g, 76%) as a yellow solid.

40

NMR (^1H , DMSO- d_6): δ 7.17 (d, 1H), 6.87 (d, 1H), 6.80 (dd, 1H), 6.56 (s, 1H), 3.86 (t, 2H), 3.76 (s, 3H), 3.06 (t, 2H), 2.15-2.14 (2s, 6H).

MS (m/z): 333/335 [MH] $^+$.

5 Intermediate 93

{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}boronic acid

10 To a mixture of triisopropyl borate (185 μL , 3 eq) and intermediate 5 (100 mg, 1 eq) in an anhydrous 1:4 mixture of THF/toluene (0.5 mL), at -70°C , under N_2 , was added $n\text{-BuLi}$ (329 μL , 2 eq) dropwise. The reaction mixture was stirred at -70°C for 2.5 hr. It was warmed up to -20°C and quenched with 1M HCl (0.5 mL, 2 eq). The mixture was warmed up to r.t. and precipitation of the boronic acid was observed. The solid was filtered and washed with CH_3CN . The title compound was obtained as a white solid (70 mg, 89%).

15 NMR (^1H , CDCl_3): δ 7.21 (d, 1H), 6.91 (d, 1H), 6.84 (dd, 1H), 6.61 (d, 1H), 4.02 (bt, 2H), 3.74 (s, 3H), 3.29 (bt, 2H), 2.21 (s, 3H), 2.15 (s, 3H).

MS (m/z): 299 [MH] $^+$.

Intermediate 94

20 N-(6-Bromo-2-pyridinyl)-N'-(2-chloroethyl)urea

To a solution of 6-bromo-2-pyridinamine (1 g, 5.78 mmol) in anhydrous THF (25 mL), at r.t., under N_2 , was added 1-chloro-2-isocyanatoethane (1.2 mL, 2.5 eq) and the reaction mixture was stirred at r.t. for 18 hr. The crude mixture was partitioned between CH_2Cl_2 and water. The phases were separated and the organic layer was dried over anhydrous Na_2SO_4 . The solids were filtered and the solvent evaporated to give the title compound (1.06 g, 66%) which was used in the next step without further purification.

25 NMR (^1H , DMSO- d_6): δ 9.56 (bs, 1H), 7.75 (m, 2H), 7.32 (t, 1H), 7.14 (t, 1H), 3.65 (t, 2H), 3.46 (m, 2H)

30 Intermediate 95

1-(6-Bromo-2-pyridinyl)-2-imidazolidinone

35 To a solution of intermediate 94 (1.06 g, 3.82 mmol) in anhydrous THF (25 mL), at 0°C , under N_2 , was added $t\text{-BuOK}$ (644 mg, 1.5 eq) and the reaction mixture was allowed to warm up to r.t. After 1 h at r.t. the reaction mixture was partitioned between CH_2Cl_2 and water. The organic layer was dried over anhydrous Na_2SO_4 , the solids were filtered and the solvent evaporated to give the title compound (0.988 g, quantitative) which was used in the next step without further purification.

40 NMR (^1H , DMSO- d_6): δ 8.14 (d, 1H), 7.61 (t, 1H), 7.33 (bs, 1H), 7.19 (d, 1H), 3.95 (t, 2H), 3.40 (t, 2H)

Intermediate 961-(6-Bromo-2-pyridinyl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a solution of intermediate 95 (0.5 g, 2.06 mmol) in anh. DMF (25 mL), at r.t., under N₂, was added NaH 60%/oil (82 mg, 1 eq) and *p*-methoxybenzyl chloride (280 μ L, 1 eq) and the mixture was stirred at r.t. for 2 hr. It was then partitioned between CH₂Cl₂ and water. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The resulting crude product was purified by flash chromatography (silica gel, CH₂Cl₂/MeOH 9:1) to give the title compound (0.635 g, 85%).

NMR (¹H, CDCl₃): δ 8.33 (d, 1H), 7.71 (t, 1H), 7.29 (d, 2H), 7.10 (d, 1H), 6.85 (d, 2H), 4.43 (s, 2H), 4.00 (t, 2H), 3.83 (s, 3H), 3.55 (t, 2H)

Intermediate 971-(6-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyridinyl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a solution of intermediate 93 (50 mg, 1 eq) and intermediate 96 (121 mg, 2 eq) in a 1:1 mixture of toluene/EtOH (5 mL), at r.t., under N₂, were added 2M Na₂CO₃ (168 μ L), Pd(PPh₃)₄ (19 mg, 0.1 eq) and tetra-*n*-butylammonium bromide (9 mg, 0.1 eq). The reaction mixture was stirred at 90°C for 2 hr in a sealed vial. It was partitioned between EtOAc and water. The phases were separated and the organic layer was washed with sat.aq. NaCl. It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a white solid (35 mg, 39%).

NMR (¹H, CDCl₃): δ 8.32 (d, 1H), 7.71 (d, 1H), 7.30-6.71 (m, 9H), 4.43 (s, 2H), 4.09 (t, 2H), 3.84-3.78 (m, 8H), 3.43-3.33 (m, 4H), 2.33 (s, 3H), 2.24 (s, 3H).

MS (*m/z*): 536 [MH]⁺.

Intermediate 98N-[3,4-Bis(methyloxy)phenyl]methyl-N'-(2-chloroethyl)urea

To a solution of 3,4-dimethoxybenzylamine (2 g, 12 mmol) in anh. THF (25 mL), at r.t., under N₂, was added 2-chloroethyl isocyanate (1.02 mL, 1 eq). The reaction was complete after the addition. It was concentrated and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 1:1 \rightarrow 7:3 EtOAc/NH₃ (0.5 in MeOH)) to give the title compound as a white solid (2.9 g, 89%).

NMR (¹H, DMSO-d₆): δ 6.85 (d, 1H), 6.82 (d, 1H), 6.73 (dd, 1H), 6.41 (t, 1H), 6.16 (t, 1H), 4.10 (d, 2H), 3.70 (s, 3H), 3.69 (s, 3H), 3.56 (t, 2H), 3.31 (m, 2H).

MS (*m/z*): 273 [MH]⁺.

Intermediate 991-{[3,4-Bis(methyloxy)phenyl]methyl}-2-imidazolidinone

To a suspension of intermediate 98 (1 g, 3.68 mmol) in anh. THF (30 mL), at 0°C, under N₂, was added *t*-BuOK (500 mg, 1.2 eq). The ice bath was removed and the reaction mixture was stirred at r.t. for 1 hr. Sat.aq. NH₄Cl was added and the solvents were
5 evaporated to dryness. The residue was purified by flash chromatography (silica gel, 100% EtOAc → EtOAc/MeOH 8:2) to give the title compound as a white solid (555 mg, 64%).

NMR (¹H, DMSO-d₆): δ 6.88 (d, 1H), 6.79 (d, 1H), 6.73 (dd, 1H), 6.33 (s, 1H), 4.12 (s, 2H), 3.70 (s, 6H), 3.16 (m, 4H).

10 MS (*m/z*): 237 [MH]⁺.

Intermediate 100

1-[3,4-Bis(methyloxy)phenyl]methyl-3-(4-chloro-2-pyrimidinyl)-2-imidazolidinone
and intermediate 101

15 1-[3,4-bis(methyloxy)phenyl]methyl-3-(2-chloro-4-pyrimidinyl)-2-imidazolidinone

To a solution of 2,4-dichloropyrimidine (600 mg, 2.54 mmol, 1 eq) and intermediate 99 (100 mg, 0.42 mmol) in anh. DMF (27 mL), at r.t., under N₂, was added NaH 60%/oil (112 mg, 1.1 eq). The reaction mixture was stirred at r.t. for 1 hr. Water and EtOAc were added
20 and the two phases were separated. The aqueous layer was further extracted with EtOAc (3x20 mL). The combined organic extracts were concentrated and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give intermediate 100 as a white solid (377 mg, 42%). The other regioisomer was collected in mixture with the unreacted intermediate 99. This crude mixture was repurified by flash chromatography
25 (silica gel, CH₂Cl₂/NH₃(0.5 in MeOH) 95:5) to give intermediate 101 as a white solid (193.1 mg, 22%).

Intermediate 100:

NMR (¹H, CDCl₃): δ 8.36 (d, 1H), 8.28 (d, 1H), 6.87 (s, 1H), 6.86 (d, 2H), 4.46 (s, 2H), 4.05 (dd, 2H), 3.91 (s, 6H), 3.43 (dd, 2H).

30 MS (*m/z*): 349 [MH]⁺.

Intermediate 101:

NMR (¹H, DMSO): δ 8.55 (d, 1H), 7.19 (d, 1H), 6.88 (d, 1H), 6.83 (d, 1H), 6.78 (dd, 1H), 4.29 (s, 2H), 3.88 (dd, 2H), 3.70 (s, 3H), 3.69 (s, 3H), 3.28 (dd, 2H).

35 MS (*m/z*): 349 [MH]⁺.

Intermediate 102

1-[3,4-Bis(methyloxy)phenyl]methyl-3-(4-bromo-2-pyrimidinyl)-2-imidazolidinone

40 To a suspension of intermediate 100 (50 mg, 0.144 mmol) in propionitrile (2 mL), at r.t., under N₂, was added TMSBr (38 μL, 2 eq). The reaction mixture was subjected to microwave irradiation (2x10 min, T=100°C). 2N NaOH and EtOAc were added to the

reaction mixture and the two phases were separated. The aqueous layer was further extracted with EtOAc (3x10 mL) and the combined organic extracts were concentrated in vacuo. The residue was purified on an SCX cartridge (100% CH₂Cl₂ → NH₃ (0.5 in MeOH)) to give the title compound as a white solid (43 mg, 76%).

5 NMR (¹H, CDCl₃): δ 8.27 (m, 2H), 6.81-6.83 (m, 3H), 4.24 (s, 2H), 4.01 (t, 2H), 3.88 (s, 3H), 3.87 (s, 3H), 3.40 (t, 2H).

MS (*m/z*): 393 [MH]⁺.

Intermediate 103

10 1-([3,4-Bis(methyloxy)phenyl]methyl)-3-(4-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-*b*]pyridin-4-yl}-2-pyrimidinyl)-2-imidazolidinone

To a solution of intermediate 102 (43 mg, 0.112 mmol) and intermediate 93 (50 mg, 1.5 eq) in a 1:1 mixture of EtOH/toluene (4 mL), at r.t., under N₂, were added Pd(PPh₃)₄ (13 mg, 0.1 eq), tetra-*n*-butylammonium bromide (4 mg, 0.1 eq) and 2N Na₂CO₃ (1.6 mL, 28.5 eq). The reaction mixture was heated at 100°C for 2 hr. It was cooled down to r.t. and poured into water. EtOAc was added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anhyd. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a yellow solid (71 mg, quantitative).

20 NMR (¹H, CDCl₃): δ 8.61 (dd, 1H), 8.24 (dd, 1H), 7.18-7.26 (m, 4H), 6.76-6.85 (m, 3H), 4.46 (s, 2H), 4.13 (t, 2H), 3.80-3.88 (m, 11H), 3.59 (t, 2H), 3.44 (t, 2H), 2.38 (s, 3H), 2.25 (s, 3H).

25 MS (*m/z*): 567 [MH]⁺.

Intermediate 104

1-([3,4-Bis(methyloxy)phenyl]methyl)-3-(2-bromo-4-pyrimidinyl)-2-imidazolidinone

30 To a suspension of intermediate 101 (188 mg, 0.54 mmol) in propionitrile (2 mL), at r.t., under N₂, was added TMSBr (143 μL, 2 eq). The reaction mixture was subjected to microwave irradiation (10 min, P=155 W, T=100°C, p=60 psi). 2N NaOH was added and the reaction mixture was concentrated in vacuo. The residue was purified on a MEGA Bond Elut silica cartridge (CH₂Cl₂/MeOH 95:5) to give the title compound as a yellow solid (33 mg, 16%).

35 NMR (¹H, DMSO-*d*₆): δ 8.44 (d, 1H), 7.35 (d, 1H), 6.80-6.90 (m, 3H), 4.31 (s, 2H), 3.90 (t, 2H), 3.73 (s, 3H), 3.72 (s, 3H), 3.22-3.34 (m, 2H).

MS (*m/z*): 393 [MH]⁺.

Intermediate 105

40 1-([3,4-Bis(methyloxy)phenyl]methyl)-3-(2-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-*b*]pyridin-4-yl}-4-pyrimidinyl)-2-imidazolidinone

To a solution of intermediate 104 (33 mg, 0.084 mmol) and intermediate 93 (37 mg, 1.5 eq) in a 1:1 mixture of EtOH/toluene (3 mL) were added Pd(PPh₃)₄ (10 mg, 0.1 eq), tetra-*n*-butylammonium bromide (3 mg, 0.1 eq) and 2N Na₂CO₃ (1.2 mL, 28.5 eq). The reaction mixture was heated at 100°C for 2.5 hr. It was cooled down to r.t. and poured into water. EtOAc was added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, CH₂Cl₂/MeOH 95:5) and on a Strata NH₂ desactivated silica cartridge (cHex/EtOAc 1:0 → cHex/EtOAc 0:1) to give 13 mg of the title compound still contaminated by unidentified by-products. This crude mixture was used in the next step without further purification.

NMR (¹H, CDCl₃): δ 8.73 (d, 1H), 7.43-7.69 (m, 4H), 7.17 (d, 1H), 6.75-6.92 (m, 2H), 6.70 (s, 1H), 4.47 (s, 2H), 4.06-4.15 (m, 2H), 3.80-3.91 (m, 8H), 3.80 (s, 3H), 3.55-3.63 (m, 2H), 3.40 (m, 2H), 2.35 (s, 3H), 2.24 (s, 3H).

MS (m/z): 567 [MH]⁺.

Intermediate 106

1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-1,2,4-triazol-3-amine

A suspension of intermediate 5 (50mg, 0.13 mmol), 1H-1,2,4-triazol-3-amine (22 mg, 2eq), CuI (145 mg, 6 eq), K₂CO₃ (37 mg, 2.1eq) and 1-2-N,N'-dimethylcyclohexanediamine (106 mg, 6eq) in anh. NMP (5 mL) at r.t., under N₂, was subjected to microwave irradiation (3x45 min, 150°C). Sat.aq. NaCl (15 mL) was then added and the reaction mixture extracted with CH₂Cl₂ (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvents evaporated in vacuo. The crude compound thus obtained was purified on an SCX cartridge (cHex/EtOAc 1:1 → EtOAc/MeOH 9:1) to give the title compound as a white solid (20 mg, 46%).

NMR (¹H, CDCl₃): δ 8.7 (s, 1H), 7.2 (d, 1H), 6.8 (d, 1H), 6.7 (dd, 2H), 6.67 (s, 1H), 5.75 (bs, 2H), 3.75 (t, 2H), 3.7 (s, 3H), 3.4 (t, 2H), 2.2 (s, 3H), 2.2 (s, 3H).

MS (m/z): 337 [MH]⁺.

Intermediate 107

N-(2-Chloroethyl)-N'-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-1,2,4-triazol-3-yl)urea

To a solution of intermediate 106 (20 mg, 0.06 mmol) in anh. DMF (2 mL), at 0°C, under N₂, was added 3-chloroethyl isocyanate (0.5 mL, excess) and the reaction mixture was stirred at r.t. for 6 days. H₂O (15 mL) was then added and the mixture extracted with CH₂Cl₂ (2x15 mL). The combined organic extracts were dried over anh. Na₂SO₄, the

solids were filtered and the solvents evaporated in vacuo. The crude product was purified on a MEGA Bond Elut silica cartridge (cHex/EtOAc 3:7 → 7:3) to give the title compound as a white solid (30 mg, 100%).

MS (*m/z*): 442 [MH]⁺.

5

Intermediate 108

1-{1-[2-Chloro-3-(2-hydroxypropyl)-6-methyl-4-pyridinyl]-1*H*-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

- 10 To a clear solution of intermediate 43 (160 mg, 0.36 mmol) in anh THF (2 mL), cooled at 0°C, was added 3.0 M MeMgBr/Et₂O (0.18 mL, 1.5 eq). The reaction mixture was stirred at 0°C for 1h and then slowly warmed to r.t.. After 1h, the reaction was complete. EtOAc and sat.aq. NH₄Cl were added and the phases were separated. The organic layer was washed with sat.aq. NaCl and dried over anh. Na₂SO₄, the solids were filtered and the
- 15 solvent evaporated. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 1:1 → 6:4) to give the title compound as a white solid (138 mg, 84%).
- NMR (¹H, CDCl₃): δ 7.85 (bs, 1H), 7.65 (d, 1H), 7.21 (d, 2H), 7.1 (d, 1H), 6.88 (d, 2H), 4.45 (q, 1H), 4.3 (m, 1H), 3.9 (t, 2H), 3.7 (s, 3H), 3.4 (t, 2H), 2.95 (d, 2H), 2.5 (s, 3H), 1.25 (d, 3H).
- 20 MS (*m/z*): 456 [MH]⁺.

Intermediate 109

1-{1-[2-Chloro-3-(2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}propyl)-6-methyl-4-pyridinyl]-1*H*-pyrazol-3-yl}-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

25

- To a clear solution of intermediate 108 (135 mg, 0.3 mmol) in anh CH₂Cl₂ (2 mL), at 0°C, under N₂, were added 2,6-lutidine (77 μL, 2.2 eq) and *tert*-butyldimethylsilyl triflate (100 μL, 1.5 eq). The reaction mixture was stirred at r.t. for 4 hr. Sat.aq. NH₄Cl was added, the phases were separated and the organic layer was washed with sat.aq. NaCl and dried
- 30 over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, EtOAc/cHex 1:1) to give the title compound as a white solid (130 mg, 76%).
- NMR (¹H, CDCl₃): δ 8.35 (bs, 1H), 7.19 (m, 3H), 7.00 (bs, 1H), 6.87 (d, 2H), 4.40 (s, 2H), 4.36 (m, 1H), 3.89 (m, 2H), 3.79 (s, 3H), 3.36 (t, 2H), 2.96 (m, 2H), 2.50 (s, 3H), 1.23 (d, 3H), 0.70 (s, 9H), -0.06 (s, 3H), -0.33 (s, 3H).
- 35 MS (*m/z*): 570 [MH]⁺.

Intermediate 110

1-[1-(3-(2-{[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}propyl)-6-methyl-2-{[2-methyl-4-(methyloxy)phenyl]amino}-4-pyridinyl)-1*H*-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

40

To a mixture of intermediate 109 (130 mg, 0.227 mmol), Pd₂(DBA)₃ (20.8 mg, 10% mol), K₃PO₄ (145 mg, 3 eq), 2-(Dicyclohexylphosphino)-2'-methylbiphenyl (24.8 mg, 30% mol) and 4-methoxy-2-methylaniline (47 mg, 1.5 eq), at r.t., under N₂, was added anh. DME (2 mL). The reaction mixture was stirred at 90°C for 3 hr. The mixture was cooled to r.t. and more Pd₂(DBA)₃ (20.8 mg, 10% mol) and 2-(Dicyclohexylphosphino)-2'-methylbiphenyl (24.8 mg, 30% mol) were added. The reaction was heated at 90°C for an additional 2 hr and left overnight at r.t. After an addition of Pd₂(DBA)₃ (20.8 mg, 10% mol) and 2-(Dicyclohexylphosphino)-2'-methylbiphenyl (24.8 mg, 30% mol), the reaction mixture was heated for an additional 2 hr at 90°C. Then it was cooled to r.t., treated with water and EtOAc, and the phases were separated. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent concentrated in vacuo. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2 → 7:3) to give the title compound as a yellow oil (84 mg), still contaminated with the unreacted aniline. The mixture was used in the next step without further purification.

MS (*m/z*): 671 [MH]⁺.

Intermediate 111

1-[1-(3-(2-Hydroxypropyl)-6-methyl-2-{[2-methyl-4-(methyloxy)phenyl]amino}-4-pyridinyl)-1H-pyrazol-3-yl]-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a solution of intermediate 110 (80 mg, 0.12 mmol) in anh. THF (2.5 mL), at r.t., under N₂, was added Et₃N·3HF (156 μL, 8 eq) and the reaction mixture was stirred at r.t. for 18 hr. EtOAc and water were added, the phases were separated and the organic layer was dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound as a pale yellow solid (23 mg, 18%, two steps).

(¹H, CDCl₃): δ 7.63 (d, 1H), 7.57 (d, 1H), 7.21 (d, 2H), 7.00 (d, 1H), 6.87 (d, 2H), 6.74 (s, 1H), 6.72 (m, 2H), 6.44 (s, 1H), 4.74 (m, 1H), 4.40 (s, 2H), 4.35 (m, 1H), 3.87 (m, 2H), 3.78 (s, 3H), 3.77 (s, 3H), 3.36 (t, 2H), 2.81 (d, 1H), 2.78 (d, 1H), 2.34 (s, 3H), 2.22 (s, 3H), 1.33 (d, 3H).

MS (*m/z*): 557 [MH]⁺.

Intermediate 112

1-(1-{2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-*b*]pyridin-4-yl}-1H-pyrazol-3-yl)-3-{[4-(methyloxy)phenyl]methyl}-2-imidazolidinone

To a clear solution of intermediate 111 (23 mg, 0.04 mmol) in anh. CH₂Cl₂ (1 mL), at r.t., under N₂, were added Et₃N (10 μL, 2 eq), triphenylphosphine (21.7 mg, 2 eq) and I₂ (21 mg, 2 eq) and the reaction mixture was stirred at r.t. for 2 hr. CH₂Cl₂ and water were added, the phases were separated, the organic layer dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (cHex/EtOAc 1:1) to give the title compound as white solid (10 mg, 46 %).

NMR (^1H , CDCl_3): δ 7.80 (d, 1H), 7.21 (d, 2H), 7.09 (d, 1H), 6.99 (d, 1H), 6.88 (d, 2H), 6.81 (d, 1H), 6.76 (dd, 1H), 6.53 (s, 1H), 4.41 (s, 2H), 4.35 (m, 1H), 3.91 (t, 2H), 3.79 (s, 6H), 3.63 (dd, 1H), 3.42 (t, 2H), 2.96 (dd, 1H), 2.28 (s, 3H), 2.17 (s, 3H), 1.18 (d, 3H).
MS (m/z): 539 $[\text{MH}]^+$.

5

Intermediate 113Methyl (4,6-dichloro-2-methyl-5-pyrimidinyl)acetate

Sodium (1.74 g, 3 eq) was added portionwise to anh. MeOH (60 mL), at 0°C, under N_2 .
10 After consumption of metallic sodium, acetamidine hydrochloride (7.06 g, 3 eq) was added. After 20 min. of stirring the precipitated NaCl was filtered off. A solution of 2-ethoxycarbonyl-succinic acid diethyl ester (6.04g, 24.5mmol) in anhydrous CH_3OH (20 mL) was added to the solution of free acetamidine and the mixture was stirred at r.t. for 2 days. The reaction mixture was concentrated to dryness *in vacuo* and the yellow foam
15 (8.69 g) obtained was then mixed with POCl_3 (6 eq) and CH_3CN (80 mL) and heated at reflux for 18 hours. The resulting solution was cooled to r.t. and poured slowly into ice/water and conc. NH_4OH with vigorous stirring. The product was extracted with EtOAc (3x50 mL). The combined organic extracts were washed with brine, dried over anh. Na_2SO_4 , filtered and concentrated *in vacuo*. The crude oil was purified by flash
20 chromatography (silica gel, cHex/EtOAc 8:2). The title compound was obtained as a yellow solid (98% in two steps)
NMR (^1H , CDCl_3): δ 5.85 (m, 1H), 5.15 (dq, 1H), 5.11 (dq, 1H), 3.61 (dt, 2H), 2.67 (s, 3H).
MS (m/z): 202 $[\text{M}]^+$ (2Cl).

25

Intermediate 1142-(4,6-Dichloro-2-methyl-5-pyrimidinyl)ethanol

To a solution of intermediate 113 (4.0 g, 0.017 mol) in anh. THF (60 mL), at -78°C, under N_2 , was added DIBAL-H 1M/THF (52.5 mL, 3 eq) dropwise. After the addition was
30 complete, the reaction mixture was stirred at -30°C for 3 hr. A Rochelle salt solution was then added at 0°C and the phases were separated. The aqueous layer was extracted with EtOAc (2x50 mL) and the combined organic extracts were dried over anh. Na_2SO_4 . The solids were filtered and the solvent evaporated. The title compound was obtained as a clear oil (3.1 gr, 89%) and was used in the next step without further purification.
35 NMR (^1H , CDCl_3): δ 4.90 (t, 2H), 3.15 (t, 2H), 2.64 (s, 3H), 1.70 (bs, 1H).
MS (m/z): 207 $[\text{MH}]^+$

Intermediate 1154,6-Dichloro-5-(2-((1,1-dimethylethyl)(dimethyl)silyloxy)ethyl)-2-methylpyrimidine

40

To a solution of intermediate 114 (3.1 g, 0.015 mol) in anh. DMF (100 mL), at 0°C, under N_2 , were added imidazole (17 g, 17 eq), *t*-butyldimethylsilyl chloride (6.35 gr, 2.8 eq) and

DMAP (catalytic amount). The solution was stirred at r.t. for 18 hr. EtOAc (100 mL) and sat.aq. NH₄Cl (50 mL) were added and the phases were separated. The organic layer was washed with sat.aq. NaCl (2x100 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 9:1) to give the title compound as a clear oil (4.6 g, 95%).

NMR (¹H, CDCl₃): δ 3.86 (t, 2H), 3.12 (t, 2H), 2.66 (s, 3H), 0.85 (s, 9H), 0.01 (s, 6H).

MS (*m/z*): 321 [MH]⁺

10 Intermediate 116

N-[2,4-Bis(trifluoromethyl)phenyl]-6-chloro-5-(2-[(1,1-dimethylethyl)(dimethyl)silyl]oxyethyl)-2-methyl-4-pyrimidinamine

To a solution of 2,4-bis-trifluoromethyl-aniline (984 μL, 1 eq) in anh. DMF (15 mL), at 0°C, under N₂, was added NaH 80%/oil (400 mg, 2.2 eq). The reaction mixture was stirred at 0°C for 30 min and was then added to a solution of intermediate 115 (2 g, 6 mmol) in anh. DMF (15 mL) at r.t., under N₂. The reaction mixture was stirred at r.t. for 30 min. The excess NaH was carefully destroyed with sat.aq. NaCl and the reaction mixture was diluted with EtOAc. The phases were separated, the organic layer was washed with sat.aq. NaCl (2x30 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude compound was purified by flash chromatography (silica gel, cHex/EtOAc 95:5 → 90:10). The title compound was obtained as a clear oil (1.84 g, 56%).

NMR (¹H, CDCl₃): δ 8.61 (d, 1H), 8.04 (bs, 1H), 7.86 (s, 1H), 7.79 (d, 1H), 4.95 (t, 2H), 3.95 (t, 2H), 2.53 (s, 3H), 0.73 (s, 9H), -0.90 (s, 6H).

MS (*m/z*): 514 [MH]⁺

Intermediate 117

2-(4-[2,4-Bis(trifluoromethyl)phenyl]amino)-6-chloro-2-methyl-5-pyrimidinyl)ethanol

To a solution of intermediate 116 (1.84 g, 3.58 mmol) in anh. DMF (30 mL), at r.t., under N₂, was added Et₃N·3HF (2.4 mL, 3 eq). The reaction mixture was stirred at r.t. for 18 hr. It was then diluted with cold sat.aq. NaCl (50 mL) and extracted with EtOAc (3x50 mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The title compound was obtained as a clear oil (1.4 gr, 98%) and was used in the next step without further purification.

NMR (¹H, CDCl₃): δ 8.59 (bs, 1H), 8.22 (d, 1H), 7.84 (s, 1H), 7.75 (d, 1H), 4.06 (t, 2H), 3.01 (t, 2H), 2.50 (s, 3H)

MS (*m/z*): 400 [MH]⁺

Intermediate 118

7-[2,4-Bis(trifluoromethyl)phenyl]-4-chloro-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine

To a solution of intermediate 117 (514 mg, 1.29 mmol) in anh. CH₂Cl₂ (20 mL), at 0°C, under N₂, were added Et₃N (712 µL, 4 eq) and methanesulfonyl chloride (197 µL, 2 eq) and the reaction mixture was stirred at r.t. for 18 hr. Water (20 mL) was then added and the phases were separated. The aqueous layer was extracted with CH₂Cl₂ (2x20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 8:2) to give the title compound as a white solid (430 mg, 87%).

NMR (¹H, CDCl₃): δ 8.04 (s, 1H), 7.93 (s, 1H), 7.53 (d, 1H), 4.00 (t, 2H), 3.24 (t, 2H), 2.42 (s, 3H).

MS (m/z): 381 [MH]⁺.

Intermediate 119

2-{4-Chloro-6-[(2,4-dichlorophenyl)amino]-2-methyl-5-pyrimidinyl}ethanol

Intermediate 114 (1.34 g, 6.47 mmol) and 2,4-dichloroaniline (1.06 g, 1 eq) were heated in a sealed vial, at 100°C, under N₂, for 18 hr. A 1:1 mixture of H₂O/MeOH was added and a white precipitate was formed. The solids were filtered and dried to give the title compound as a white solid (960 mg, 44%).

MS (m/z): 332 [M]⁺.

Intermediate 120

4-Chloro-7-(2,4-dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine

To a solution of intermediate 119 (960 mg, 2.87 mmol) in anh. CH₂Cl₂ (10 mL), at 0°C, under N₂, were added Et₃N (1.21 mL, 3 eq) and MsCl (0.5 mL, 2.3 eq). The reaction mixture was kept at r.t. for 4 hr. Then Et₃N (0.6 mL, 2 eq) was added and the mixture was refluxed for 3 hr. The reaction mixture was diluted with CH₂Cl₂ and washed with 10% HCl (15 mL). The organic phases were separated and washed with sat.aq. NaCl. It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The title compound was obtained as a white solid (900 mg, quantitative yield) and was used as such in the next step without further purification.

NMR (¹H, CDCl₃): δ 7.45 (d, 1H), 7.3 (d, 2H), 4.05 (t, 2H), 3.16 (t, 2H), 2.45 (s, 3H).

MS (m/z): 315 [MH]⁺.

Intermediate 121

3-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}aniline

A suspension of intermediate 5 (100 mg, 0.263 mmol), 3-aminophenylboronic acid (61 mg, 1.5 eq), Pd(PPh₃)₄ (30 mg, 0.1 eq), TBAB (8 mg, 0.1 eq) and 2N Na₂CO₃ (3.7 ml, 28.5 eq), at r.t., under N₂, in a 1:1 mixture of anh. EtOH/Toluene (10 mL) was heated at 100°C for 2.5 h. It was cooled down to r.t. and poured into water. EtOAc was added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified on an SCX cartridge (100% CH₂Cl₂ → NH₃ (0.5 in MeOH)) and on a MEGA Bond Elut silica cartridge (CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (91 mg, quantitative yield).

NMR (¹H, DMSO-d₆): δ 7.18 (d, 1H), 7.09 (t, 1H), 6.87 (d, 1H), 6.81 (dd, 1H), 6.76 (d, 1H), 6.69 (d, 2H), 6.61 (d, 2H), 6.41 (s, 1H), 5.18 (bs, 2H), 3.8 (m, 5H), 3.15 (t, 2H), 2.2 (s, 6H). MS (m/z): 346 [MH]⁺.

Intermediate 122

N-(2-Chloroethyl)-N'-(3-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}phenyl)urea

To a solution of intermediate 121 (91 mg, 0.26 mmol) in anh. THF (3 mL), at r.t., under N₂, was added 2-chloroethyl isocyanate (51 μL, 2 eq). The reaction mixture was stirred at r.t. for 2 hr. It was evaporated to dryness and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 7:3 → EtOAc/Et₃N 1:0.02) to give the title compound as a white solid (113.4 mg, 97 %).

NMR (¹H, DMSO-d₆): δ 8.76 (s, 1H), 7.69 (s, 1H), 7.28 (m, 2H), 7.14 (d, 1H), 7.05 (t, 1H), 8.23 (d, 1H), 6.74 (dd, 1H), 6.4 (m, 2H), 3.75 (m, 5H), 3.6 (m, 2H), 3.4 (m, 2H), 3.1 (t, 2H), 2.15 (s, 3H), 2.15 (s, 3H).

MS (m/z): 451 [MH]⁺.

Intermediate 123

5-Methyl-1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-amine

A solution of intermediate 5 (200mg, 0.52 mmol), 5-methyl-3-aminopyrazole (200 mg, 2eq), CuI (285 mg, 3 eq), K₂CO₃ (150mg, 2.1eq), N-N'-dimethyltranscyclohexandiamine (213 mg, 3eq) in anh. NMP (1 mL), was heated at 150°C for 36 hr. H₂O (50 mL) was then added and the solution extracted with CH₂Cl₂ (3x25 mL). The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvents evaporated in vacuo. The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 9:1 → 3:7) to give the title compound as a white solid (60 mg, 33%).

NMR (¹H, CDCl₃): 7.15 (d, 1H); 6.85 (d, 1H); 6.75 (m, 1H); 6.45 (s, 1H); 5.48 (s, 1H); 4.74 (s, 2H); 3.71 (s, 3H); 3.23 (t, 2H); 3.12 (t, 2H); 2.20 (s, 3H), 2.11 (s, 6H) δ.

MS (m/z): 350 [MH]⁺.

Intermediate 124

N-(2-Chloroethyl)-N'-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-1,2,4-triazol-3-yl)urea

- 5 To a solution of intermediate 123 (60 mg, 0.17 mmol) in anh. DMF (2 mL), at 0°C, under N₂, was added 2-chloroethyl isocyanate (0.2 mL, excess) and the reaction mixture was stirred at r.t. for 16 hr. H₂O (10 mL) was then added and the solution extracted with CH₂Cl₂ (2x10 mL). The combined organic extracts was dried over anh. Na₂SO₄, the solids were filtered and the solvents evaporated in vacuo. The crude product was purified on an
- 10 SCX cartridge (CH₂Cl₂, then 0.05 M NH₃/MeOH) to give the title compound as a white solid (30 mg, 40%).
- MS (m/z): 455 [MH]⁺.


Intermediate 125

- 15 1-Acetyl-3-[1-(1-{4-[(difluoromethyl)oxy]-2-methylphenyl}-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone

- To a solution of intermediate 29 (2.87 g, 4.63 mmols) in anh. DMF (80 mL), under N₂, at r.t., was added NaH 60%/oil (0.240 g, 1.2 eq). The reaction mixture was stirred at r.t. for
- 20 10 min, then the flask was sealed with a rubber septum. CF₂Br₂ (2.5 mL, 6 eq) was added and the mixture heated at 60°C for 3 hr. The mixture was cooled down to r.t., quenched with sat.aq. NaHCO₃ and extracted with CH₂Cl₂ (1x50 mL). The organic layer was washed with sat.aq. NaCl and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The residue was purified by flash chromatography twice (silica gel, 2.5%
- 25 MeOH/CH₂Cl₂) to give 554 mg of a crude compound still contaminated by side products. It was re-purified by fraction lynx chromatography (M+H= 483) and the resulting fractions (174 mg), still contaminated, were re-purified by flash chromatography (silica gel, 2% MeOH/CH₂Cl₂) to give the title compound (76 mg, 3.4%) as a white solid.
- 30 NMR (¹H, CDCl₃): δ 7.93 (d, 1H), 7.23 (dd, 1H), 7.1-7.0 (m, 3H), 6.63 (s, 1H), 6.54 (t, 1H), 4.07 (m, 4H), 4.03 (t, 2H), 3.53 (t, 2H), 2.63 (s, 3H), 2.40 (bs, 3H), 2.31 (s, 3H).

EXAMPLE 1

Synthesis of compounds of general formula (II),



in which


5

Y

is $-CR_7$;


W

is a W2 derivative:



Z

is a pyrazolyl, phenyl, pyridyl, pyrimidinyl, trazolyl, derivative and



10

m

is an integer from 0 to 2;

q

is an integer from 0 to 4.

Example 1-1

15

1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one

20

In a sealed vial, at r.t., under N_2 , are mixed together intermediate 5 (60 mg, 0.158 mmol), CuI (6 mg, 0.2 eq) and K_2CO_3 (4.5 mg, 2.5 eq). A solution of dodecane (14.3 μ L, 0.4 eq), *trans*-cyclohexanediamine (14 μ L, 0.6 eq) and intermediate 8 (48 mg, 2 eq) in anh. NMP (5 mL) was added and the reaction mixture was stirred at 130°C for 3.5 hr. It was then cooled down to r.t. and poured in EtOAc/ H_2O . The phases were separated and the aqueous layer was extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (EtOAc/cHex 6:4, then 1:1, then 3:7) followed by an SCX cartridge (100% MeOH, then 2M NH_3 /MeOH) to give the title compound as a white solid (34 mg, 53%).

25

30

Alternatively, to a suspension of CuI (8 mg, 0.02 eq) in anh. DMF (1.8 mL), at r.t., under N_2 , was added (1*R*,2*R*)-*N,N'*-dimethyl-1,2-cyclohexanediamine (90 mg, 0.3 eq) and the blue solution obtained stirred at r.t. for 1.5 hr. Intermediate 8 (0.80 g, 2.5 eq) and K_2CO_3 (0.87 g, 3.0 eq) were added followed by intermediate 92 (0.7 g, 21 mmol) in anh. DMF (1.8 mL). The resulting mixture was heated at 125°C for 30 hr. The mixture was cooled at 60°C and water (10 mL) was added dropwise. The suspension was stirred at room temperature for 1 hr and the white precipitate was filtered and washed once with a 1:2

mixture of DMF/water (10 mL), then twice with water (10 mL). The collected solid was dried at 80°C for 24 hr. The crude solid thus obtained was dissolved at r.t. in a 9:1 mixture of CH₂Cl₂/MeOH (10 mL). The solution was filtered through a carbon pad and the cake washed with the same solvent (10 mL). Heptane (20 mL) was added dropwise at r.t., the resulting suspension was left standing for 2 hr, filtered and washed with MeOH. The collected solid was dried at 80°C for 24 hr to obtain the title compound (410 mg, 48%) as a white solid.

Example 1-2

10 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-3-methylimidazolidin-2-one

To a solution of example 1 (20 mg, 0.05 mmol) in anh. THF (1 mL), at r.t., under N₂, was added KO^t-Bu (5 mg, 1 eq) and the reaction mixture was stirred for 15 min. Methyl iodide (6 µL, 2 eq) was then added and the reaction mixture was stirred at r.t. for 3 hr. It was then poured into EtOAc/H₂O and the phases were separated. The aqueous layer was extracted with EtOAc (2x20 mL) and the combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give the title compound as a yellow solid (6 mg, 29%).

Example 1-3

1-{1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one

To a solution of intermediate 37 (25 mg, 0.062 mmol) and 1-(1H-pyrazol-3-yl)-2-imidazolidinone (18.8 mg, 2 eq) in anh. NMP (2 mL), at r.t., under N₂, were added K₂CO₃ (26 mg, 3 eq), CuI (1.2 mg, 0.1 eq) and (1R,2R)-diaminoethylcyclohexane (2.9 mg, 0.3 eq) and the reaction mixture was stirred at 100°C for 1 hr, at 120°C for 1 hr, at 150°C for 1 hr and at 180°C for 2 hr. The reaction mixture was then cooled to r.t., then partitioned between EtOAc/sat.aq. NaCl (100 mL/50 mL). The phases were separated and the organic layer was dried over anh. Na₂SO₄, the solids were filtered, the solvent evaporated and the crude product was purified by flash chromatography (silica gel, cHex/EtOAc 2:8) to give the title compound as a white solid (2 mg, 7%).

Example 1-4

35 1-(1-{1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 81 (120 mg, 0.19 mmol) in TFA (12 mL), at r.t., under N₂, was added anisole (61 µL, 3 eq) and the reaction mixture was stirred at 80°C for 2 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (CH₂Cl₂ → CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (80 mg, 84%).

Example 1-5

1-{1-[1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone

- 5 To a solution of example 1 (131 mg, 0.324 mmol) in anh. CH₂Cl₂ (6.5 mL), at 0°C, under N₂, was added BBr₃ 1M/CH₂Cl₂ (1.6 mL, 5 eq) and the reaction mixture was stirred at 0°C for 3 hr. MeOH (5 mL) was slowly added and the solvents were evaporated. The residue was taken up in CH₂Cl₂ and the organic layer was washed with sat.aq. NaHCO₃ (2x20 mL) and dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The
- 10 crude compound was purified by flash chromatography (silica gel, 100% EtOAc → 5% MeOH/EtOAc) to give the title compound as a yellow solid (65 mg, 51%).

Example 1-6

1-Acetyl-3-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

- 15 To a solution of example 1 (205 mg, 0.507 mmol) in anh. DMF (10 mL), at r.t., under N₂, was added NaH 60%/oil (24 mg, 1.2 eq). The reaction mixture was stirred at r.t. for 20 min. It was then cooled to 0°C and acetyl chloride (72 µL, 2 eq) was added slowly. The reaction mixture was stirred at 0°C for 15 min (a white precipitate formed) and at r.t. for 30
- 20 min. It was then poured into EtOAc/sat.aq. NaCl and the phases were separated. The organic layer was washed with sat.aq. NaCl (2x20 mL) and the combined aqueous phases extracted back with CH₂Cl₂ (2x20 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude compound was purified by flash chromatography (silica gel, 2.5% MeOH/CH₂Cl₂). The title compound was obtained as a yellow solid (190 mg, 84%)
- 25

Example 1-7

1-(1-[1-[4-(Ethoxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone

- 30 To a solution of intermediate 30 (5 mg, 0.011 mmol) in an anh. 3:1 mixture of MeOH/CH₂Cl₂ (1 mL), at r.t., under N₂, was added Cs₂CO₃ (18 mg, 5 eq) and the reaction mixture was stirred at r.t. for 1 hr. The solvent was evaporated and the residue purified by flash chromatography (MEGA-BondElut, 500 mg, cHex/EtOAc 1:1) to give the title compound (2.3 mg, 50%) as a white solid.

Example 1-8

1-[1-(6-Methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone

- 40 To a solution of intermediate 31 (11 mg, 0.023 mmol) in an anh. 3:1 mixture of MeOH/CH₂Cl₂ (1 mL), at r.t., under N₂, was added Cs₂CO₃ (38 mg, 5 eq) and the reaction mixture was stirred at r.t. for 2 hr. The solvent was evaporated and the residue purified by

flash chromatography (MEGA-BondElut, 1 gr, cHex/EtOAc 1:1) to give the title compound (2.1 mg, 21%) as a white solid.

Example 1-9

5 1-[1-(6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone

To a solution of intermediate 48 (140 mg, 0.242 mmol) in TFA (3.0 mL), under N₂, was added anisole (263 µL, 10 eq) and the reaction mixture was stirred and heated at 80°C for 2 hr. It was then cooled down to r.t., TFA was evaporated and the reaction mixture was
10 partitioned between CH₂Cl₂/sat.aq. NaHCO₃. The phases were separated and the organic layer was washed with sat. aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (110 mg, 99%).

15 Example 1-10

3-Methyl-4-{6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile

To a solution of intermediate 51 (120 mg, 0.23 mmol) in TFA (15 mL), at r.t., under N₂,
20 was added anisole (75 µL, 3 eq) and the reaction mixture was stirred at 80°C for 1.5 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with a sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on an SCX cartridge (CH₂Cl₂ → CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (58 mg, 63%).

25 Example 1-11

1-(1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 54 (95 mg, 0.169 mmol) in TFA (2.0 mL), under N₂, was
30 added anisole (184 µL, 10 eq) and the reaction mixture was stirred and heated at 80°C for 2 hr. It was then cooled down to r.t., TFA was evaporated and the reaction mixture was partitioned between CH₂Cl₂/sat.aq. NaHCO₃. The phases were separated and the organic layer was washed with sat.aq. NaCl (2x10 mL). It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash
35 chromatography (silica gel, CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (77 mg, 99%).

Example 1-12

40 4-{6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-(trifluoromethyl)benzonitrile

To a solution of intermediate 57 (70 mg, 0.122 mmol) in TFA (2.0 mL), under N₂, was added anisole (133 µL, 10 eq) and the reaction mixture was stirred and heated at 80°C for

2 hr. It was then cooled down to r.t., TFA was evaporated and the crude product was directly purified on an SCX cartridge (100% CH₂Cl₂ → CH₂Cl₂/MeOH and then 2.0M Et₃N/MeOH) to give the title compound as a white solid (55 mg, 99%).

5 Example 1-13

1-(1-{1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 60 (19.6 mg, 0.035 mmol) in TFA (4 mL), at r.t., under N₂, was added anisole (12 µL, 0.003 eq). The reaction mixture was stirred for 2 hr. Sat.aq. NaHCO₃ was added until neutral pH and the mixture was evaporated to dryness. The residue was purified on an SCX cartridge (0.5M NH₃/MeOH) to give the title compound as a white foam (7.2 mg, 47 %).

Example 1-14

15 4-{6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-[(trifluoromethyl)oxy]benzonitrile

To a solution of intermediate 63 (115 mg, 0.19 mmol) in TFA (12 mL), at r.t., under N₂, was added anisole (61 µL, 3 eq) and the reaction mixture was stirred at 80°C for 1.5 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on an SCX cartridge (CH₂Cl₂ → CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (52.9 mg, 59%).

25 Example 1-15

3-Ethyl-4-{6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile

To a solution of intermediate 66 (70 mg, 0.13 mmol) in TFA (9 mL), at r.t., under N₂, was added anisole (42 µL, 3 eq) and the reaction mixture was stirred at 80°C for 1 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on an SCX cartridge (100% CH₂Cl₂ → CH₂Cl₂/MeOH 95:5) to give the title compound as a white solid (29 mg, 54%).

35 Example 1-16

1-(1-{6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 69 (72 mg, 0.12 mmol) in TFA (7.5 mL), at r.t., under N₂, was added anisole (41 µL, 3 eq) and the reaction mixture was stirred at 80°C for 1.5 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered

and the solvent evaporated. The crude product was purified on an SCX cartridge (CH₂Cl₂/0.5M NH₃/MeOH 95:5) to give the title compound as a white solid (35 mg, 64%).

Example 1-17

5 1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone

To a solution of intermediate 72 (41 mg, 0.076 mmol) in TFA (4.7 mL), at r.t., under N₂, was added anisole (25 µL, 3 eq) and the reaction mixture was stirred at 80°C for 1.5 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on an SCX cartridge (100% CH₂Cl₂ → CH₂Cl₂/MeOH 98:2) to give the title compound as a white solid (25 mg, 79%).

Example 1-18

15 1-(1-{6-Methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To intermediate 75 (16 mg, 0.028 mmol) were added TFA (1 mL) and anisole (10 µL, 3 eq) . The reaction mixture was stirred at r.t. for 3 hr, and the solvent was evaporated under reduced pressure. The crude mixture was partitioned between CH₂Cl₂/sat.aq. NaHCO₃. The phases were separated and the organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, 100% CH₂Cl₂ → CH₂Cl₂/MeOH 97:3) followed by a further purification on an SCX SPE cartridge (100% CH₂Cl₂ to CH₂Cl₂/MeOH/2M NH₃ in MeOH 80:19:1) to give the title compound as a white solid (9.5 mg, 71 %).

Example 1-19

1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone

30 To a solution of intermediate 78 (20 mg, 0.037 mmol) in TFA (2.3 mL), at r.t., under N₂, was added anisole (12 µL, 3 eq.) and the reaction mixture was stirred at 80°C for 2 hr. The solution was concentrated *in vacuo*. The residue was diluted with CH₂Cl₂ and washed with sat.aq. NaHCO₃. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on an SCX cartridge (CH₂Cl₂ → CH₂Cl₂/MeOH 98:2) to give the title compound as a white solid (12.4 mg, 76%).

Example 1-20

40 1-(6-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyridinyl)-2-imidazolidinone

To a solution of intermediate 97 (30 mg, 1 eq) in TFA (0.75 ml), at r.t., under N₂, were added Anisole (18.3 µL, 3 eq) and a drop of H₂SO₄. The reaction mixture was refluxed for

3 h. It was concentrated and then partitioned between EtOAc and NaHCO₃ss. The phases were separated and the organic layer was washed with sat.aq. NaCl. It was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The compound was obtained as a white solid (22 mg, 98%).

5

Example 1-21

1-(4-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyrimidinyl)-2-imidazolidinone

To a solution of intermediate 103 (71 mg, 0.125 mmol) in TFA (1 mL), at r.t., under N₂, was added anisole (50 µL, 3.7 eq). The reaction mixture was refluxed for 3 hr. No traces of the desired product were detected by MS analysis. To the cooled reaction mixture was added conc. H₂SO₄ (2 drops). The reaction mixture was refluxed for 75 min, cooled down to r.t. and neutralized with solid Na₂CO₃. The solvents were evaporated and the residue was purified on a MEGA Bond Elut silica cartridge (CH₂Cl₂/Et₂O/EtOAc 1:1:2 → CH₂Cl₂/MeOH/Et₃N 1:1:0.02) to give the title compound as a yellow solid (24.2 mg, 47%).

Example 1-22

1-(2-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-4-pyrimidinyl)-2-imidazolidinone

To a solution of intermediate 105 (13 mg, 0.023 mmol) in TFA (1 mL), at r.t., under N₂, was added anisole (10 µL, 4 eq) and conc. H₂SO₄ (2 drops). The reaction mixture was refluxed for 2 hr and neutralized with solid NaHCO₃. The reaction mixture was partitioned between EtOAc and water. The aqueous layer was further extracted with EtOAc (3x10 mL) and the combined organic extracts were concentrated in vacuo. The residue was purified by flash chromatography (silica gel, 100% CH₂Cl₂ → CH₂Cl₂/MeOH 95:5) and on an SCX cartridge (100% CH₂Cl₂ → NH₃ (0.5 in MeOH)) to give the title compound as a white solid (2.8 mg, 10%, 2 steps).

Example 1-23

1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 107 (30 mg, 0.06 mmol) in anh. THF (2 mL), at r.t., under N₂, was added KOt-Bu (9 mg, 1.2 eq) and the reaction mixture was stirred for 1 hr. Water (0.5 mL) was added and the solvent was evaporated. The aqueous phase was diluted with H₂O and extracted with CH₂Cl₂ (3x20 mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified on a MEGA Bond Elut silica cartridge (100% EtOAc → EtOAc/MeOH 9:1) to give the title compound as a white solid (6 mg, 25%).

Example 1-24

1-(1-{2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 112 (10 mg, 0.018 mmol) in TFA (1.1 mL), at r.t., under N₂, was added anisole (10 µL, 5 eq) and the reaction mixture was stirred at 80°C for 1.5 hr. The solution was then concentrated *in vacuo*. The residue was diluted with CH₂Cl₂, washed with sat.aq. NaHCO₃ and the phases were separated. The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was purified on a MEGA Bond Elut silica cartridge (100% CH₂Cl₂ → CH₂Cl₂/MeOH 98:2) to give the title compound (racemate) as a white solid (6 mg, 80%).

Example 1-25

1-(3-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}phenyl)-2-imidazolidinone

To a suspension of intermediate 122 (60 mg, 0.13 mmol) in anh. THF (3 mL), at r.t., under N₂, was added *t*-BuOK (18 mg, 1.2 eq). The reaction mixture was stirred at r.t. for 3 hr. Sat.aq. NH₄Cl and EtOAc were added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, cHex/EtOAc 8:2 → 100% EtOAc) to give the desired compound still contaminated with aliphatic impurities. This crude product was further purified by preparative HPLC (Column: X Terra MS C18 5 mm, 30 x 75 mm, Mobile phase: A: H₂O + 0.1% TFA, B: CH₃CN + 0.1% TFA, Gradient:10% (B) for 1 min, from 10% (B) to 90% (B) in 12 min, Flow rate (ml/min):43, UV wavelength range (nm):200-400 Mass range (amu):100-900, Ionization: ES+) to give the title compound as a white solid (31.3 mg, 58 %).

Example 1-26

1-(5-Methyl-1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 124 (35 mg, 0.072 mmol) in anh. THF (2 mL), at r.t., under N₂, was added *t*-BuOK (9.8 mg, 1.2 eq) and the reaction mixture was stirred at r.t. for 18 hr. Water (0.5 mL) was added and the solvent was evaporated. The aqueous phase was diluted with H₂O and extracted with CH₂Cl₂ (3x10 mL). The combined organic extracts were dried over anh. Na₂SO₄. The solids were filtered and the solvent evaporated. The crude product was purified on a MEGA Bond Elut silica cartridge (EtOAc/cHex 2:8 → 3:7) to give the title compound as a white solid (12 mg, 39%).

Example 1-27




1-[1-(1-{4-[(difluoromethyl)oxy]-2-methylphenyl}-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone






To a suspension of intermediate 125 (76 mg, 0.156 mmol) in a 3:1 mixture of MeOH/CH₂Cl₂ (10 mL), at r.t., was added Cs₂CO₃ (0.257 g, 5 eq). The mixture was stirred at r.t. for 1 hr. The solvent was evaporated and the residue purified by flash






chromatography (silica gel, 2% MeOH/CH₂Cl₂) to give the title compound (45 mg, 71%) as white solid.






All the analytical data are set forth in the following Table 1-1 and in which:





- 5 R₁ is -CH₃;
 R₅ is hydrogen;
 R₆ is hydrogen,
 R₇ is hydrogen;
 D corresponds to -CR₈R₉;
 10 G corresponds to -CR₁₀R₁₁;
 R₈, R₉, R₁₀, R₁₁ are all hydrogen, except for example 1-24 where R₁₀ is a methyl group.






Cpd. No.	R	R ₁₂	Z	Analytical Data
1-1	2-methyl-4-methoxy-phenyl	H		NMR (¹ H, CDCl ₃): δ 8.29 (d, 1H), 7.15 (d, 1H), 7.04 (s, 1H), 6.85 (d, 1H), 6.79-6.74 (m, 3H), 3.91 (t, 2H), 3.82 (t, 2H), 3.75 (s, 3H), 3.44 (t, 4H), 2.17 (s, 3H), 2.15 (s, 3H) Structure confirmed by NOE experiment MS (m/z): 405 [MH] ⁺
1-2	2-methyl-4-methoxy-phenyl	CH ₃		NMR (¹ H, CDCl ₃): δ 7.76 (d, 1H), 7.15 (d, 1H), 6.93 (d, 1H), 6.77 (d, 1H), 6.75 (dd, 1H), 6.52 (s, 1H), 3.96 (t, 2H), 3.84 (t, 2H), 3.77 (s, 3H), 3.50 (t, 2H), 3.42 (t, 2H), 3.89 (s, 3H), 2.28 (s, 3H), 2.20 (s, 3H) MS (m/z): 419 [MH] ⁺
1-3	2,4-dichloro-phenyl	H		NMR (¹ H, CDCl ₃): δ 7.82δ (s,1H), 7.44 (s,1H), 7.42 (s,1H), 7.26 (s,1H), 6.95 (s,1H), 6.66 (s,1H), 4.57 (bs,1H), 4.09 (t,1H), 3.96 (t,1H), 3.61 (t,1H), 3.48 (t,1H), 2.34 (s,3H). Structure confirmed by NOE experiment MS (m/z): 429 [M] ⁺

1-4	2,4-bis-trifluoromethyl-phenyl	H		NMR (^1H , CDCl_3): δ 7.96 (s, 1H), 7.83 (d, 1H), 7.80 (bs, 1H), 7.61 (d, 1H), 6.97 (d, 1H), 6.70 (s, 1H), 4.66 (bs, 1H), 4.08 (t, 2H), 3.91 (t, 2H), 3.61 (t, 2H), 3.50 (t, 2H), 2.31 (s, 3H). MS (m/z): 497 $[\text{MH}]^+$
1-5	2-methyl-4-hydroxy-phenyl	H		NMR (^1H , $\text{DMSO}-d_6$): δ 9.31 (bs, 1H), 8.31 (d, 1H), 7.07 (bs, 1H), 7.04 (d, 1H), 6.78 (d, 1H), 6.75 (s, 1H), 6.68 (d, 1H), 6.62 (dd, 1H), 3.93 (t, 2H), 3.81 (t, 2H), 3.46 (m, 4H), 3.18 (s, 3H), 2.10 (s, 3H). MS (m/z): 391 $[\text{MH}]^+$
1-6	2-methyl-4-methoxy-phenyl	Ac		NMR (^1H , CDCl_3): δ 7.85 (d, 1H), 7.15 (d, 1H), 6.95 (d, 1H), 6.80 (d, 1H), 6.75 (dd, 1H), 6.55 (s, 1H), 4.00 (m, 4H), 3.85 (t, 2H), 3.80 (s, 3H), 3.45 (t, 2H), 2.60 (s, 3H), 2.30 (s, 3H), 2.20 (s, 3H). MS (m/z): 447 $[\text{MH}]^+$
1-7	2-methyl-4-ethoxy-phenyl	H		NMR (^1H ,): δ 7.82 (d, 1H), 7.15 (d, 1H), 6.90 (d, 1H), 6.78 (d, 1H), 6.75 (dd, 1H), 6.70 (dd, 1H), 4.70 (bs, 1H), 4.2-4.0 (m, 4H), 3.80 (t, 2H), 3.60 (t, 2H), 3.40 (t, 2H), 2.30 (s, 3H), 2.25 (s, 2H), 1.45 (t, 3H). Structure confirmed by NOE experiment MS (m/z): 419 $[\text{MH}]^+$
1-8	2-methyl-4-isopropoxy-phenyl	H		NMR (^1H ,): δ 7.90 (d, 1H), 7.10 (d, 1H), 6.90 (d, 1H), 6.8-6.7 (m, 2H), 6.55 (s, 1H), 4.60 (bs, 1H), 4.50 (m, 1H), 4.10 (t, 2H), 3.90 (t, 2H), 3.60 (t, 2H), 3.45 (t, 2H), 2.30 (s, 3H), 2.20 (s, 3H), 1.26 (d, 6H). MS (m/z): 475 $[\text{MH}]^+$

1-9	2-methyl-4-trifluoromethoxy-phenyl	H		NMR (^1H , CDCl_3): δ 7.84 (d, 1H), 7.30 (d, 1H), 7.12 (s, 1H), 7.09 (d, 1H), 6.98 (d, 1H), 6.63 (s, 1H), 4.68 (s, 1H), 4.10 (t, 2H), 3.91 (t, 2H), 3.63 (t, 2H), 3.50 (t, 2H), 2.36 (s, 3H), 2.29 (s, 3H). MS (m/z): 459 $[\text{MH}]^+$.
1-10	2-methyl-4-cyano-phenyl	H		NMR (^1H , CDCl_3): δ 7.82 (d, 1H), 7.54 (bs, 1H), 7.48 (dd, 1H), 7.36 (d, 1H), 6.96 (d, 1H), 6.67 (s, 1H), 4.55 (bs, 1H), 4.11 (t, 2H), 3.95 (t, 2H), 3.62 (t, 2H), 3.49 (t, 2H), 2.34 (s, 3H), 2.29 (s, 3H). MS (m/z): 400 $[\text{MH}]^+$.
1-11	2-methyl-4-(pyrazol-1-yl)-phenyl	H		NMR (^1H , CDCl_3): δ 7.90 (d, 1H), 7.84 (d, 1H), 7.72 (d, 1H), 7.68 (m, 1H), 7.64 (m, 1H), 7.37 (d, 1H), 6.97 (d, 1H), 6.62 (s, 1H), 6.45 (t, 1H), 4.77 (s, 1H), 4.11 (t, 2H), 3.94 (t, 2H), 3.63 (t, 2H), 3.50 (t, 2H), 2.34 (s, 6H). MS (m/z): 441 $[\text{MH}]^+$.
1-12	2-trifluoromethyl-4-cyano-phenyl	H		NMR (^1H , CDCl_3): δ 8.01 (d, 1H), 7.85 (d, 1H), 7.84 (dd, 1H), 7.69 (d, 1H), 7.00 (d, 1H), 6.75 (s, 1H), 4.65 (s, 1H), 4.10 (t, 2H), 3.98 (t, 2H), 3.64 (t, 2H), 3.51 (t, 2H), 2.36 (s, 3H). MS (m/z): 454 $[\text{MH}]^+$.
1-13	2-difluoromethyl-4-methoxy	H		NMR (^1H , CDCl_3): δ 7.84 (d, 1H), 7.21 (m, 2H), 7.02 (dd, 1H), 6.87 (t, 1H, $J_{\text{H-F}} = 57$ Hz), 6.97 (d, 1H), 6.64 (s, 1H), 4.84 (bs, 1H), 4.13 (t, 2H), 3.93 (t, 2H), 3.9 (s, 3H), 3.66 (t, 2H), 3.53 (t, 2H), 2.33 (s, 3H). MS (m/z): 441 $[\text{MH}]^+$.


1-14	2-trifluoromethoxy-4-cyano-phenyl	H		NMR (^1H , CDCl_3): δ 8.05 (d, 1H), 7.84 (m, 1H), 7.54 (bs, 1H), 7.5 (m, 1H), 6.98 (m, 1H), 6.78 (s, 1H), 4.63 (bs, 1H), 4.11 (m, 4H), 3.62 (t, 2H), 3.48 (t, 2H), 2.41 (s, 3H). MS (m/z): 470 $[\text{MH}]^+$.
1-15	2-ethyl-4-cyano-phenyl	H		NMR (^1H , CDCl_3): δ 7.82 (d, 1H), 7.6 (bs, 1H), 7.49 (m, 1H), 7.34 (m, 1H), 6.96 (d, 1H), 6.65 (s, 1H), 4.7 (bs, 1H), 4.11 (t, 2H), 3.92 (t, 2H), 3.62 (t, 2H), 3.49 (t, 2H), 2.66 (m, 2H), 2.41 (s, 3H), 1.22 (t, 3H). MS (m/z): 414 $[\text{MH}]^+$.
1-16	2-methoxy-4-(pyrazol-1-yl)-phenyl	H		NMR (^1H , CDCl_3): δ 7.89 (d, 1H), 7.82 (d, 1H), 7.69 (d, 1H), 7.58 (d, 1H), 7.42 (d, 1H), 7.16 (dd, 1H), 6.94 (d, 1H), 6.62 (s, 1H), 6.44 (t, 1H), 4.68 (bs, 1H), 4.13-3.66 (t/t, 4H), 3.89 (s, 3H), 3.93-3.53 (t/t, 4H), 2.34 (s, 3H). MS (m/z): 457 $[\text{MH}]^+$.
1-17	2-methyl-4,5-benzodioxolyl	H		NMR (^1H , CDCl_3): δ 7.8 (d, 1H), 6.95 (d, 1H), 6.8 (s/s, 2H), 6.5 (s, 1H), 5.95 (s, 2H), 4.5 (bs, 1H), 4.1-3.5 (t/t, 4H), 3.8-3.6 (t/t, 4H), 2.2 (s, 3H), 2.1 (s, 3H). MS (m/z): 419 $[\text{MH}]^+$.
1-18	2,4,6-trimethoxy-phenyl	H		NMR (^1H , $\text{DMSO}-d_6$): δ 8.26 (bs, 1H), 7.04 (bs, 1H), 6.76 (bs, 1H), 6.65 (bs, 1H), 6.29 (bs, 1H), 3.92-3.46 (t,t, 4H), 3.81-3.46 (t,t, 4H), 3.79 (s, 3H), 3.69 (s, 6H), 2.13 (s, 3H). MS (m/z): 451 $[\text{MH}]^+$.

1-19	2-methyl-3,4-benzodioxolyl	H		NMR (^1H , CDCl_3): δ 7.81 (d, 1H), 6.94 (d, 1H), 6.75 (dd, 2H), 6.56 (s, 1H), 5.95 (s, 2H), 4.61 (bs, 1H), 4.09 (t, 2H), 3.84 (t, 2H), 3.60 (t, 2H), 3.43 (t, 2H), 2.31 (s, 3H), 2.08 (s, 3H). MS (m/z): 419 $[\text{MH}]^+$
1-20	2-methyl-4-methoxyphenyl	H		NMR (^1H , CDCl_3): 8.15 (d, 1H), 7.77 (t, 1H), 7.42 (d, 1H), 7.14 (d, 1H), 6.86 (d, 1H), 6.8 (m, 1H), 6.79 (s, 1H), 4.22 (t, 2H), 3.84 (t, 2H), 3.78 (s, 3H), 3.51 (m, 4H), 2.26 (s, 3H), 2.21 (s, 3H) δ . MS (m/z): 416 $[\text{MH}]^+$
1-21	2-methyl-4-methoxyphenyl	H		NMR (^1H , $\text{DMSO}-d_6$): δ 8.62 (d, 1H), 8.1 (d, 1H), 7.65 (bs, 1H), 7.21 (s, 1H), 7.18 (d, 1H), 6.86 (d, 1H), 6.79 (d, 1H), 4.13 (t, 2H), 3.85 (t, 2H), 3.75 (s, 3H), 3.57 (t, 2H), 3.47 (t, 2H), 2.21 (s, 3H), 2.16 (s, 3H). Structure confirmed by NOE experiment MS (m/z): 417 $[\text{MH}]^+$
1-22	2-methyl-4-methoxyphenyl	H		NMR (^1H , CDCl_3): δ 8.77 (d, 1H), 7.29 (d, 1H), 7.2 (d, 1H), 6.83 (d, 1H), 6.76 (dd, 1H), 6.71 (s, 1H), 4.95 (bs, 1H), 4.28 (t, 2H), 3.93 (t, 2H), 3.81 (s, 3H), 3.61 (t, 2H), 3.58 (t, 2H), 2.37 (s, 3H), 2.25 (s, 3H). Structure confirmed by NOE experiment MS (m/z): 417 $[\text{MH}]^+$

1-23	2-methyl-4-methoxy-phenyl	H		NMR (^1H , CDCl_3): δ 8.98 (s, 1H), 7.14 (d, 1H), 7.05 (s, 1H), 6.83 (d, 1H), 6.76 (m, 2H), 3.89 (t, 2H), 3.37 (t, 2H), 3.82 (t, 2H), 3.41 (t, 2H), 3.71 (s, 3H), 2.17 (s, 3H), 2.11 (s, 3H). Structure confirmed by NOE experiment MS (m/z): 406 $[\text{MH}]^+$.
1-24	2-methyl-4-methoxy-phenyl	H		NMR (^1H , CDCl_3): δ 7.80 (d, 1H), 7.09 (d, 1H), 6.93 (d, 1H), 6.81 (d, 1H), 6.77 (dd, 1H), 6.53 (s, 1H), 4.56 (bs, 1H), 4.25 (m, 1H), 4.10 (t, 2H), 3.79 (s, 3H), 3.61 (m, 3H), 2.97 (dd, 1H), 2.27 (s, 3H), 2.17 (s, 3H), 1.21 (d, 3H). MS (m/z): 419 $[\text{MH}]^+$.
1-25	2-methyl-4-methoxy-phenyl			NMR (^1H , $\text{DMSO}-d_6$): δ 7.79 (s, 1H), 7.6 (d, 1H), 7.43 (t, 1H), 7.2 (d, 2H), 7.02 (bs, 1H), 6.89 (d, 1H), 6.83 (dd, 1H), 6.49 (s, 1H), 3.85 (t, 2H), 3.8 (t, 2H), 3.77 (s, 3H), 3.4 (t, 2H), 3.2 (t, 2H), 2.21 (s, 6H). MS (m/z): 415 $[\text{MH}]^+$.
1-26	2-methyl-4-methoxy-phenyl	H		NMR (^1H , CDCl_3): δ 7.18 (d, 1H); 6.9 (d, 1H); 7.85 (d, 1H); 6.77 (m, 1H); 6.53 (s, 2H); 6.43 (s, 1H); 3.80 (t, 2H); 3.75 (s, 3H); 3.41 (t, 2H); 3.3 (s, 3H); 3.15 (t, 2H); 2.34 (s, 3H), 2.18 (s, 3H), 2.17 (s, 3H). MS (m/z): 418.2 $[\text{MH}]^+$.
1-27	2-methyl-4-difluoro-methoxyphenyl	H		NMR (^1H , CDCl_3): δ 7.87 (d, 1H), 7.30 (dd, 1H), 7.08 (d, 1H), 7.01 (dd, 1H), 7.00 (d, 1H), 6.64 (s, 1H), 6.53 (t, 1H), 4.66 (s, 1H), 4.14 (t, 2H), 3.92 (t, 2H), 3.66 (t, 2H), 3.51 (t, 2H), 2.38 (bs, 3H), 2.31 (s, 3H). MS (m/z): 441 $[\text{MH}]^+$.

EXAMPLE 2

Synthesis of compounds of general formula (II)




5 in which

Y

is $-\text{CR}_7$;


W

is a W9 derivative:



Z

is a pyrazolyl derivative



10

m

is an integer from 0 to 2;

n

is an integer from 0 to 6.

Example 2-1

1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}pyrrolidin-2-one

15

In a sealed vial, at r.t., under N_2 , are mixed together intermediate 5 (50 mg, 0.16 mmol), CuI (6 mg, 0.2 eq) and K_2CO_3 (46 mg, 2.1 eq). A solution of dodecane (14.5 μL , 0.4 eq), *trans*-cyclohexanediamine (11.5 μL , 0.6 eq) and intermediate 10 (30 mg, 1.2 eq) in anh. NMP (1.5 mL) was added and the reaction mixture was subjected to microwave irradiation (150°C) for three cycles (5 min, 10 min, 15 min). It was then cooled down to r.t. and poured in EtOAc/ H_2O . The phases were separated and the aqueous layer was extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The crude product was purified on a first SCX cartridge (cHex/EtOAc 9:1), a second SCX cartridge ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1) and finally preparative HPLC (Column: X Terra MS C18 5 μm , 50 x 4.6 mm, Mobile phase: A: H_2O + 0.1% TFA.; B: CH_3CN + 0.1% TFA, Gradient: 10% (B) for 1 min, from 10% (B) to 90% (B) in 12 min, Flow rate: 1 ml/min, UV wavelenght range: 200-400 nm, Mass range: 150-900 amu, Ionization: ES+) to give the title compound as a pale yellow solid (21 mg, 35%)

30

All the analytical data are set forth in the following Table 2-1 and in which:

 R_1 is $-\text{CH}_3$; R_5


is hydrogen;

- R_6 is hydrogen,
 R_7 is hydrogen;
 D corresponds to $-CR_8R_9$;
 G corresponds to $-CR_{10}R_{11}$;
 5 R_8, R_9, R_{10}, R_{11} are all hydrogen.

Cpd. No.	R	Analytical Data
2-1	2-methyl-4-methoxy-phenyl	NMR (1H , DMSO): δ 8.35 (d, 1H), 7.20 (d, 1H), 6.95 (d, 1H), 6.85 (d, 1H), 6.75 (m, 2H), 3.90 (m, 4H), 3.70 (s, 3H), 3.45 (t, 2H), 2.50 (m, 2H), 2.15 (s, 3H), 2.10 (m, 2H), 2.10 (s, 3H). MS (m/z): 404 $[MH]^+$

EXAMPLE 3

- 10 Synthesis of compounds of general formula (II),




in which

Y

is $-CR_7$;

W


is a W3 derivative:



15

Z

is a pyrazolyl derivative



m

is an integer from 0 to 2;

n

is an integer from 0 to 6.

Example 3-11-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}tetrahydropyrimidin-2(1H)-one

- In a sealed vial, at r.t., under N₂, are mixed together intermediate 5 (15 mg, 0.04 mmol),
 5 Cul (1.5 mg, 0.2 eq) and K₂CO₃ (11.6 mg, 2.1 eq). A solution of dodecane (2 µL, 0.2 eq),
trans-cyclohexanediamine (2 µL, 0.3 eq) and intermediate 13 (8 mg, 1 eq) in anh. NMP (2
 mL) was added and the reaction mixture was stirred at 130°C for 6 hr. It was then cooled
 down to r.t. and poured in EtOAc/H₂O. The phases were separated and the aqueous layer
 was extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh.
 10 Na₂SO₄, the solids were filtered and the solvent evaporated. The crude product was
 purified on an SCX cartridge (EtOAc/cHex 6:4, then 100% EtOAc, then, 5%
 MeOH/EtOAc) to give the title compound as a white solid (5.1 mg, 25%)


All the analytical data are set forth in the following Table 3-1 and in which:

- 15 R₁ is -CH₃;
 R₅ is hydrogen;
 R₆ is hydrogen,
 R₇ is hydrogen;
 R₁₂ is hydrogen;
 20 D corresponds to -CR₈R₉;
 G corresponds to -CR₁₀R₁₁;
 R₈, R₉, R₁₀, R₁₁ are all hydrogen.

Cpd. No.	R	Analytical Data
3-1	2-methyl-4-methoxy-phenyl	NMR (¹ H, CDCl ₃): δ 7.80 (d, 1H), 7.2 (d, 1H), 7.0 (d, 1H), 6.80 (d, 1H), 6.75 (dd, 1H), 6.60 (s, 1H), 4.95 (bs, 1H), 4.05 (dd, 2H), 3.90 (t, 2H), 3.80 (s, 3H), 3.45 (t, 2H), 3.40 (bm, 2H), 2.45 (s, 3H), 2.25 (s, 3H), 2.05 (m, 2H). MS (m/z): 419 [MH] ⁺

EXAMPLE 4

Synthesis of compounds of general formula (II),



in which


5

Y

is $-\text{CR}_7$;

W


is a W11 derivative:



;

Z

is a pyrazolyl derivative



10

m

is an integer from 0 to 2;

q

is an integer from 0 to 4.

Example 4-1

3-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,3-oxazolidin-2-one

15

To a vial under N_2 were added intermediate 5 (38 mg, 0.1 mmol), intermediate 16 (15 mg, 0.1 mmol), CuI (1.9 mg, 0.1 eq), (1*R*,2*R*)-diaminomethylcyclohexane (4.3 mg, 0.3 eq), K_2CO_3 (41 mg, 0.3 mmol) and anh. NMP (1mL). The vial was sealed and the reaction mixture was stirred at 130°C for 4 hr. It was poured into water/EtOAc. The phases were separated and the aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na_2SO_4 , the solids were filtered and the solvent evaporated. The residue was purified by flash chromatography (silica gel, EtOAc/cHex 1:1) to give the title compound as a white solid (20 mg, 49%).

20

All the analytical data are set forth in the following Table 4-1 and in which:

25

 R_1 is $-\text{CH}_3$; R_5

is hydrogen;

 R_6

is hydrogen,

 R_7

is hydrogen;

D

corresponds to $-\text{CR}_8\text{R}_9$;

30

G


corresponds to $-\text{CR}_{10}\text{R}_{11}$; $\text{R}_8, \text{R}_9, \text{R}_{10}, \text{R}_{11}$

are all hydrogen.

Cpd. No.	R	Analytical Data
4-1	2-methyl-4-methoxy-phenyl	NMR (¹ H, CDCl ₃): δ 7.85 (d, 1H), 7.16 (d, 1H), 6.93 (d, 1H), 6.81 (d, 1H), 6.77 (dd, 1H), 6.55 (s, 1H), 4.54 (t, 2H), 4.2 (t, 2H), 3.87 (t, 2H), 3.8 (s, 3H), 3.44 (t, 2H), 2.32 (s, 3H), 2.24 (s, 3H). MS (m/z): 406 [MH] ⁺ .

EXAMPLE 5

Synthesis of compounds of general formula (II),




5 in which

Y

is -CR₇;


W

is a W10 derivative:



Z

is a pyrazolyl derivative



10

m

is an integer from 0 to 2;

q

is an integer from 0 to 4.

Example 5-1

15 Methyl 5-(1-{6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide)

To a vial under N₂ were added intermediate 21 (20 mg, 0.052 mmol), (methoxycarbonylsulfamoyl)triethylammonium hydroxide inner salt (40 mg, 3.2 eq) and anh. THF (1 mL). The reaction mixture was refluxed for 1 hr. It was cooled down to r.t.
20 and diluted with CH₂Cl₂. 1N HCl was added and the phases were separated. The aqueous layer was further extracted with CH₂Cl₂ (3x10 mL). The combined organic extracts were concentrated and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as a white solid (8.2 mg, 32%).

Example 5-24-[3-(1,1-Dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methoxyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine

- To a solution of example 5-1 (7.2 mg, 0.0144 mmol) in anh. MeOH (1 mL) and anh. CH₂Cl₂ (2 mL), at r.t., under N₂, was added 25% NaOH (40 µL). The reaction mixture was stirred at r.t. for 30 min. It was then poured into sat.aq. NaHCO₃ and CH₂Cl₂ was added. The phases were separated and the aqueous layer was further extracted with CH₂Cl₂ (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated to give the title compound (6.4 mg, quantitative yield) as a white solid.


All the analytical data are set forth in the following Table 5-1 and in which:

- R₁ is -CH₃;
 R₅ is hydrogen;
 R₆ is hydrogen,
 R₇ is hydrogen;
 D corresponds to -CR₈R₉;
 G corresponds to -CR₁₀R₁₁;
 R₈, R₉, R₁₀, R₁₁ are all hydrogen.

Cpd. No.	R	R ₁₂	Analytical Data
5-1	2-methyl-4-methoxy-phenyl	CO ₂ Me	NMR (¹ H, CDCl ₃): δ 7.88 (d, 1H), 7.17 (d, 1H), 6.82 (d, 1H), 6.77 (dd, 1H), 6.51 (s, 1H), 6.5 (d, 1H), 4.1 (bst, 4H), 3.95 (s, 3H), 3.87 (t, 2H), 3.81 (s, 3H), 3.46 (t, 2H), 2.32 (s, 3H), 2.24 (s, 3H). MS (m/z): 499 [MH] ⁺
5-2	2-methyl-4-methoxy-phenyl	H	NMR (¹ H, DMSO-d ₆): δ 8.37 (d, 1H), 7.71 (bs, 1H), 7.15 (d, 1H), 6.84 (d, 1H), 6.76 (dd, 1H), 6.74 (s, 1H), 6.31 (d, 1H), 3.93 (t, 2H), 3.82 (t, 2H), 3.74 (s, 3H), 3.50 (t, 2H), 3.42 (t, 2H), 2.16 (s, 3H), 2.13 (s, 3H). MS (m/z): 441 [MH] ⁺

EXAMPLE 6

Synthesis of compounds of general formula (II),




in which

Y

is $-\text{CR}_7$;


W

is a W12 derivative:



Z

is a pyrazolyl derivative



m

is an integer from 0 to 2;

n

is an integer from 0 to 6.

Example 6-1

4-[3-(1,1-Dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine

Intermediate 22 (10 mg, 0.022 mmol) and POCl_3 (1 mL) were mixed together in a vial under N_2 . The reaction mixture was refluxed for 1 hr. Sat.aq. NaHCO_3 was added until neutral pH and the mixture was partitioned between water and EtOAc. The two phases were separated and the aqueous layer was further extracted with EtOAc (3x10 mL). The combined organic extracts were concentrated and the residue was purified by flash chromatography (silica gel, cHex/EtOAc 1:1 \rightarrow EtOAc /sol. NH_3 in MeOH (0.5 M) 7:3) to give the title compound as a white solid (4.2 mg, 50%).

All the analytical data are set forth in the following Table 6-1 and in which:

R_1 is $-\text{CH}_3$;

R_5 is hydrogen;

R_6 is hydrogen,

R_7 is hydrogen;

D corresponds to $-\text{CR}_8\text{R}_9$;

G corresponds to $-\text{CR}_{10}\text{R}_{11}$;


$\text{R}_8, \text{R}_9, \text{R}_{10}, \text{R}_{11}$ are all hydrogen.

Cpd. No.	R	Analytical Data
----------	---	-----------------

6-1	2-methyl-4-methoxy-phenyl	NMR (^1H , CDCl_3): δ 7.84 (d, 1H), 7.16 (d, 1H), 6.82 (d, 1H), 6.77 (dd, 1H), 6.52 (s, 1H), 6.51 (d, 1H), 3.98 (t, 2H), 3.87 (t, 2H), 3.80 (s, 3H), 3.46 (m, 2H), 3.37 (t, 2H), 2.57 (m, 2H), 2.32 (s, 3H), 2.23 (s, 3H). IR (film, cm^{-1}): - MS (m/z): 439 $[\text{M}]^+$.
-----	---------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EXAMPLE 7

Synthesis of compounds of general formula (II),



5


in which

Y

is $-\text{CR}_7$;

W

is a W13 derivative:




;

10

Z

is a pyrazolyl derivative



m

is an integer from 0 to 2;

q

is an integer from 0 to 4.

15

Example 7-1

3-Methyl-1-(1-{6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2(1H)-pyridinone

20

A solution of intermediate 5 (20 mg, 0.05 mmol), intermediate 26 (14 mg, 2 eq), CuI (10 mg, 1 eq), K_2CO_3 (15 mg, 2.1 eq) and N-N'-dimethyl *trans*-cyclohexanediamine (9 mg, 1 eq) in anh. NMP (1 mL) at r.t., was heated at 150°C for 18 hr. Sat.aq. NH_4Cl (10 mL) was then added and the solution extracted with CH_2Cl_2 (25 mL). The organic layer was dried over anh. Na_2SO_4 , the solids were filtered and the solvents evaporated in vacuo. The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 1:9) to give 5.5 mg (44%) of the title compound as a white solid.


All the analytical data are set forth in the following Table 7-1 and in which:

R_1 is $-\text{CH}_3$;
 R_5 is hydrogen;
 R_6 is hydrogen,
 R_7 is hydrogen;
 D corresponds to $-\text{CR}_8\text{R}_9$;
 G corresponds to $-\text{CR}_{10}\text{R}_{11}$;
 R_8, R_9, R_{10}, R_{11} are all hydrogen.

Cpd. No.	R	Analytical Data
7-1	2-methyl-4-methoxy-phenyl	NMR (^1H , CDCl_3): δ 8.00 (dd, 1H), 7.9 (d, 1H), 7.3 (m, 2H), 7.25 (d, 1H), 6.8 (m, 2H), 6.7 (s, 1H), 6.2 (t, 1H), 3.9 (t, 2H), 3.4 (t, 2H), 3.7 (s, 3H), 2.4 (s, 3H), 2.3 (s, 3H), 2.25 (s, 3H), MS (m/z): 428 $[\text{MH}]^+$.

EXAMPLE 8

Synthesis of compounds of general formula (II),




in which

Y

is $-\text{CR}_7$;


W

is a W14 derivative:



Z

is a pyrazolyl derivative



m

is an integer from 0 to 2;

p

is an integer from 0 to 3.

Example 8-1

2-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-3(2H)-pyridazinone

A solution of intermediate 5 (25 mg, 0.06 mmol), intermediate 28 (20 mg, 2 eq), CuI (10 mg, 1 eq), K₂CO₃ (15 mg, 2.1 eq) and N-N'-dimethyl *trans*-cyclohexanediamine (9 mg, 1 eq) in anh. NMP (1 mL) was heated at 150°C for 3 days. Sat.aq. NH₄Cl (10 mL) was then added and the solution extracted with CH₂Cl₂ (25 ml). The organic layer was dried over anh. Na₂SO₄, the solids were filtered and the solvents evaporated in vacuo. The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 1:9) to give 6 mg (24%) of the title compound as a white solid.


All the analytical data are set forth in the following Table 8-1 and in which:

R₁ is -CH₃;
 R₅ is hydrogen;
 R₆ is hydrogen;
 R₇ is hydrogen;
 D corresponds to -CR₈R₉;
 G corresponds to -CR₁₀R₁₁;
 R₈, R₉, R₁₀, R₁₁ are all hydrogen.

Cpd. No.	R	Analytical Data
8-1	2-methyl-4-methoxy-phenyl	NMR (¹ H, CDCl ₃): δ 7.96 (dd-d, 2H), 7.27 (dd, 1H), 7.16 (d, 1H), 6.98 (d, 1H), 6.82 (d, 1H), 6.77 (dd, 1H), 6.64 (s, 1H), 3.88 (t, 2H), 3.8 (s, 3H), 3.46 (t, 2H), 2.33 (s, 3H), 2.23 (s, 3H). MS (m/z): 415 [MH] ⁺ .

EXAMPLE 9


Synthesis of compounds of general formula (II),




in which

Y is -CR₇;

W is a W1 derivative:



Z is a pyrazolyl derivative



m is an integer from 0 to 2.

5

Example 9-1

1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,3-dihydro-2H-imidazol-2-one

To a solution of intermediate 24 (50 mg, 0.1 mmol), in anh. CH₂Cl₂ (2 mL) was added HCl 6N (200 μL). The reaction mixture was stirred at rt. for 45 min. It was then neutralized with 1M NaHCO₃ (1 mL) and the solvents were evaporated in vacuo. The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give 18 mg (45%) of the title compound as a white solid.

All the analytical data are set forth in the following Table 9-1 and in which:


R₁ is -CH₃;
 R₅ is hydrogen;
 R₆ is hydrogen,
 R₇ is hydrogen;
 R₁₂ is hydrogen;
 D corresponds to -CR₈R₉;
 G corresponds to -CR₁₀R₁₁;
 R₈, R₉, R₁₀, R₁₁ are all hydrogen.

Cpd. No.	R	Analytical Data
9-1	2-methyl-4-methoxy-phenyl	NMR (¹ H, CDCl ₃): δ 7.85 (d, 1H), 7.79 (bs, 1H), 7.12 (d, 1H), 7.03 (d, 1H), 6.96 (m, 1H), 6.76 (d, 1H), 6.72 (dd, 1H), 6.52 (s, 1H), 6.33 (m, 1H), 3.82 (t, 2H), 3.74 (s, 3H), 3.41(t, 2H), 3.27(s, 3H), 2.18(s, 3H). MS (m/z): 403 [MH] ⁺ .

25

Example 10

Synthesis of compounds of general formula (II),




in which

Y

is $-\text{CR}_7$;


W

is a W2 derivative:



Z

is a pyrazolyl derivative



m

is an integer from 0 to 2;

q

is an integer from 0 to 4.

Example 10-1

1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of example 1 (90 mg, 0.223 mmol) in anh. CH_2Cl_2 (6 mL) at r.t., under N_2 , was added DDQ (56 mg, 5eq). The reaction mixture was stirred at r.t. for 24 hr. The solvent was evaporated in vacuo. The crude compound thus obtained was purified by flash chromatography (silica gel, cHex/EtOAc 1:1) to give 14.8 mg of a white solid, which was further purified by Mass Direct Autoprep (Fraction Lynks), affording the title compound as white solid (9 mg, 10%).

All the analytical data are set forth in the following Table 10-1 and in which:

R_1 is $-\text{CH}_3$;

R_5 is hydrogen;

R_6 is hydrogen,

R_7 is hydrogen;

R_{12} is hydrogen;

D corresponds to $-\text{CR}_8$;

G corresponds to $-\text{CR}_{10}$;


D and G are double bonded;

$\text{R}_8, \text{R}_{10}$ are all hydrogen.

Cpd. No.	R	Analytical Data
10-1	2-methyl-4-methoxy-phenyl	NMR (¹ H, CDCl ₃): 8.57 (d, 1H), 7.42 (d, 1H), 7.37 (s, 1H), 7.21 (d, 1H), 7.18 (d, 1H), 7.09 (bs, 1H), 6.97 (d, 1H), 6.89 (dd, 1H), 4.00 (m, 2H), 3.81 (s, 3H), 3.48 (m, 2H), 2.46 (s, 3H), 1.95 (s, 3H)δ. MS (m/z): 403 [MH] ⁺ .

EXAMPLE 11

Synthesis of compounds of general formula (II),



5


in which

Y

is nitrogen;


W

is a W2 derivative for example 11-1:




10

is a W11 derivative for example 11-2



Z

is a pyrazolyl derivative



m

is an integer from 0 to 2;

15

q

is an integer from 0 to 4.

Example 11-1

1-(1-{7-[2,4-bis(trifluoromethyl)phenyl]-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone

To a solution of intermediate 8 (7 mg, 2 eq) in anh. DMF (3.5 mL), at r.t., under N₂, was added NaH 60%/oil (2 mg, 2 eq). The reaction mixture was stirred at r.t. for 20 min. A

- 5 solution of intermediate 118 (8 mg, 0.021 mmol) in anh. DMF (3 mL) was added to the reaction mixture and it was heated at 80°C for 5 hr. Water and EtOAc were added and the phases were separated. The aqueous layer was further extracted with EtOAc (2x10 mL). The combined organic extracts were dried over anh. Na₂SO₄, the solids were filtered and the solvent evaporated. The residue was purified on a MEGA Bond Elut silica cartridge (100% cHex → 100% EtOAc) to give the title compound as a white solid (1.2 mg, 12%).



Example 11-2

10 1-{1-[7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-1H-pyrazol-3-yl}-2-pyrrolidinone

- To a suspension of NaH 60%/oil (5 mg, 3.0 eq) in anh. DMF (1 mL) at r.t., under N₂, was added intermediate 10 (30 mg, 3 eq). The reaction mixture was stirred at 80°C for 30 min. Intermediate 120 (20 mg, 0.064 mmol) was then added and the reaction mixture was heated at 100°C for 5h. It was then cooled down to r.t., poured into EtOAc, washed with sat.aq. NaCl (3x10 mL) and dried over anh. Na₂SO₄. The solid was filtered and the solvent evaporated. The crude product was purified by flash chromatography (silica gel, cHex/EtOAc 7:3) to give the title compound as white solid (10 mg, 35%).

All the analytical data are set forth in the following Table 11-1 and in which:

- 20 R₁ is -CH₃;
 R₅ is hydrogen;
 R₆ is hydrogen;
 R₁₂ is hydrogen;
 D corresponds to -CR₈R₉;
 25 G corresponds to -CR₁₀R₁₁;
 R₈, R₉, R₁₀, R₁₁ are all hydrogen.

Cpd. No.	R	W	Analytical Data
11-1	2,4-bis-tri-fluoromethyl-phenyl		NMR (¹ H, CDCl ₃): δ 8.43 (d, 1H), 7.94 (d, 1H), 7.83 (dd, 1H), 7.45 (d, 1H), 6.88 (d, 1H), 4.05 (t, 2H), 3.89 (t, 2H), 3.85 (t, 2H), 3.85 (t, 2H), 2.35 (s, 3H). MS (m/z): 498 [MH] ⁺ .
11-2	2,4-dichloro-phenyl		NMR (¹ H, CDCl ₃): δ 8.50 (d, 1H), 7.47 (d, 1H), 7.34 (d, 1H), 7.29 (dd, 1H), 7.08 (d, 1H), 4.08 (m, 4H), 3.60 (t, 4H), 2.60 (t, 2H), 2.42 (s, 2H), 2.19 (t, 2H). MS (m/z): 429 [MH] ⁺ .

EXAMPLE 12
CRF Binding Activity

5 CRF binding affinity has been determined in vitro by the compounds' ability to displace ^{125}I -oCRF and ^{125}I -Sauvagine for CRF1 and CRF2 SPA, respectively, from recombinant human CRF receptors expressed in Chinese Hamster Ovary (CHO) cell membranes. For membrane preparation, CHO cells from confluent T-flasks were collected in SPA buffer (HEPES/KOH 50mM, EDTA 2mM, MgCl_2 10mM, pH 7.4.) in 50mL centrifuge tubes, 10 homogenized with a Polytron and centrifuged (50'000g for 5min at 4°C: Beckman centrifuge with JA20 rotor). The pellet was resuspended, homogenized and centrifuged as before.

The SPA experiment has been carried out in Optiplate by the addition of 100 μL the reagent mixture to 1 μL of compound dilution (100% DMSO solution) per well. The assay 15 mixture was prepared by mixing SPA buffer, WGA SPA beads (2.5 mg/mL), BSA (1 mg/mL) and membranes (50 and 5 μg of protein/mL for CRF1 and CRF2 respectively) and 50 pM of radioligand.

The plate was incubated overnight (>18 hrs) at room temperature and read with the Packard Topcount with a WGA-SPA ^{125}I counting protocol.

20

EXAMPLE 13
CRF functional assay

Compounds of the invention were characterised in a functional assay for the 25 determination of their inhibitory effect. Human CRF-CHO cells were stimulated with CRF and the receptor activation was evaluated by measuring the accumulation of cAMP.

CHO cells from a confluent T-flask were resuspended with culture medium without G418 and dispensed in a 96-well plate, 25'000c/well, 100 μL /well and incubated overnight. After the incubation the medium was replaced with 100 μL of cAMP IBMX buffer warmed at 30 37°C (5mM KCl, 5mM NaHCO_3 , 154mM NaCl, 5mM HEPES, 2.3mM CaCl_2 , 1mM MgCl_2 , 1g/L glucose, pH 7.4 additioned by 1mg/mL BSA and 1mM IBMX) and 1 μL of antagonist dilution in neat DMSO. After 10 additional minutes of incubation at 37°C in a plate incubator without CO_2 , 1 μL of agonist dilution in neat DMSO was added. As before, the plate was incubated for 10 minutes and then cAMP cellular content was measured by 35 using the Amersham RPA 538 kit.


All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though 40 fully set forth.

It is to be understood that the present invention covers all combinations of particular and preferred groups described herein above.

- 5 The application of which this description and claims forms part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any feature or combination of features described herein. They may take the form of product, composition, process, or use claims and may include, by way of example and without limitation, the following claims:

Claims

1. Compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof



wherein

the dashed line may represent a double bond;

R is aryl or heteroaryl, each of which may be substituted by 1 to 4 groups J selected from:

halogen, C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkoxy, -C(O)R₂, nitro, hydroxy, -NR₃R₄, cyano or a group Z;

R₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 thioalkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C1-C6 alkoxy, halogen, NR₃R₄ or cyano;

R₂ is a C1-C4 alkyl, -OR₃ or -NR₃R₄;

R₃ is hydrogen or C1-C6 alkyl;

R₄ is hydrogen or C1-C6 alkyl;

R₅ is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;

R₆ is a C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxy, halo C1-C6 alkoxy, C3-C7 cycloalkyl, hydroxy, halogen, nitro, cyano, -NR₃R₄; -C(O)R₂;

R₇ is hydrogen, C1-C6 alkyl, halogen or halo C1-C6 alkyl;

R₈ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;

R₉ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;

R₁₀ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;


R₁₁ is hydrogen, C3-C7 cycloalkyl, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, NR₃R₄ or cyano;

R₁₂ is R₃ or -C(O)R₂;

D is CR₈R₉ or is CR₈ when double bonded with G;

- G is $\text{CR}_{10}\text{R}_{11}$ or is CR_{10} when double bonded with D or is CR_{10} when double bonded with X when X is carbon;
 X is carbon or nitrogen;
 Y is nitrogen or $-\text{CR}_7$;
 5 W is a 4-8 membered ring, which may be saturated or may contain one to three double bonds, and in which:
 - one carbon atom is replaced by a carbonyl or $\text{S}(\text{O})_m$; and
 - one to four carbon atoms may optionally be replaced by oxygen, nitrogen or NR_{12} , $\text{S}(\text{O})_m$, carbonyl, and such ring may be further substituted by 1 to 8 R_6 groups;
 10 Z is a 5-6 membered heterocycle, which may be substituted by 1 to 8 R_5 groups or a phenyl ring, which may be substituted by 1 to 4 R_5 groups;
 15 m is an integer from 0 to 2.

2. Compounds according to claim 1, in which W is selected among the following groups:



in which:

W1 represents a 1,3-dihydro-2H-imidazol-2-one derivative;

W2 represents a imidazolidin-2-one derivative;

W3 represents a tetrahydropyrimidin-2(1H)-one derivative;

W4 represents a 2,5-dihydro-1,2,5-thiadiazole 1-oxide derivative;

W5 represents a 1,2,5-thiadiazolidine 1-oxide derivative;


W6 represents a 2,5-dihydro-1,2,5-thiadiazole 1,1-dioxide derivative;

W7 represents a 1,2,6-thiadiazinane 1-oxide derivative;

W8 represents a 1,2,6-thiadiazinane 1,1-dioxide derivative;
 W9 represents a pyrrolidin-2-one derivative;
 W10 represents a 2,5-dihydro-1,2,5-thiadiazolidine 1,1-dioxide derivative;
 W11 represents a 1,3-oxazolidin-2-one derivative;
 W12 represents a isothiazolidine 1,1-dioxide derivative;
 W13 represents a 2(1H)-pyridinone derivative;
 W14 represents a 3(2H)-pyridazinone;
 W15 represents a 2,3-piperazinedione derivative;
 and

q is an integer from 0 to 4,
 n is an integer from 0 to 6,
 p is an integer from 0 to 3 and
 m, R₆ and R₁₂ are defined as in claim 1.

3. Compounds according to claim 1, having formula (II)




in which X is nitrogen or carbon and R, R₁, Y, Z, W, D, and G have the meanings as defined in claim 1.

4. Compounds according to claim 3, of formula (II), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13, and W14.

5. Compounds according to claim 3 of formula (II), in which Z is selected in the following group: pyrimidine, pyridine, thiazole, pyrazole, triazole and phenyl.


6. Compounds according to any of claims from 2 to 3 of formula (II), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13 and W14 and in which Z is selected from the following heterocyclic groups: pyrimidine, pyridine, thiazole, pyrazole, triazole and phenyl.

7. Compounds according to any one from claim 1 to claim 6 of formula (IIb), (IIc), (IId), (IIe), (IIf), and (IIg)



where R, R₁, R₇, Z, W, D, and G have the meanings as defined in claim 1.

- 5 8. Compounds according to claim 7 of formula (IIb), (IIc), (IId), (IIe), (IIf) and (IIg), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13 and W14.
- 10 9. Compounds according to claims 7 and 8 of formula (IIb), (IIc), (IId), (IIe), (IIf) and (IIg), in which Z is selected in the group consisting from: pyrimidine, pyridine, thiazole, pyrazole, triazole and phenyl.
- 15 10. Compounds according to any of claims from 7 to 9 of formula (IIb), (IIc), (IId), (IIe), (IIf) and (IIg), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13 and W14 and in which Z is a derivative of the following heterocyclic group: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.
- 20 11. Compounds according to claim 7 of formula (IIr), which correspond to the compounds of formula (II), where D and G are -CH₂-.




- 25 12. Compounds according to claim 11 of formula (IIr), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13 and W14.

13. Compounds according to claims 11 and 12 of formula (IIr), in which Z is selected in the group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.

5 14. Compounds according to any of claims from 11 to 13 of formula (IIr), in which W is selected in the group consisting from: W1, W2, W3, W9, W10, W11, W12, W13 and W14 and in which Z is selected in the group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl.


10 15. Compounds according to claim 3 of formula (III),




in which Z is a pyrazolyl derivative and R, R₁, R₅, Y, W, D, m and G have the meanings as defined in claim 1 and the dashed line may represent a double bond.

15


16. Compounds according to claim 15 of formula (IIIa), (IIIb), (IIIc) and (IIId),




(IIIa)



(IIIb)



(IIIc)



(IIId)


in which R, R₁, R₅, R₇, R₈, R₉, R₁₀, R₁₁, W, D, m and G have the meanings as defined in claim 1.

20

17. Compounds according to claim 16 of formula (IIIa), (IIIb), (IIIc) and (IIId), in which W is selected in the group consisting from: W1, W2, W3, W9, W10,

W11, W12, W13, W14 and R, R₁, R₅, R₇, R₈, R₉, R₁₀, R₁₁, and m have the meanings as defined in claim 1.


18. Compounds according to claim 15 of formula (IV),




5

in which R, R₁, R₅, R₆, R₇, R₁₂, m, q, D and G have the meanings as defined in claim 1 and 2 and the dashed line may represent a double bond.


19. Compounds according to claim 18 of formula (IVa), (IVb) and (IVc),



(IVa)



(IVb)




(IVc)

10

R, R₁, R₅, R₆, R₇, R₁₂, m, q, D and G have the meanings as defined in claim 1 and the dashed line may represent a double bond.


20. Compounds according to claim 3 of formula (V),



15


Z, R, R₁, R₆, q, Y, W, D and G have the meanings as defined in claim 1 and 2, and the dashed line may represent a double bond.

21. Compounds according to claim 20 of formula (VI),




in which Z, R, R₁, R₆, R₇, q, Y, W, D and G have the meanings as defined in claim 1 and 2, and the dashed line may represent a double bond.


- 5 22. Compounds according to claim 21 of formula (VIa), (VIb) and (VIc),



(VIa)



(VIb)



(VIc)

in which R, R₁, R₆, R₈, R₉, R₁₀, R₁₁, R₁₂, q, D and G have the meanings as defined in claim 1 and 2 and the dashed line may represent a double bond.

- 10 23. Compounds according to claim 22 of formula (VIa), (VIb) and (VIc), in which Z is selected in the group consisting from: pyrimidine, pyridine, thiazol, pyrazol, triazol and phenyl and R, R₁, R₆, R₈, R₉, R₁₀, R₁₁, R₁₂, q, D and G have the meanings as defined in claim 1 and 2.

- 15 24. Compounds according to any of claims from 1 to 23 of formula (I), (IIb), (IIc), (IIId), (IIe), (IIIf), (IIg), (IIr), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (V), (VI), (VIa), (VIb), (VIc), wherein:

R₁ is C1-C3 alkyl group or halo C1-C3 alkyl group,

R₇ is hydrogen;

- 20 R₈, (R₉), R₁₀, (R₁₁) are hydrogen;

R is an aryl group selected from: 2,4-dichlorophenyl, 2-chloro-4-methylphenyl, 2-chloro-4-trifluoromethylphenyl, 2-chloro-4-methoxyphenyl, 2,4,5-trimethylphenyl, 2,4-dimethylphenyl, 2-methyl-4-methoxyphenyl, 2-methyl-4-ethoxyphenyl, 2-methyl-4-isopropoxyphenyl, 2-methyl-4-hydroxyphenyl, 2-methyl-4-chlorophenyl, 2-methyl-4-trifluoromethylphenyl, 2,4-dimethoxyphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-chlorophenyl, 3-methoxy-4-chlorophenyl, 2,5-dimethoxy-4-chlorophenyl, 2-methoxy-4-isopropylphenyl, 2-methoxy-4-trifluoromethylphenyl, 2-methoxy-4-

25


isopropylphenyl, 2-methoxy-4-methylphenyl, 2-trifluoromethyl-4-chlorophenyl, 2,4-bis-trifluoromethylphenyl, 2-trifluoromethyl-4-methylphenyl, 2-trifluoromethyl-4-methoxyphenyl, 2-difluoromethyl-4-methoxyphenyl, 2-bromo-4-isopropylphenyl, 2-methyl-4-cyanophenyl, 2-chloro-4-cyanophenyl, 2-trifluoromethyl-4-cyanophenyl, 2-trifluoromethoxy-4-cyanophenyl, 2-ethyl-4-cyanophenyl, 2-methyl-4-trifluoromethoxyphenyl, 4-methyl-6-dimethylaminopyridin-3-yl, 2,6-bismethoxy-pyridin-3-yl, 2-methyl-6-methoxy-pyridin-3-yl, 2-trifluoromethyl-6-methoxy-pyridin-3-yl, 3-chloro-5-trichloromethyl-pyridin-2-yl, 2-methyl-4-(pyrazol-1-yl)-phenyl, 2-methoxy-4-(pyrazol-1-yl)-phenyl, 2,4,6-trimethoxyphenyl, 2-methyl-4,5-benzodioxolyl, 2-methyl-3,4-benzodioxolyl.

25. Compounds of formula (I), (IIb), (IIc), (IId), (IIe), (IIf), (IIg), (III), (IIIa), (IIIb), (IIIc), (IIId), (IV), (IVa), (IVb), (IVc), (V), (VI), (VIa), (VIb), (VIc), according to any of claims from 1 to 24 selected in the group consisting from:
- 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one (compound 1-1);
- 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-3-methylimidazolidin-2-one (compound 1-2);
- 1-{1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}imidazolidin-2-one (compound 1-3);
- 1-(1-{1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-4);
- 1-{1-[1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone (compound 1-5);
- 1-Acetyl-3-(1-{6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-5);
- 1-Acetyl-3-(1-{6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-6);
- 1-(1-{1-[4-(Ethoxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-7);
- 1-[1-(6-Methyl-1-{2-methyl-4-[(1-methylethyl)oxy]phenyl}-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone (compound 1-8);
- 1-[1-(6-Methyl-1-{2-methyl-4-[(trifluoromethyl)oxy]phenyl}-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone (compound 1-9);
- 3-Methyl-4-{6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile (compound 1-10);
- 1-(1-{6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-11);
- 4-{6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-(trifluoromethyl)benzonitrile (compound 1-12);

- 1-(1-{1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-13);
- 5 4-{6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}-3-[(trifluoromethyl)oxy]benzonitrile (compound 1-14);
- 3-Ethyl-4-{6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl}benzonitrile (compound 1-15);
- 10 1-(1-{6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-16);
- 1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone (compound 1-17);
- 15 1-(1-{6-Methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-18);
- 1-{1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}-2-imidazolidinone (compound 1-19);
- 1-(6-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyridinyl)-2-imidazolidinone (compound 1-20);
- 20 1-(4-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-2-pyrimidinyl)-2-imidazolidinone (compound 1-21);
- 1-(2-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-4-pyrimidinyl)-2-imidazolidinone (compound 1-22);
- 1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-23);
- 25 1-(1-{2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-24);
- 1-(3-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}phenyl)-2-imidazolidinone (compound 1-25);
- 30 1-(5-Methyl-1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 1-26);
- 1-[1-(1-{4-[(difluoromethyl)oxy]-2-methylphenyl}-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-1H-pyrazol-3-yl]-2-imidazolidinone (compound 1-27);
- 35 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}pyrrolidin-2-one (compound 2-1);
- 1-{1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl}tetrahydropyrimidin-2(1H)-one (compound 3-1);
- 40 3-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,3-oxazolidin-2-one (compound 4-1);

- Methyl 5-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,2,5-thiadiazolidine-2-carboxylate 1,1-dioxide) (compound 5-1);
- 5 4-[3-(1,1-Dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (compound 5-2).
- 4-[3-(1,1-Dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (compound 6-1);
- 10 3-Methyl-1-(1-{6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2(1H)-pyridinone (compound 7-1);
- 2-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-3(2H)-pyridazinone (compound 8-1);
- 15 1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-1,3-dihydro-2H-imidazol-2-one (compound 9-1);
- 1-(1-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl}-1H-pyrazol-3-yl)-2-imidazolidinone (compound 10-1);
- 1-(6-{6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl}-3-pyridinyl)-2-imidazolidinone (compound 11-1);
- 20 1-{1-[7-(2,4-Dichlorophenyl)-2-methyl-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-1H-pyrazol-3-yl}-2-pyrrolidinone (compound 11-2).
26. Process for the preparation of the compounds of formula (II), starting from compounds of formula (VII), comprising the following steps as in Scheme 1:
- 25

Scheme 1



- step a stands for conversion of the leaving group L, selected in a group consisting from: halogen or reactive residue of sulphonic acid (e.g. mesylate, tosylate), preferably chloride, in the compounds (VIII), by reaction with the suitable Z-W derivative;
- step b stands for reduction of the ester group (E) with a suitable reducing agent (such as DIBAL-H) to hydroxy group of compounds (IX);
- step c stands for suitable protection of an NH group eventually present in W group with a P group, such as a p-methoxybenzyl group;
- step d stands for oxidation of the hydroxy group with a suitable oxidizing agent (such as Dess-Martin periodinane) to the aldehyde group of compounds (XI);

- steps e + f stands for formation of the aldehyde group of compounds (XIII) by Wittig reaction in the usual conditions, through formation of enol ether followed by acid hydrolysis (step f);
- 5 step g stands for the optional alkylation of the α position of the aldehyde by deprotonation with a suitable base (such as $\text{LiN}(\text{SiMe}_3)_2$), followed by the addition of a suitable alkylating agent (such as MeI) to form the alkylated aldehyde of compounds (XIV), (XV);
- 10 step h stands for the conversion of the aldehyde group group by a Grignard reagent (such as MeMgBr) into an alcohol group of compounds (XVI) and (XVIII);
- step i stands for oxidation of the hydroxy group with a suitable oxidizing agent (such as Dess-Martin periodinane) to the ketone group of compounds (XVII);
- 15 step j stands for conversion of the hydroxy group in the suitable protecting group of compounds (XIX) (such as TBS: tert-butyldimethylsilyl);
- step k stands for a Buchwald coupling reaction with the suitable amine RNH_2 to give the compounds of formula (XX);
- 20 step l stands for the deprotection reaction to give the hydroxy group of compounds (XXI);
- step m stands for intramolecular cyclisation after conversion of the hydroxy group of compounds (XXI) in a suitable leaving group (such as bromide, by reaction with CBr_4 and PPh_3) to give the cyclized compounds (XXII);
- 25 step n stands for the deprotection reaction of the protected NH group eventually present in W group, to give final compounds (II);
- step o stands for oxidation by a suitable oxidating agent (such as DDQ) in order to give formation of the double bond of compounds (II), when D is CHR_8 and G is CHR_{10} .
- 30
27. The use of a compound according to any of claims from 1 to 25, in the preparation of a medicament for use in the treatment of conditions mediated by CRF (corticotropin-releasing factor).
- 35 28. The use of a compound according to claim 27, in the preparation of a medicament for use in the treatment of depression and anxiety.
29. The use of a compound according to claim 27, in the preparation of a medicament for use in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease).
- 40

30. A compound according to any of claims from 1 to 25, for use in the treatment of conditions mediated by CRF (corticotropin-releasing factor).
- 5 31. A compound according to claim 30, for use in the treatment of depression and anxiety.
32. A compound according to claim 30, for use in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease).
- 10 33. A pharmaceutical composition comprising a compound according to any of claims from 1 to 25, in admixture with one or more physiologically acceptable carriers or excipients.
- 15 34. A method for the treatment of a mammal, including man, in particular in the treatment of conditions mediated by CRF (corticotropin-releasing factor), comprising administration of an effective amount of a compound according to any of claims from 1 to 25.
- 20 35. A method, according to claim 34, in the treatment of depression and anxiety, comprising administration of an effective amount of a compound according to any of claims 1 to 25.
- 25 36. A method, according to claim 34, in the treatment of IBS (irritable bowel disease) and IBD (inflammatory bowel disease), comprising administration of an effective amount of a compound according to any of claims 1 to 25.

INTERNATIONAL SEARCH REPORT

National Application No
T/IB2004/001350

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/04 C07D487/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 03/008412 A (GLAXO GROUP LTD ; ST-DENIS YVES (IT); DI FABIO ROMANO (IT); MICHELI FA) 30 January 2003 (2003-01-30) cited in the application page 31 - page 34; claims 1-22 -----	1-36
Y	WO 02/088095 A (GLAXO GROUP LTD ; MARCHIONNI CHIARA (IT); ST-DENIS YVES (IT); FABIO RO) 7 November 2002 (2002-11-07) cited in the application page 75 - page 81; claims 1-25 -----	1-36
Y	WO 02/100863 A (GLAXO GROUP LTD ; MARCHIONNI CHIARA (IT); ST-DENIS YVES (IT); DI FABIO) 19 December 2002 (2002-12-19) page 33 - page 35; claims 1-20 ----- -/-	1-36

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 September 2004

Date of mailing of the international search report

30/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

national Application No

PCT/IB2004/001350

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 99/51599 A (HORVATH RAYMOND F ; GE PING (US); NEUROGEN CORP (US); LOMBAERT STEPHAN) 14 October 1999 (1999-10-14) page 58 - page 64; claims 1-9 -----	1-36

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB2004/001350

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 34-36 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB2004/001350

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03008412	A	30-01-2003	BR 0211171 A CA 2451530 A1 WO 03008412 A2 EP 1425280 A2 GB 2378702 A US 2004171607 A1 US 2004174520 A1	10-08-2004 30-01-2003 30-01-2003 09-06-2004 19-02-2003 02-09-2004 09-09-2004
WO 02088095	A	07-11-2002	BR 0209267 A CA 2446514 A1 CZ 20032946 A3 EP 1383747 A1 WO 02088095 A1 HU 0304054 A2 NO 20034836 A US 2004176400 A1 EP 1395591 A1 WO 02100863 A1	15-06-2004 07-11-2002 12-05-2004 28-01-2004 07-11-2002 28-04-2004 29-10-2003 09-09-2004 10-03-2004 19-12-2002
WO 02100863	A	19-12-2002	EP 1395591 A1 WO 02100863 A1 BR 0209267 A CA 2446514 A1 CZ 20032946 A3 EP 1383747 A1 WO 02088095 A1 HU 0304054 A2 NO 20034836 A US 2004176400 A1	10-03-2004 19-12-2002 15-06-2004 07-11-2002 12-05-2004 28-01-2004 07-11-2002 28-04-2004 29-10-2003 09-09-2004
WO 9951599	A	14-10-1999	AU 3378799 A CA 2326383 A1 EP 1068206 A1 JP 2002510687 T WO 9951599 A1 US 6310063 B1 US 6436932 B1	25-10-1999 14-10-1999 17-01-2001 09-04-2002 14-10-1999 30-10-2001 20-08-2002